,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"TRANSFORMING LIVES BOSTON SCIENTIFIC  2018 PERFORMANCE REPORTBoston Scientific   by the Numbers 13   Meaningful Innovation 15   Corporate Social   Responsibility at   Boston Scientific 53   Non-GAAP   ReconciliationsOur Mission   and Core Values 04   A Message from   Our Chairman and CEO Financial Highlights 11   Boston Scientific  at a Glance Throughout this   document, unless   otherwise noted,   all revenue and other  growth rates represent  fiscal year 2018   compared to fiscal   year 2017.
","('Human_Rights_And_Community_Relations', 0.3662518858909607)","('Business_Model_Resilience', 0.24250854551792145)","('Management_Of_Legal_And_Regulatory_Framework', 0.06327749788761139)","('NON-ESG', 0.3662518858909607)","('NON-ESG', 0.24250854551792145)","('NON-ESG', 0.06327749788761139)"
Line 2,"TABLE OF CONTENTS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.17   OUR PLANET  Climate Change    Environmental Impact   Recognitions for   Sustainability   Leadership   Green Team   Environmental   Sustainability   Initiatives24   OUR PEOPLE   Accelerating Diversity  and Inclusion   Attracting and   Engaging Diverse   Talent   Leadership   Commitment   Listening to Support   an Inclusive Culture   Employee Resource  Groups   Setting the Bar Higher   Employee Growth   and Development   Compensation and  Benefits   Embracing New   Life-Work Needs    Promoting Health   Equity   Inspiring the Next   Generation of Leaders   Giving Back to   Our Communities42  OUR PRACTICES   Working   Responsibly  Governance   Compliance, Ethics  and Integrity   Developing   Innovative Products   Quality and Safety   Sustainable Supply  Chain   Packaging and   Labeling   Supporting Small  Business and   Supplier Diversity     BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.OUR MISSION AND CORE VALUES Boston Scientific provides health grants to   organizations such as the Dimock Center in   Boston, Massachusetts, which is committed to   providing the local community with equitable   access to comprehensive healthcare and   education.Boston Scientific is dedicated to transforming lives   through innovative medical solutions that improve the   health of patients around the world.
","('Employee_Engagement_Inclusion_And_Diversity', 0.974850594997406)","('Employee_Health_And_Safety', 0.002189667196944356)","('Human_Rights_And_Community_Relations', 0.001963866874575615)","(['Human Capital Development'], 0.974850594997406)","('NON-ESG', 0.002189667196944356)","('NON-ESG', 0.001963866874575615)"
Line 3,"TABLE OF CONTENTS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.17   OUR PLANET  Climate Change    Environmental Impact   Recognitions for   Sustainability   Leadership   Green Team   Environmental   Sustainability   Initiatives24   OUR PEOPLE   Accelerating Diversity  and Inclusion   Attracting and   Engaging Diverse   Talent   Leadership   Commitment   Listening to Support   an Inclusive Culture   Employee Resource  Groups   Setting the Bar Higher   Employee Growth   and Development   Compensation and  Benefits   Embracing New   Life-Work Needs    Promoting Health   Equity   Inspiring the Next   Generation of Leaders   Giving Back to   Our Communities42  OUR PRACTICES   Working   Responsibly  Governance   Compliance, Ethics  and Integrity   Developing   Innovative Products   Quality and Safety   Sustainable Supply  Chain   Packaging and   Labeling   Supporting Small  Business and   Supplier Diversity     BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.OUR MISSION AND CORE VALUES Boston Scientific provides health grants to   organizations such as the Dimock Center in   Boston, Massachusetts, which is committed to   providing the local community with equitable   access to comprehensive healthcare and   education.Boston Scientific is dedicated to transforming lives   through innovative medical solutions that improve the   health of patients around the world.
","('Product_Quality_And_Safety', 0.32222527265548706)","('Supply_Chain_Management', 0.2232743501663208)","('Product_Design_And_Lifecycle_Management', 0.1190323606133461)","('NON-ESG', 0.32222527265548706)","('NON-ESG', 0.2232743501663208)","('NON-ESG', 0.1190323606133461)"
Line 4,"TABLE OF CONTENTS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.17   OUR PLANET  Climate Change    Environmental Impact   Recognitions for   Sustainability   Leadership   Green Team   Environmental   Sustainability   Initiatives24   OUR PEOPLE   Accelerating Diversity  and Inclusion   Attracting and   Engaging Diverse   Talent   Leadership   Commitment   Listening to Support   an Inclusive Culture   Employee Resource  Groups   Setting the Bar Higher   Employee Growth   and Development   Compensation and  Benefits   Embracing New   Life-Work Needs    Promoting Health   Equity   Inspiring the Next   Generation of Leaders   Giving Back to   Our Communities42  OUR PRACTICES   Working   Responsibly  Governance   Compliance, Ethics  and Integrity   Developing   Innovative Products   Quality and Safety   Sustainable Supply  Chain   Packaging and   Labeling   Supporting Small  Business and   Supplier Diversity     BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.OUR MISSION AND CORE VALUES Boston Scientific provides health grants to   organizations such as the Dimock Center in   Boston, Massachusetts, which is committed to   providing the local community with equitable   access to comprehensive healthcare and   education.Boston Scientific is dedicated to transforming lives   through innovative medical solutions that improve the   health of patients around the world.
","('Access_And_Affordability', 0.891385018825531)","('Employee_Health_And_Safety', 0.010836252942681313)","('Critical_Incident_Risk_Management', 0.010512039996683598)","(['Health Outcome Contribution'], 0.891385018825531)","('NON-ESG', 0.010836252942681313)","('NON-ESG', 0.010512039996683598)"
Line 5,"Our work is guided by core values that define Boston Scientific culture and empower our employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4398714005947113)","('Human_Rights_And_Community_Relations', 0.1414116770029068)","('Business_Ethics', 0.0518542118370533)","('NON-ESG', 0.4398714005947113)","('NON-ESG', 0.1414116770029068)","('NON-ESG', 0.0518542118370533)"
Line 6,"CARING: We act with integrity and compassion to support patients, customers, our communities   and each other.
","('Human_Rights_And_Community_Relations', 0.5304297208786011)","('Employee_Health_And_Safety', 0.07141490280628204)","('Access_And_Affordability', 0.06660056114196777)","(['Community Relations'], 0.5304297208786011)","('NON-ESG', 0.07141490280628204)","('NON-ESG', 0.06660056114196777)"
Line 7,"DIVERSITY: We embrace diversity and value unique talents, ideas and experiences of our employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9739351868629456)","('Employee_Health_And_Safety', 0.0023431109730154276)","('Human_Rights_And_Community_Relations', 0.0016249357722699642)","(['Human Capital Development'], 0.9739351868629456)","('NON-ESG', 0.0023431109730154276)","('NON-ESG', 0.0016249357722699642)"
Line 8,"GLOBAL COLLABORATION: We work collaboratively to pursue global opportunities that extend   the reach of our medical solutions.
","('Access_And_Affordability', 0.25804880261421204)","('Human_Rights_And_Community_Relations', 0.09680265933275223)","('Business_Model_Resilience', 0.07002060860395432)","('NON-ESG', 0.25804880261421204)","('NON-ESG', 0.09680265933275223)","('NON-ESG', 0.07002060860395432)"
Line 9,"HIGH PERFORMANCE: We strive for high performance to benefit our patients, clinicians and   shareholders.
","('Access_And_Affordability', 0.33572569489479065)","('Business_Ethics', 0.09544331580400467)","('Human_Rights_And_Community_Relations', 0.07622038573026657)","('NON-ESG', 0.33572569489479065)","('NON-ESG', 0.09544331580400467)","('NON-ESG', 0.07622038573026657)"
Line 10,"MEANINGFUL INNOVATION: We foster an environment of creativity to transform new ideas   intro breakthrough services and solutions that create value for patients, customers and employees.
","('Product_Design_And_Lifecycle_Management', 0.4509609639644623)","('Business_Model_Resilience', 0.18321789801120758)","('Customer_Welfare', 0.062283486127853394)","('NON-ESG', 0.4509609639644623)","('NON-ESG', 0.18321789801120758)","('NON-ESG', 0.062283486127853394)"
Line 11,"WINNING SPIRIT: We adapt to change and act with speed, agility and accountability to further   improve patient care.In our early days as a   company, Boston Scientific   established a mission to   transform lives through   innovative medical solutions  that improve the health of   patients around the world.
","('Access_And_Affordability', 0.5055248737335205)","('Product_Design_And_Lifecycle_Management', 0.06361377239227295)","('Customer_Welfare', 0.049224257469177246)","(['Health Outcome Contribution'], 0.5055248737335205)","('NON-ESG', 0.06361377239227295)","('NON-ESG', 0.049224257469177246)"
Line 12,"Throughout our history, our leaders and innovators  played a significant role in advancing science   through more accessible, lower cost and lower   trauma medical innovations.
","('Product_Design_And_Lifecycle_Management', 0.29305508732795715)","('Access_And_Affordability', 0.16551604866981506)","('Customer_Welfare', 0.14256635308265686)","('NON-ESG', 0.29305508732795715)","('NON-ESG', 0.16551604866981506)","('NON-ESG', 0.14256635308265686)"
Line 13,"This year will mark   the company’s 40th anniversary, and our mission   continues to hold true and inspire our work today.
","('Business_Model_Resilience', 0.20193170011043549)","('Human_Rights_And_Community_Relations', 0.1531689167022705)","('Employee_Engagement_Inclusion_And_Diversity', 0.13532672822475433)","('NON-ESG', 0.20193170011043549)","('NON-ESG', 0.1531689167022705)","('NON-ESG', 0.13532672822475433)"
Line 14,"It challenges us to do more for our customers   and the patients we serve together, while driving   sustainable and inclusive business practices.
","('Product_Design_And_Lifecycle_Management', 0.16397935152053833)","('Customer_Welfare', 0.14921163022518158)","('Employee_Engagement_Inclusion_And_Diversity', 0.11173522472381592)","('NON-ESG', 0.16397935152053833)","('NON-ESG', 0.14921163022518158)","('NON-ESG', 0.11173522472381592)"
Line 15,"I am extremely proud that our global team of dedicated  employees demonstrated high performance across  all businesses, functions and regions in 2018.
","('Employee_Engagement_Inclusion_And_Diversity', 0.25507915019989014)","('Business_Model_Resilience', 0.13799569010734558)","('Employee_Health_And_Safety', 0.06554216891527176)","('NON-ESG', 0.25507915019989014)","('NON-ESG', 0.13799569010734558)","('NON-ESG', 0.06554216891527176)"
Line 16,"We  delivered on our financial commitments to shareholders  while investing for durable, long-term growth and  most importantly, we worked together to help improve  the lives of approximately 30 million patients – more  people than at any time in our history.
","('Access_And_Affordability', 0.6389139294624329)","('Human_Rights_And_Community_Relations', 0.07816499471664429)","('Employee_Engagement_Inclusion_And_Diversity', 0.042702578008174896)","(['Health Outcome Contribution'], 0.6389139294624329)","('NON-ESG', 0.07816499471664429)","('NON-ESG', 0.042702578008174896)"
Line 17,"We held  ourselves to the highest standards of quality   and safety and fueled our pipeline by investing   approximately $1 billion in research and development.
","('Product_Quality_And_Safety', 0.6862837076187134)","('Employee_Health_And_Safety', 0.1777334362268448)","('Access_And_Affordability', 0.016749965026974678)","(['Product Quality & Recall Management'], 0.6862837076187134)","('NON-ESG', 0.1777334362268448)","('NON-ESG', 0.016749965026974678)"
Line 18,"We also announced 10 strategic acquisitions in   support of our category leadership strategy and   continued expansion into high growth markets.
","('Business_Model_Resilience', 0.6773825287818909)","('Systemic_Risk_Management', 0.1285020262002945)","('Competitive_Behavior', 0.041711773723363876)","(['Codes of Business Conduct'], 0.6773825287818909)","('NON-ESG', 0.1285020262002945)","('NON-ESG', 0.041711773723363876)"
Line 19,"I also know that we can’t be satisfied with the status  quo.
","('Competitive_Behavior', 0.48769092559814453)","('Business_Ethics', 0.14045540988445282)","('Management_Of_Legal_And_Regulatory_Framework', 0.08162666112184525)","('NON-ESG', 0.48769092559814453)","('NON-ESG', 0.14045540988445282)","('NON-ESG', 0.08162666112184525)"
Line 20,"The healthcare industry continues to undergo   transformation, with external forces presenting  wide-ranging challenges and opportunities, including  a growing burden of chronic conditions, an aging  population, increasing consumerism, industry   consolidation, and technology companies moving  into healthcare.
","('Systemic_Risk_Management', 0.5399689674377441)","('Supply_Chain_Management', 0.16320191323757172)","('Business_Model_Resilience', 0.10141931474208832)","(['Risk & Crisis Management'], 0.5399689674377441)","('NON-ESG', 0.16320191323757172)","('NON-ESG', 0.10141931474208832)"
Line 21,"Addressing these changes will   require agility, responsiveness and bold new thinking.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2651936411857605)","('Business_Model_Resilience', 0.22211067378520966)","('Systemic_Risk_Management', 0.0755443200469017)","('NON-ESG', 0.2651936411857605)","('NON-ESG', 0.22211067378520966)","('NON-ESG', 0.0755443200469017)"
Line 22,"Our mission and values will continue to guide us as  we rise to meet future needs.
","('Human_Rights_And_Community_Relations', 0.26182305812835693)","('Business_Model_Resilience', 0.2507112920284271)","('Director_Removal', 0.07324393838644028)","('NON-ESG', 0.26182305812835693)","('NON-ESG', 0.2507112920284271)","('NON-ESG', 0.07324393838644028)"
Line 23,"2018 BUSINESS RESULTS   2018 was yet another strong year for Boston   Scientific with results that extend our track record   of excellent performance over the five-year 2014   to 2018 period.
","('Business_Model_Resilience', 0.5927385687828064)","('Systemic_Risk_Management', 0.12344764173030853)","('Physical_Impacts_Of_Climate_Change', 0.03934420645236969)","(['Codes of Business Conduct'], 0.5927385687828064)","('NON-ESG', 0.12344764173030853)","('NON-ESG', 0.03934420645236969)"
Line 24,"During this time, Boston Scientific   has grown operational sales at an average rate of   8 percent and organic sales at an average rate of   7 percent.1,2 We’ve improved adjusted operating   margin 530 basis points and leveraged that to  drive an average 14 percent growth in adjusted   earnings per share over the five-year period,   excluding the $0.07 net tax benefit in 2018.1 Our  common stock returned 43 percent, and our   five- and three-year total shareholder returns   have consistently outpaced the S&P 500 index,   growing 194 percent and 92 percent, respectively.
","('Systemic_Risk_Management', 0.3651493787765503)","('Business_Model_Resilience', 0.27845528721809387)","('Competitive_Behavior', 0.08404827862977982)","('NON-ESG', 0.3651493787765503)","('NON-ESG', 0.27845528721809387)","('NON-ESG', 0.08404827862977982)"
Line 25,"During this time, Boston Scientific   has grown operational sales at an average rate of   8 percent and organic sales at an average rate of   7 percent.1,2 We’ve improved adjusted operating   margin 530 basis points and leveraged that to  drive an average 14 percent growth in adjusted   earnings per share over the five-year period,   excluding the $0.07 net tax benefit in 2018.1 Our  common stock returned 43 percent, and our   five- and three-year total shareholder returns   have consistently outpaced the S&P 500 index,   growing 194 percent and 92 percent, respectively.
","('Systemic_Risk_Management', 0.696961522102356)","('Business_Model_Resilience', 0.06413562595844269)","('Competitive_Behavior', 0.051838479936122894)","(['Risk & Crisis Management'], 0.696961522102356)","('NON-ESG', 0.06413562595844269)","('NON-ESG', 0.051838479936122894)"
Line 26,"Our full-year sales in 2018 were $9.823 billion,   representing 8.0 percent operational revenue   growth and 7.2 percent organic revenue growth,  which excludes 80 basis points of growth from   certain recent acquisitions.2,3 Organic sales growth  was 8.2 percent in MedSurg†, 7.6 percent in Rhythm  and Neuro† and 6 percent in Cardiovascular.3 In   addition to our strong revenue growth, we delivered  a 50 basis point improvement in adjusted operating   margin and full-year adjusted earnings per share  growth of 17 percent to $1.47, which includes a $0.07  net tax benefit for the year.1 Excluding this net tax   benefit of $0.07, our adjusted earnings per share Mike Mahoney,   Chairman and   Chief Executive   Officer † Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments.
","('Business_Model_Resilience', 0.3952227830886841)","('Systemic_Risk_Management', 0.2552635967731476)","('Competitive_Behavior', 0.054061245173215866)","('NON-ESG', 0.3952227830886841)","('NON-ESG', 0.2552635967731476)","('NON-ESG', 0.054061245173215866)"
Line 27,"Our full-year sales in 2018 were $9.823 billion,   representing 8.0 percent operational revenue   growth and 7.2 percent organic revenue growth,  which excludes 80 basis points of growth from   certain recent acquisitions.2,3 Organic sales growth  was 8.2 percent in MedSurg†, 7.6 percent in Rhythm  and Neuro† and 6 percent in Cardiovascular.3 In   addition to our strong revenue growth, we delivered  a 50 basis point improvement in adjusted operating   margin and full-year adjusted earnings per share  growth of 17 percent to $1.47, which includes a $0.07  net tax benefit for the year.1 Excluding this net tax   benefit of $0.07, our adjusted earnings per share Mike Mahoney,   Chairman and   Chief Executive   Officer † Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6256332993507385)","('Business_Model_Resilience', 0.047194890677928925)","('Systemic_Risk_Management', 0.03842620551586151)","(['Corporate Governance'], 0.6256332993507385)","('NON-ESG', 0.047194890677928925)","('NON-ESG', 0.03842620551586151)"
Line 28,"The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly  created Rhythm and Neuro segment, which includes Cardiac Rhythm Management (CRM), Electrophysiology and Neuromodulation.
","('Customer_Welfare', 0.13358162343502045)","('Employee_Health_And_Safety', 0.1101444661617279)","('Competitive_Behavior', 0.08332479745149612)","('NON-ESG', 0.13358162343502045)","('NON-ESG', 0.1101444661617279)","('NON-ESG', 0.08332479745149612)"
Line 29,"In addition, we reclassified the Middle East and Africa (MEA) regions from the former AMEA region with Europe to create the new EMEA region.
","('Business_Model_Resilience', 0.2115519791841507)","('Management_Of_Legal_And_Regulatory_Framework', 0.13475532829761505)","('Ecological_Impacts', 0.10872787982225418)","('NON-ESG', 0.2115519791841507)","('NON-ESG', 0.13475532829761505)","('NON-ESG', 0.10872787982225418)"
Line 30,"The new Asia-Pacific (APAC) region   was also previously part of the former AMEA region.
","('Business_Model_Resilience', 0.24135148525238037)","('Ecological_Impacts', 0.1615029275417328)","('Management_Of_Legal_And_Regulatory_Framework', 0.09355935454368591)","('NON-ESG', 0.24135148525238037)","('NON-ESG', 0.1615029275417328)","('NON-ESG', 0.09355935454368591)"
Line 31,"Prior year balances and year over year growth rates (denoted with †) have been revised accordingly.
","('Systemic_Risk_Management', 0.45771247148513794)","('Business_Model_Resilience', 0.2153695672750473)","('Physical_Impacts_Of_Climate_Change', 0.054521702229976654)","('NON-ESG', 0.45771247148513794)","('NON-ESG', 0.2153695672750473)","('NON-ESG', 0.054521702229976654)"
Line 32,"1 Adjusted operating margin, adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impacts of certain charges  (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation related net charges and credits, pension termination charges, certain debt extinguishment  charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.
","('Business_Ethics', 0.5129973888397217)","('Management_Of_Legal_And_Regulatory_Framework', 0.2460324615240097)","('Competitive_Behavior', 0.08250627666711807)","(['Business Ethics'], 0.5129973888397217)","('NON-ESG', 0.2460324615240097)","('NON-ESG', 0.08250627666711807)"
Line 33,"1 Adjusted operating margin, adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impacts of certain charges  (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation related net charges and credits, pension termination charges, certain debt extinguishment  charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9503116607666016)","('Energy_Management', 0.008901149965822697)","('Competitive_Behavior', 0.004593710880726576)","(['Corporate Governance'], 0.9503116607666016)","('NON-ESG', 0.008901149965822697)","('NON-ESG', 0.004593710880726576)"
Line 34,"2 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5612218379974365)","('Systemic_Risk_Management', 0.2325957864522934)","('Competitive_Behavior', 0.031772784888744354)","(['Corporate Governance'], 0.5612218379974365)","('NON-ESG', 0.2325957864522934)","('NON-ESG', 0.031772784888744354)"
Line 35,"3 Organic   revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the first twelve months of sales from the acquisitions of the electrophysiology business of C.R. Bard Inc., the Interventional Division of Bayer AG, the American Medical Systems male urology portfolio,   EndoChoice Holdings, Inc., Symetis SA, NxThera, Inc., Claret Medical, Inc.
","('Systemic_Risk_Management', 0.4251444339752197)","('Competitive_Behavior', 0.19525349140167236)","('Business_Model_Resilience', 0.08154980093240738)","('NON-ESG', 0.4251444339752197)","('NON-ESG', 0.19525349140167236)","('NON-ESG', 0.08154980093240738)"
Line 36,"and Augmenix, Inc., since there are  no prior period related net sales; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.42149171233177185)","('Systemic_Risk_Management', 0.23259325325489044)","('Competitive_Behavior', 0.05646457150578499)","('NON-ESG', 0.42149171233177185)","('NON-ESG', 0.23259325325489044)","('NON-ESG', 0.05646457150578499)"
Line 37,"DEAR SHAREHOLDERS: A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.12/18 12/17 12/16 12/15 12/14 12/13$grew 11 percent.1 Through increased productivity   and reduced costs, we were able to redirect savings  to high-growth technologies that strengthen our  portfolio and capabilities for the future.
","('Business_Model_Resilience', 0.5005334615707397)","('Product_Design_And_Lifecycle_Management', 0.08596224337816238)","('Systemic_Risk_Management', 0.08103729784488678)","(['Codes of Business Conduct'], 0.5005334615707397)","('NON-ESG', 0.08596224337816238)","('NON-ESG', 0.08103729784488678)"
Line 38,"These results  also generated more than $2 billion of adjusted   free cash flow, representing 20 percent growth over  the prior year.4 We were able to invest a significant  portion of these funds to augment future growth   via multiple exciting acquisitions.
","('Systemic_Risk_Management', 0.790418803691864)","('Business_Model_Resilience', 0.07411040365695953)","('Competitive_Behavior', 0.017083384096622467)","(['Risk & Crisis Management'], 0.790418803691864)","('NON-ESG', 0.07411040365695953)","('NON-ESG', 0.017083384096622467)"
Line 39,"In global markets, we continued expanding our   business with broad-based growth across regions.
","('Business_Model_Resilience', 0.532787024974823)","('Systemic_Risk_Management', 0.14673975110054016)","('Competitive_Behavior', 0.11299613118171692)","(['Codes of Business Conduct'], 0.532787024974823)","('NON-ESG', 0.14673975110054016)","('NON-ESG', 0.11299613118171692)"
Line 40,"Total annual sales from Emerging Markets increased  21.4 percent operational compared to 2017.2,5 We  expect to continue to grow our presence in new  markets and regions and to make our technologies  accessible to more people in need.Our strategy of category leadership in key markets   and portfolio diversification into high growth   adjacencies is working.
","('Business_Model_Resilience', 0.7531144022941589)","('Systemic_Risk_Management', 0.08177449554204941)","('Competitive_Behavior', 0.021923353895545006)","(['Codes of Business Conduct'], 0.7531144022941589)","('NON-ESG', 0.08177449554204941)","('NON-ESG', 0.021923353895545006)"
Line 41,"Our goal is to continue to  execute against our strategic plan objectives and  deliver top-tier sales and adjusted earnings per   share growth over the next five years.
","('Business_Model_Resilience', 0.76183021068573)","('Systemic_Risk_Management', 0.0727325826883316)","('Competitive_Behavior', 0.017355527728796005)","(['Codes of Business Conduct'], 0.76183021068573)","('NON-ESG', 0.0727325826883316)","('NON-ESG', 0.017355527728796005)"
Line 42,"We believe  that the combination of long-term, consistent,   above market revenue growth, adjusted operating  margin expansion, targeted double-digit earnings  per share growth, and the improved ability to deploy  our strong free cash flow uniquely position Boston  Scientific to continue to drive shareholder value.
","('Business_Model_Resilience', 0.5715002417564392)","('Systemic_Risk_Management', 0.19122496247291565)","('Competitive_Behavior', 0.06462443619966507)","(['Codes of Business Conduct'], 0.5715002417564392)","('NON-ESG', 0.19122496247291565)","('NON-ESG', 0.06462443619966507)"
Line 43,"SOLUTIONS THAT MATTER MOST Our work at Boston Scientific is driven by our   commitment to better understand unmet health  needs and collaborate with diverse healthcare  stakeholders to solve them, from patient education  resources and technology breakthroughs to strategic  investments that deepen our expertise and impact.
","('Access_And_Affordability', 0.6029418706893921)","('Critical_Incident_Risk_Management', 0.0658666342496872)","('Employee_Health_And_Safety', 0.0418931283056736)","(['Health Outcome Contribution'], 0.6029418706893921)","('NON-ESG', 0.0658666342496872)","('NON-ESG', 0.0418931283056736)"
Line 44,"Our approach to innovation includes a mix of organic  programs, collaborations and strategic acquisitions  that are focused on enriching our capabilities in   the medical specialties that we serve.
","('Business_Model_Resilience', 0.4280462861061096)","('Product_Design_And_Lifecycle_Management', 0.10757245868444443)","('Customer_Welfare', 0.08196809142827988)","('NON-ESG', 0.4280462861061096)","('NON-ESG', 0.10757245868444443)","('NON-ESG', 0.08196809142827988)"
Line 45,"We believe   that this clinical depth and category leadership   strategy are helping us create value for patients,   physicians and payers and enabling us to grow   faster than our underlying markets and most peers.
","('Competitive_Behavior', 0.5521013736724854)","('Business_Model_Resilience', 0.1324799358844757)","('Systemic_Risk_Management', 0.07116056233644485)","(['Business Ethics'], 0.5521013736724854)","('NON-ESG', 0.1324799358844757)","('NON-ESG', 0.07116056233644485)"
Line 46,"Expansion into New Markets The investments we’ve made and platform   technologies we have built enable greater agility   to reach additional patient populations with   critical unmet needs.
","('Access_And_Affordability', 0.4944041669368744)","('Customer_Welfare', 0.07535430788993835)","('Systemic_Risk_Management', 0.04556011036038399)","('NON-ESG', 0.4944041669368744)","('NON-ESG', 0.07535430788993835)","('NON-ESG', 0.04556011036038399)"
Line 47,"We will continue to expand   our business in exciting growth areas and expect   that our technology development efforts and   acquisitions have positioned us to enter new   adjacencies that will represent approximately $20  billion in addressable market opportunity by 2022.
","('Business_Model_Resilience', 0.8009782433509827)","('Systemic_Risk_Management', 0.05768384039402008)","('Customer_Welfare', 0.01502942480146885)","(['Codes of Business Conduct'], 0.8009782433509827)","('NON-ESG', 0.05768384039402008)","('NON-ESG', 0.01502942480146885)"
Line 48,"The Boston Scientific Interventional Cardiology   business is leading the way on this front as we   continue the global expansion of our WATCHMAN™  Left Atrial Appendage Closure (LAAC) Technology,  with more than 70,000 patients implanted.
","('Access_And_Affordability', 0.29952096939086914)","('Customer_Welfare', 0.11694414913654327)","('Employee_Engagement_Inclusion_And_Diversity', 0.06274501234292984)","('NON-ESG', 0.29952096939086914)","('NON-ESG', 0.11694414913654327)","('NON-ESG', 0.06274501234292984)"
Line 49,"The  WATCHMAN Device is designed to reduce the risk   of stroke for patients with non-valvular atrial   fibrillation (AF) and is now recognized in medical   society guidelines as a therapeutic option for   patients who need an alternative to long-term   oral anticoagulant therapy.
","('Customer_Welfare', 0.19480663537979126)","('Access_And_Affordability', 0.17674905061721802)","('Employee_Health_And_Safety', 0.13740114867687225)","('NON-ESG', 0.19480663537979126)","('NON-ESG', 0.17674905061721802)","('NON-ESG', 0.13740114867687225)"
Line 50,"We further expanded our structural heart portfolio  and strengthened our commitment to improving  transcatheter aortic valve replacement (TAVR) patient  outcomes through the addition of the Sentinel™  Cerebral Protection System, which is the only device  cleared by the U.S. Food and Drug Administration  (FDA) to protect patients against the risk of stroke  during TAVR and has been used in nearly 10,000  procedures.
","('Employee_Health_And_Safety', 0.6697526574134827)","('Access_And_Affordability', 0.05943763628602028)","('Product_Quality_And_Safety', 0.036814842373132706)","(['Operational Eco-Efficiency'], 0.6697526574134827)","('NON-ESG', 0.05943763628602028)","('NON-ESG', 0.036814842373132706)"
Line 51,"In addition, we continue to develop our  A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.COMPARISON OF 5-YEAR   CUMULATIVE TOTAL RETURN*   Boston Scientific Corporation   S&P Health Care Equipment   S&P * $100 invested on 12/31/13 in stock or index, including   reinvestment of dividends.
","('Systemic_Risk_Management', 0.68304443359375)","('Business_Model_Resilience', 0.11602181941270828)","('Competitive_Behavior', 0.04295210540294647)","(['Risk & Crisis Management'], 0.68304443359375)","('NON-ESG', 0.11602181941270828)","('NON-ESG', 0.04295210540294647)"
Line 52,"Fiscal year ending December 31.
","('Physical_Impacts_Of_Climate_Change', 0.11935177445411682)","('Director_Removal', 0.10407575964927673)","('Systemic_Risk_Management', 0.0989169329404831)","('NON-ESG', 0.11935177445411682)","('NON-ESG', 0.10407575964927673)","('NON-ESG', 0.0989169329404831)"
Line 53,"© 2019 Standard & Poor’s, a division of S&P Global.
","('Systemic_Risk_Management', 0.7544190287590027)","('Business_Ethics', 0.03158537298440933)","('Business_Model_Resilience', 0.02804259955883026)","(['Risk & Crisis Management'], 0.7544190287590027)","('NON-ESG', 0.03158537298440933)","('NON-ESG', 0.02804259955883026)"
Line 54,"All rights reserved.
","('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 55,"1 Adjusted operating margin, adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits,   restructuring and restructuring-related net charges and credits, litigation related net charges and credits, pension termination charges, certain debt extinguishment charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.
","('Business_Ethics', 0.5129973888397217)","('Management_Of_Legal_And_Regulatory_Framework', 0.2460324615240097)","('Competitive_Behavior', 0.08250627666711807)","(['Business Ethics'], 0.5129973888397217)","('NON-ESG', 0.2460324615240097)","('NON-ESG', 0.08250627666711807)"
Line 56,"1 Adjusted operating margin, adjusted earnings per share and their related growth rates are non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits,   restructuring and restructuring-related net charges and credits, litigation related net charges and credits, pension termination charges, certain debt extinguishment charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9503116607666016)","('Energy_Management', 0.008901149965822697)","('Competitive_Behavior', 0.004593710880726576)","(['Corporate Governance'], 0.9503116607666016)","('NON-ESG', 0.008901149965822697)","('NON-ESG', 0.004593710880726576)"
Line 57,"2 Operational  revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5612218379974365)","('Systemic_Risk_Management', 0.2325957864522934)","('Competitive_Behavior', 0.031772784888744354)","(['Corporate Governance'], 0.5612218379974365)","('NON-ESG', 0.2325957864522934)","('NON-ESG', 0.031772784888744354)"
Line 58,"4 Adjusted free cash flow and its related growth rate are non-GAAP measures that exclude the cash component of certain charges (credits) that are also excluded   from adjusted net income as well as any cash tax benefits of such charges.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9670511484146118)","('Business_Ethics', 0.003600139170885086)","('Energy_Management', 0.0034317111130803823)","(['Corporate Governance'], 0.9670511484146118)","('NON-ESG', 0.003600139170885086)","('NON-ESG', 0.0034317111130803823)"
Line 59,"In addition, we exclude tax settlements payments that relate to prior periods.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7367276549339294)","('Business_Ethics', 0.1641804426908493)","('Director_Removal', 0.012294664978981018)","(['Corporate Governance'], 0.7367276549339294)","('NON-ESG', 0.1641804426908493)","('NON-ESG', 0.012294664978981018)"
Line 60,"The GAAP measure that is most directly comparable to adjusted free cash flow is free cash flow on a GAAP basis.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6733338236808777)","('Systemic_Risk_Management', 0.16615670919418335)","('Business_Ethics', 0.020327165722846985)","(['Corporate Governance'], 0.6733338236808777)","('NON-ESG', 0.16615670919418335)","('NON-ESG', 0.020327165722846985)"
Line 61,"Free cash flow on a GAAP basis is calculated   by subtracting net purchases of property, plant and equipment from cash provided by operating activities; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6559758186340332)","('Systemic_Risk_Management', 0.09796614944934845)","('Business_Ethics', 0.053138069808483124)","(['Corporate Governance'], 0.6559758186340332)","('NON-ESG', 0.09796614944934845)","('NON-ESG', 0.053138069808483124)"
Line 62,"5 We define Emerging Markets as including certain countries that we believe have strong growth potential based on their economic conditions, healthcare  sectors, and our global capabilities.
","('Business_Model_Resilience', 0.37285709381103516)","('Systemic_Risk_Management', 0.23705923557281494)","('Competitive_Behavior', 0.20207752287387848)","('NON-ESG', 0.37285709381103516)","('NON-ESG', 0.23705923557281494)","('NON-ESG', 0.20207752287387848)"
Line 63,"Currently, we include 20 countries in our definition of Emerging Markets.dual-valve TAVR strategy with the ACURATE neo™  valve6 — the fastest growing valve in Europe — and  the LOTUS Edge™ Aortic Valve System7, which upon  FDA approval will provide customers with the only  fully repositionable valve system on the market.
","('Energy_Management', 0.12739777565002441)","('Product_Quality_And_Safety', 0.11830681562423706)","('Product_Design_And_Lifecycle_Management', 0.10260950028896332)","('NON-ESG', 0.12739777565002441)","('NON-ESG', 0.11830681562423706)","('NON-ESG', 0.10260950028896332)"
Line 64,"In endoluminal surgery, our goal is to transform  gastrointestinal cancer resections by developing a  comprehensive portfolio that allows the procedures  to be performed endoscopically.
","('Employee_Health_And_Safety', 0.26977795362472534)","('Access_And_Affordability', 0.10143659263849258)","('Employee_Engagement_Inclusion_And_Diversity', 0.08301745355129242)","('NON-ESG', 0.26977795362472534)","('NON-ESG', 0.10143659263849258)","('NON-ESG', 0.08301745355129242)"
Line 65,"Worldwide, 2.8  million people suffer from gastrointestinal cancers.8  There is a tremendous opportunity for a less invasive  endoscopic alternative to surgical resection of cancer  or pre-cancer to enhance patient recovery, while   also reducing length of stay, adverse events and   cost of care.
","('Employee_Health_And_Safety', 0.3690711557865143)","('Access_And_Affordability', 0.19809813797473907)","('Product_Quality_And_Safety', 0.06813213229179382)","('NON-ESG', 0.3690711557865143)","('NON-ESG', 0.19809813797473907)","('NON-ESG', 0.06813213229179382)"
Line 66,"Strategic Acquisitions An important part of our story in 2018 involved   strategic investments across business units.
","('Business_Model_Resilience', 0.7743767499923706)","('Systemic_Risk_Management', 0.06181609630584717)","('Supply_Chain_Management', 0.016030002385377884)","(['Codes of Business Conduct'], 0.7743767499923706)","('NON-ESG', 0.06181609630584717)","('NON-ESG', 0.016030002385377884)"
Line 67,"We   announced an agreement to acquire BTG plc, a   leader in minimally invasive therapies targeting   cancer and vascular diseases.
","('Access_And_Affordability', 0.27088481187820435)","('Customer_Welfare', 0.10103384405374527)","('Product_Quality_And_Safety', 0.07805962860584259)","('NON-ESG', 0.27088481187820435)","('NON-ESG', 0.10103384405374527)","('NON-ESG', 0.07805962860584259)"
Line 68,"Our Urology and   Pelvic Health business expanded our women’s  health portfolio with the addition of nVision Medical,  offering a platform for potential earlier diagnosis  of ovarian cancer — a condition for which there are  currently no recommended early screening tests.
","('Employee_Health_And_Safety', 0.6089790463447571)","('Employee_Engagement_Inclusion_And_Diversity', 0.11551967263221741)","('Product_Quality_And_Safety', 0.033977776765823364)","(['Operational Eco-Efficiency'], 0.6089790463447571)","('NON-ESG', 0.11551967263221741)","('NON-ESG', 0.033977776765823364)"
Line 69,"We also invested in novel therapies for men’s health  with Augmenix, including the SpaceOAR™ Hydrogel  System to help reduce common and debilitating side  effects that men may experience after receiving  prostate cancer radiotherapy, and NxThera, the   developer of the Rezūm™ System, a minimally  invasive treatment option for patients with benign  prostatic hyperplasia.
","('Employee_Health_And_Safety', 0.21935664117336273)","('Access_And_Affordability', 0.19733721017837524)","('Employee_Engagement_Inclusion_And_Diversity', 0.13163210451602936)","('NON-ESG', 0.21935664117336273)","('NON-ESG', 0.19733721017837524)","('NON-ESG', 0.13163210451602936)"
Line 70,"Adding to our Interventional  Cardiology business, we acquired Claret Medical, and  its Sentinel™ Cerebral Protection System, providing a  new layer of safety and peace of mind for physicians  and their patients undergoing TAVR procedures.
","('Employee_Health_And_Safety', 0.6489429473876953)","('Product_Quality_And_Safety', 0.1793959140777588)","('Product_Design_And_Lifecycle_Management', 0.029019257053732872)","(['Operational Eco-Efficiency'], 0.6489429473876953)","('NON-ESG', 0.1793959140777588)","('NON-ESG', 0.029019257053732872)"
Line 71,"With the acquisition of Cryterion Medical, our  Electrophysiology business added to our portfolio a  single-shot cryoablation platform for atrial fibrillation  treatment, making Boston Scientific the first to offer  physicians both cryothermal and radiofrequency   (RF) single-shot, balloon-based ablation therapies.
","('Customer_Welfare', 0.256816029548645)","('Competitive_Behavior', 0.15874555706977844)","('GHG_Emissions', 0.07305639237165451)","('NON-ESG', 0.256816029548645)","('NON-ESG', 0.15874555706977844)","('NON-ESG', 0.07305639237165451)"
Line 72,"PURSUIT OF EXCELLENCE We constantly strive to improve our offerings to  patients and healthcare systems with technology  advancements that are supported with a strong   body of clinical evidence.
","('Access_And_Affordability', 0.1659867763519287)","('Customer_Welfare', 0.11632883548736572)","('Employee_Engagement_Inclusion_And_Diversity', 0.11570358276367188)","('NON-ESG', 0.1659867763519287)","('NON-ESG', 0.11632883548736572)","('NON-ESG', 0.11570358276367188)"
Line 73,"Our teams work with a  sense of urgency and purpose to bring forward   new solutions with quality and safety as the top  priority.
","('Employee_Health_And_Safety', 0.5916435122489929)","('Product_Quality_And_Safety', 0.2644909918308258)","('Product_Design_And_Lifecycle_Management', 0.02121073007583618)","(['Operational Eco-Efficiency'], 0.5916435122489929)","('NON-ESG', 0.2644909918308258)","('NON-ESG', 0.02121073007583618)"
Line 74,"A disciplined portfolio management strategy  guides our investment in clinical trials and research  and development, and as we support our customers   and champion their transition to value-based care,  we are gaining new perspectives that help us   innovate and improve patient outcomes."" Our approach to innovation  includes a mix of organic   programs, collaborations   and strategic acquisitions   that are focused on enriching  our capabilities in the   medical specialties that we  serve.
","('Business_Model_Resilience', 0.24783974885940552)","('Customer_Welfare', 0.14477568864822388)","('Product_Design_And_Lifecycle_Management', 0.09000734984874725)","('NON-ESG', 0.24783974885940552)","('NON-ESG', 0.14477568864822388)","('NON-ESG', 0.09000734984874725)"
Line 75,"We believe that this  clinical depth and category  leadership strategy are   helping us create value   for patients, physicians and  payers and enabling us   to grow faster than our   underlying markets and   most peers.""  — Mike Mahoney    A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.
","('Business_Model_Resilience', 0.32532671093940735)","('Competitive_Behavior', 0.2429915815591812)","('Systemic_Risk_Management', 0.11820121109485626)","('NON-ESG', 0.32532671093940735)","('NON-ESG', 0.2429915815591812)","('NON-ESG', 0.11820121109485626)"
Line 76,"6 Caution: ACURATE neo is an investigational device in the U.S. Not available for sale.
","('Selling_Practices_And_Product_Labeling', 0.36185556650161743)","('Customer_Welfare', 0.3145630359649658)","('Product_Quality_And_Safety', 0.06279180943965912)","('NON-ESG', 0.36185556650161743)","('NON-ESG', 0.3145630359649658)","('NON-ESG', 0.06279180943965912)"
Line 77,"CE Marked.
","('Labor_Practices', 0.08904173225164413)","('Business_Model_Resilience', 0.08857164531946182)","('Customer_Privacy', 0.06937264651060104)","('NON-ESG', 0.08904173225164413)","('NON-ESG', 0.08857164531946182)","('NON-ESG', 0.06937264651060104)"
Line 78,"7 Caution: LOTUS Edge Aortic Valve System is an investigational device in the U.S. and not available for sale.
","('Employee_Health_And_Safety', 0.3833889961242676)","('Product_Quality_And_Safety', 0.09484657645225525)","('Customer_Welfare', 0.062020786106586456)","('NON-ESG', 0.3833889961242676)","('NON-ESG', 0.09484657645225525)","('NON-ESG', 0.062020786106586456)"
Line 79,"CE Marked.
","('Labor_Practices', 0.08904173225164413)","('Business_Model_Resilience', 0.08857164531946182)","('Customer_Privacy', 0.06937264651060104)","('NON-ESG', 0.08904173225164413)","('NON-ESG', 0.08857164531946182)","('NON-ESG', 0.06937264651060104)"
Line 80,"8 https://www.who.int/news-room/fact-sheets/detail/cancer.
","('Access_And_Affordability', 0.16513513028621674)","('Management_Of_Legal_And_Regulatory_Framework', 0.12439969182014465)","('Ecological_Impacts', 0.08459926396608353)","('NON-ESG', 0.16513513028621674)","('NON-ESG', 0.12439969182014465)","('NON-ESG', 0.08459926396608353)"
Line 81,"In men’s health we are addressing benign prostatic  hyperplasia (BPH) treatment with Rezūm™ Water  Vapor Therapy, a minimally invasive treatment we  acquired via NxThera.
","('Access_And_Affordability', 0.3509449064731598)","('Employee_Health_And_Safety', 0.16580478847026825)","('Employee_Engagement_Inclusion_And_Diversity', 0.06776781380176544)","('NON-ESG', 0.3509449064731598)","('NON-ESG', 0.16580478847026825)","('NON-ESG', 0.06776781380176544)"
Line 82,"BPH is an enlargement of the  prostate that affects 110 million men worldwide   and can cause problems with urinary and sexual   function.13,14 A four-year randomized clinical trial  recently demonstrated that patients treated with  Rezūm Therapy experienced significant and   sustained improvement in their symptoms and  quality of life.
","('Employee_Health_And_Safety', 0.3720347583293915)","('Employee_Engagement_Inclusion_And_Diversity', 0.16173627972602844)","('Access_And_Affordability', 0.09420466423034668)","('NON-ESG', 0.3720347583293915)","('NON-ESG', 0.16173627972602844)","('NON-ESG', 0.09420466423034668)"
Line 83,"Supporting Value-Based Care In addition to providing technologies that improve  patient outcomes, we are focused on diagnostics,  digital health and services that can take cost out of  the healthcare system and improve how hospitals  operate.
","('Access_And_Affordability', 0.5650365352630615)","('Customer_Welfare', 0.07823496311903)","('Energy_Management', 0.07179035246372223)","(['Health Outcome Contribution'], 0.5650365352630615)","('NON-ESG', 0.07823496311903)","('NON-ESG', 0.07179035246372223)"
Line 84,"Understanding the broader challenges healthcare  systems face allows us to make decisions on new  technologies and shift our portfolio mix to deliver  technologies that will help customers meet their   outcome and economic objectives.
","('Business_Model_Resilience', 0.22924980521202087)","('Product_Design_And_Lifecycle_Management', 0.1596209555864334)","('Supply_Chain_Management', 0.1147225871682167)","('NON-ESG', 0.22924980521202087)","('NON-ESG', 0.1596209555864334)","('NON-ESG', 0.1147225871682167)"
Line 85,"An example is   our RESONATE™ family of devices, which includes  our HeartLogic™ Heart Failure Diagnostic.
","('Employee_Health_And_Safety', 0.28438419103622437)","('Critical_Incident_Risk_Management', 0.27753448486328125)","('Product_Quality_And_Safety', 0.05606875568628311)","('NON-ESG', 0.28438419103622437)","('NON-ESG', 0.27753448486328125)","('NON-ESG', 0.05606875568628311)"
Line 86,"Annually,   heart failure accounts for more than 1.1 million   hospitalizations15 with 25 percent of heart failure  patients re-admitted within 30 days of initial hospital- ization.16,17 The HeartLogic diagnostic tool tracks key  physiological trends related to heart failure and was  validated to predict heart failure events more than Firsts in Vascular Interventional Technology Our Peripheral Interventions business launched   the Eluvia™ Drug-Eluting Vascular Stent System,   specifically developed for the treatment of peripheral  artery disease (PAD).
","('Employee_Health_And_Safety', 0.7461166381835938)","('Critical_Incident_Risk_Management', 0.09751881659030914)","('Access_And_Affordability', 0.015372857451438904)","(['Operational Eco-Efficiency'], 0.7461166381835938)","('NON-ESG', 0.09751881659030914)","('NON-ESG', 0.015372857451438904)"
Line 87,"Annually,   heart failure accounts for more than 1.1 million   hospitalizations15 with 25 percent of heart failure  patients re-admitted within 30 days of initial hospital- ization.16,17 The HeartLogic diagnostic tool tracks key  physiological trends related to heart failure and was  validated to predict heart failure events more than Firsts in Vascular Interventional Technology Our Peripheral Interventions business launched   the Eluvia™ Drug-Eluting Vascular Stent System,   specifically developed for the treatment of peripheral  artery disease (PAD).
","('Employee_Health_And_Safety', 0.17503029108047485)","('Access_And_Affordability', 0.15540534257888794)","('Business_Ethics', 0.0789763331413269)","('NON-ESG', 0.17503029108047485)","('NON-ESG', 0.15540534257888794)","('NON-ESG', 0.0789763331413269)"
Line 88,"The Eluvia System is the first   peripheral vascular interventional technology  approved in the U.S. to offer sustained release of  an antiproliferative drug to treat patients with PAD.
","('Access_And_Affordability', 0.23584063351154327)","('Customer_Welfare', 0.1584644764661789)","('Employee_Health_And_Safety', 0.07813949882984161)","('NON-ESG', 0.23584063351154327)","('NON-ESG', 0.1584644764661789)","('NON-ESG', 0.07813949882984161)"
Line 89,"Approximately 8.5 million people in the U.S. are   affected by PAD, which occurs when fatty or calcified  atherosclerotic material builds up on the walls of   the arteries of the legs.9  Eleven percent of patients with PAD develop critical  limb ischemia (CLI), a chronic lack of blood supply to  the lower legs.10,11 Research has shown that within  one year of being diagnosed with CLI, 30 percent of  patients will have undergone amputation.
","('Employee_Health_And_Safety', 0.8008361458778381)","('Employee_Engagement_Inclusion_And_Diversity', 0.03687082231044769)","('Access_And_Affordability', 0.01556343026459217)","(['Operational Eco-Efficiency'], 0.8008361458778381)","('NON-ESG', 0.03687082231044769)","('NON-ESG', 0.01556343026459217)"
Line 90,"To address  this clinical need, we began enrollment in the SAVAL  Trial, studying the SAVAL™ Below the Knee (BTK)  Drug-Eluting Stent System, the first stent designed to  treat CLI.
","('Customer_Welfare', 0.24675635993480682)","('Competitive_Behavior', 0.14540010690689087)","('Access_And_Affordability', 0.11383400112390518)","('NON-ESG', 0.24675635993480682)","('NON-ESG', 0.14540010690689087)","('NON-ESG', 0.11383400112390518)"
Line 91,"Due to the absence of effective treatment  options for patients suffering from CLI, the FDA   granted the Expedited Access Pathway (EAP)   designation to the SAVAL BTK Stent System, the   first CLI device to receive this designation.
","('Access_And_Affordability', 0.4776080250740051)","('Product_Quality_And_Safety', 0.09395269304513931)","('Customer_Welfare', 0.07262412458658218)","('NON-ESG', 0.4776080250740051)","('NON-ESG', 0.09395269304513931)","('NON-ESG', 0.07262412458658218)"
Line 92,"Helping Physicians Tailor Therapy in Neuromodulation Our Neuromodulation business recently launched  the Vercise™ Primary Cell (PC) and Vercise Gevia™  Deep Brain Stimulation (DBS) Systems with the  Cartesia™ Directional Lead.
","('Access_And_Affordability', 0.33312398195266724)","('Customer_Welfare', 0.10541534423828125)","('Competitive_Behavior', 0.06693945825099945)","('NON-ESG', 0.33312398195266724)","('NON-ESG', 0.10541534423828125)","('NON-ESG', 0.06693945825099945)"
Line 93,"The new systems feature technology designed to allow physicians to control  the range, shape, position and direction of electrical  stimulation to treat the symptoms of Parkinson's   disease (PD) through highly-personalized therapy.
","('Employee_Health_And_Safety', 0.32403460144996643)","('Energy_Management', 0.09295478463172913)","('Access_And_Affordability', 0.06929843872785568)","('NON-ESG', 0.32403460144996643)","('NON-ESG', 0.09295478463172913)","('NON-ESG', 0.06929843872785568)"
Line 94,"More than 10 million people are living with PD,12 and  the progression of the disease requires a therapy  that can evolve with the patient over time.
","('Access_And_Affordability', 0.4761715829372406)","('Employee_Health_And_Safety', 0.0983353927731514)","('Product_Quality_And_Safety', 0.06659255176782608)","('NON-ESG', 0.4761715829372406)","('NON-ESG', 0.0983353927731514)","('NON-ESG', 0.06659255176782608)"
Line 95,"The  INTREPID study further documented the safety and  effectiveness of the Vercise DBS System as an   important treatment option for patients living with  this debilitating condition.
","('Access_And_Affordability', 0.3065747618675232)","('Employee_Health_And_Safety', 0.24664545059204102)","('Product_Quality_And_Safety', 0.12095751613378525)","('NON-ESG', 0.3065747618675232)","('NON-ESG', 0.24664545059204102)","('NON-ESG', 0.12095751613378525)"
Line 96,"We also invested in research and expanded treat - ment options for chronic pain with the Spectra  WaveWriter™ Spinal Cord Stimulator (SCS) System,  a potential non-opioid solution for the millions of  people suffering from debilitating lower limb and  back pain.
","('Employee_Health_And_Safety', 0.9357035756111145)","('Employee_Engagement_Inclusion_And_Diversity', 0.0066205523908138275)","('Product_Design_And_Lifecycle_Management', 0.00397819047793746)","(['Operational Eco-Efficiency'], 0.9357035756111145)","('NON-ESG', 0.0066205523908138275)","('NON-ESG', 0.00397819047793746)"
Line 97,"Positive results from the WHISPER study  and WaveWriter real-world outcomes study provided  further evidence of the value of providing patients  with multiple waveform therapies for the relief of  chronic pain.
","('Employee_Health_And_Safety', 0.8783676624298096)","('Critical_Incident_Risk_Management', 0.014227323234081268)","('Access_And_Affordability', 0.012242259457707405)","(['Operational Eco-Efficiency'], 0.8783676624298096)","('NON-ESG', 0.014227323234081268)","('NON-ESG', 0.012242259457707405)"
Line 98,"Innovation in Flexible Ureteroscopy and Men’s Health The Boston Scientific Urology and Pelvic Health   business launched the LithoVue Empower™   Retrieval Deployment Device.
","('Employee_Health_And_Safety', 0.7525804042816162)","('Employee_Engagement_Inclusion_And_Diversity', 0.04105057939887047)","('Customer_Welfare', 0.029274992644786835)","(['Operational Eco-Efficiency'], 0.7525804042816162)","('NON-ESG', 0.04105057939887047)","('NON-ESG', 0.029274992644786835)"
Line 99,"One in eleven people  are affected by kidney stones, and the LithoVue   Empower Device is designed to enable this procedure   to be performed more efficiently by one clinician   and is an example of how we are adapting our   technology to meet clinical needs.
","('Access_And_Affordability', 0.3704550266265869)","('Employee_Health_And_Safety', 0.28647729754447937)","('Employee_Engagement_Inclusion_And_Diversity', 0.0516459085047245)","('NON-ESG', 0.3704550266265869)","('NON-ESG', 0.28647729754447937)","('NON-ESG', 0.0516459085047245)"
Line 100,"A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4466809630393982)","('GHG_Emissions', 0.11226976662874222)","('Ecological_Impacts', 0.10012765973806381)","('NON-ESG', 0.4466809630393982)","('NON-ESG', 0.11226976662874222)","('NON-ESG', 0.10012765973806381)"
Line 101,"9 Centers for Disease Control: https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_pad.htm Accessed February 2019    10 Mozaffarian D, Benjamin EJ, Go AS, et al.
","('Access_And_Affordability', 0.17051266133785248)","('Systemic_Risk_Management', 0.15223900973796844)","('Management_Of_Legal_And_Regulatory_Framework', 0.13201330602169037)","('NON-ESG', 0.17051266133785248)","('NON-ESG', 0.15223900973796844)","('NON-ESG', 0.13201330602169037)"
Line 102,"Heart disease and stroke statistics—2015 update: a report from the American Heart Association.
","('Employee_Health_And_Safety', 0.2286490499973297)","('Product_Quality_And_Safety', 0.08042022585868835)","('Systemic_Risk_Management', 0.06833472847938538)","('NON-ESG', 0.2286490499973297)","('NON-ESG', 0.08042022585868835)","('NON-ESG', 0.06833472847938538)"
Line 103,"Circulation .
","('Management_Of_Legal_And_Regulatory_Framework', 0.12892770767211914)","('Data_Security', 0.09273944795131683)","('Energy_Management', 0.07897735387086868)","('NON-ESG', 0.12892770767211914)","('NON-ESG', 0.09273944795131683)","('NON-ESG', 0.07897735387086868)"
Line 104,"2015 Jan 27;131(4):e29-322.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48486563563346863)","('Competitive_Behavior', 0.15196655690670013)","('Business_Ethics', 0.062468044459819794)","('NON-ESG', 0.48486563563346863)","('NON-ESG', 0.15196655690670013)","('NON-ESG', 0.062468044459819794)"
Line 105,"Cited in  Clarivate Analytics, Incidence and Prevalence Database.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2477009892463684)","('Employee_Health_And_Safety', 0.13690140843391418)","('Access_And_Affordability', 0.11648088693618774)","('NON-ESG', 0.2477009892463684)","('NON-ESG', 0.13690140843391418)","('NON-ESG', 0.11648088693618774)"
Line 106,"11 Nehler MR, Duval S, Diao L, et al.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31794312596321106)","('Competitive_Behavior', 0.114048533141613)","('GHG_Emissions', 0.10741505771875381)","('NON-ESG', 0.31794312596321106)","('NON-ESG', 0.114048533141613)","('NON-ESG', 0.10741505771875381)"
Line 107,"Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population.
","('Employee_Health_And_Safety', 0.6020166873931885)","('Critical_Incident_Risk_Management', 0.07798100262880325)","('Access_And_Affordability', 0.07641595602035522)","(['Operational Eco-Efficiency'], 0.6020166873931885)","('NON-ESG', 0.07798100262880325)","('NON-ESG', 0.07641595602035522)"
Line 108,"J Vasc Surg .
","('Management_Of_Legal_And_Regulatory_Framework', 0.27360886335372925)","('Business_Ethics', 0.0879521295428276)","('Access_And_Affordability', 0.07672812789678574)","('NON-ESG', 0.27360886335372925)","('NON-ESG', 0.0879521295428276)","('NON-ESG', 0.07672812789678574)"
Line 109,"2014 Sep;60(3):686-95.e2.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3289801776409149)","('Competitive_Behavior', 0.16295184195041656)","('GHG_Emissions', 0.044351726770401)","('NON-ESG', 0.3289801776409149)","('NON-ESG', 0.16295184195041656)","('NON-ESG', 0.044351726770401)"
Line 110,"12 http://parkinson.org/Understanding-Parkinsons/Causes-and-Statistics/ Statistics    13 https://www.healthline.com/health/enlarged-prostate#symptoms    14 https://www.physiciansweekly.com/tag/benign-prostatic-hyperplasia/    15 Boehmer JP, Hariharan R, Devecchi FG, et al.
","('Employee_Health_And_Safety', 0.2710886597633362)","('Employee_Engagement_Inclusion_And_Diversity', 0.13956841826438904)","('Ecological_Impacts', 0.09339873492717743)","('NON-ESG', 0.2710886597633362)","('NON-ESG', 0.13956841826438904)","('NON-ESG', 0.09339873492717743)"
Line 111,"A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from  the MultiSENSE study.
","('Employee_Health_And_Safety', 0.5724717974662781)","('Critical_Incident_Risk_Management', 0.16115470230579376)","('Access_And_Affordability', 0.02695627696812153)","(['Operational Eco-Efficiency'], 0.5724717974662781)","('NON-ESG', 0.16115470230579376)","('NON-ESG', 0.02695627696812153)"
Line 112,"JACC Heart Fail .
","('Business_Ethics', 0.45626702904701233)","('Systemic_Risk_Management', 0.12038931995630264)","('Critical_Incident_Risk_Management', 0.0566781610250473)","('NON-ESG', 0.45626702904701233)","('NON-ESG', 0.12038931995630264)","('NON-ESG', 0.0566781610250473)"
Line 113,"2017 Mar;5(3):216-25    16 Fonarow GC, Abraham WT, Albert NM, et al.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3920164406299591)","('Competitive_Behavior', 0.10092975199222565)","('Business_Ethics', 0.06287882477045059)","('NON-ESG', 0.3920164406299591)","('NON-ESG', 0.10092975199222565)","('NON-ESG', 0.06287882477045059)"
Line 114,"Association between performance measures and clinical outcomes for patients hospitalized with heart failure.
","('Employee_Health_And_Safety', 0.5917704105377197)","('Critical_Incident_Risk_Management', 0.08985645323991776)","('Access_And_Affordability', 0.06756364554166794)","(['Operational Eco-Efficiency'], 0.5917704105377197)","('NON-ESG', 0.08985645323991776)","('NON-ESG', 0.06756364554166794)"
Line 115,"JAMA .
","('Data_Security', 0.19058115780353546)","('Business_Ethics', 0.12321178615093231)","('Employee_Engagement_Inclusion_And_Diversity', 0.06833604723215103)","('NON-ESG', 0.19058115780353546)","('NON-ESG', 0.12321178615093231)","('NON-ESG', 0.06833604723215103)"
Line 116,"2007 Jan 3;297(1):61-70.
","('Management_Of_Legal_And_Regulatory_Framework', 0.40228235721588135)","('Competitive_Behavior', 0.07059188932180405)","('Data_Security', 0.0665963739156723)","('NON-ESG', 0.40228235721588135)","('NON-ESG', 0.07059188932180405)","('NON-ESG', 0.0665963739156723)"
Line 117,"17 O’Connor CM, Abraham WT, Albert NM, et al.
","('Management_Of_Legal_And_Regulatory_Framework', 0.40901339054107666)","('Ecological_Impacts', 0.08470509201288223)","('Human_Rights_And_Community_Relations', 0.061899881809949875)","('NON-ESG', 0.40901339054107666)","('NON-ESG', 0.08470509201288223)","('NON-ESG', 0.061899881809949875)"
Line 118,"Predictors of  mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF).
","('Employee_Health_And_Safety', 0.7369653582572937)","('Critical_Incident_Risk_Management', 0.07989125698804855)","('Access_And_Affordability', 0.03441077098250389)","(['Operational Eco-Efficiency'], 0.7369653582572937)","('NON-ESG', 0.07989125698804855)","('NON-ESG', 0.03441077098250389)"
Line 119,"Am Heart J .
","('Access_And_Affordability', 0.16034331917762756)","('Management_Of_Legal_And_Regulatory_Framework', 0.11266522854566574)","('Business_Ethics', 0.0975484773516655)","('NON-ESG', 0.16034331917762756)","('NON-ESG', 0.11266522854566574)","('NON-ESG', 0.0975484773516655)"
Line 120,"2008 Oct;156(4):662-73.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4608129858970642)","('Competitive_Behavior', 0.06052035465836525)","('Data_Security', 0.049840185791254044)","('NON-ESG', 0.4608129858970642)","('NON-ESG', 0.06052035465836525)","('NON-ESG', 0.049840185791254044)"
Line 121,"faced barriers accessing quality healthcare, our Close  the Gap teams shared data with healthcare providers  to help them develop action plans and track progress  in eliminating inequities among high-risk patients.
","('Access_And_Affordability', 0.7727558016777039)","('Systemic_Risk_Management', 0.02539842016994953)","('Critical_Incident_Risk_Management', 0.019355712458491325)","(['Health Outcome Contribution'], 0.7727558016777039)","('NON-ESG', 0.02539842016994953)","('NON-ESG', 0.019355712458491325)"
Line 122,"Our health equity efforts also included community  education and outreach to populations most affected  by disparities in heart disease treatment, assistance  with continuing healthcare professional education  and advocacy for adherence to clinical guidelines to  help ensure equitable care.
","('Access_And_Affordability', 0.8910952806472778)","('Product_Quality_And_Safety', 0.011280118487775326)","('Employee_Health_And_Safety', 0.010706964880228043)","(['Health Outcome Contribution'], 0.8910952806472778)","('NON-ESG', 0.011280118487775326)","('NON-ESG', 0.010706964880228043)"
Line 123,"In addition to advancing science and improving pa- tient health and access to care, we have the privilege  and responsibility to use our resources to enrich  communities.
","('Access_And_Affordability', 0.8970799446105957)","('Human_Rights_And_Community_Relations', 0.017621511593461037)","('Employee_Health_And_Safety', 0.01042705588042736)","(['Health Outcome Contribution'], 0.8970799446105957)","('NON-ESG', 0.017621511593461037)","('NON-ESG', 0.01042705588042736)"
Line 124,"Boston Scientific employees around  the world continue to invest thousands of hours each  year to support environmental restoration projects  and programs to improve local schools and commu- nities.
","('Ecological_Impacts', 0.9396368265151978)","('Human_Rights_And_Community_Relations', 0.012642784044146538)","('GHG_Emissions', 0.006169927306473255)","(['Natural Capital'], 0.9396368265151978)","('NON-ESG', 0.012642784044146538)","('NON-ESG', 0.006169927306473255)"
Line 125,"Many of these programs are fueling the next  generation of life science professionals by encour - aging students to achieve in Science, Technology,  Engineering and Math (STEM).
","('Employee_Engagement_Inclusion_And_Diversity', 0.6416851282119751)","('Access_And_Affordability', 0.06710121780633926)","('Product_Design_And_Lifecycle_Management', 0.03813673183321953)","(['Human Capital Development'], 0.6416851282119751)","('NON-ESG', 0.06710121780633926)","('NON-ESG', 0.03813673183321953)"
Line 126,"We also recognize  the need to ensure that the manufacturing of our  products does not have a negative impact on the  environment and are reducing our global environ- mental footprint through increased use of renewable  and cleaner energy sources.
","('Product_Design_And_Lifecycle_Management', 0.957738995552063)","('Energy_Management', 0.01023805607110262)","('Product_Quality_And_Safety', 0.0036199900787323713)","(['Product Stewardship'], 0.957738995552063)","('NON-ESG', 0.01023805607110262)","('NON-ESG', 0.0036199900787323713)"
Line 127,"In 2018 we reduced our  greenhouse gas emissions 47 percent and decreased  water consumption 30 percent relative to our 2009  measurement baseline.
","('GHG_Emissions', 0.9686070680618286)","('Ecological_Impacts', 0.003465033369138837)","('Management_Of_Legal_And_Regulatory_Framework', 0.0028744935989379883)","(['Climate Change'], 0.9686070680618286)","('NON-ESG', 0.003465033369138837)","('NON-ESG', 0.0028744935989379883)"
Line 128,"Our commitment to sustain- ability and making a positive environmental impact   is an important part of how we live by our values.four weeks in advance,15 allowing earlier intervention  with patients and avoiding hospitalizations by   shifting reactive treatment to proactive care.
","('Access_And_Affordability', 0.6028258204460144)","('Employee_Health_And_Safety', 0.17792099714279175)","('Critical_Incident_Risk_Management', 0.04473627358675003)","(['Health Outcome Contribution'], 0.6028258204460144)","('NON-ESG', 0.17792099714279175)","('NON-ESG', 0.04473627358675003)"
Line 129,"Another area of focus is the work underway with   our Endoscopy business to build a comprehensive   product portfolio designed to help customers   meet or exceed guidelines for infection prevention.
","('Employee_Health_And_Safety', 0.5110052824020386)","('Product_Quality_And_Safety', 0.1657494753599167)","('Access_And_Affordability', 0.05416868254542351)","(['Operational Eco-Efficiency'], 0.5110052824020386)","('NON-ESG', 0.1657494753599167)","('NON-ESG', 0.05416868254542351)"
Line 130,"The Exalt™ Single-Use Duodenoscope18 has the   potential to reduce cross-contamination risk,   minimize capital investment and reduce reprocessing  issues and is targeted to launch by the end of 2019.
","('Product_Design_And_Lifecycle_Management', 0.2409498691558838)","('Supply_Chain_Management', 0.20073077082633972)","('Systemic_Risk_Management', 0.05535200238227844)","('NON-ESG', 0.2409498691558838)","('NON-ESG', 0.20073077082633972)","('NON-ESG', 0.05535200238227844)"
Line 131,"We are also helping customers achieve and sustain  cost, quality and growth targets with our ADVANTICS™  Innovative Healthcare Solutions portfolio.
","('Product_Design_And_Lifecycle_Management', 0.3315920829772949)","('Business_Model_Resilience', 0.14258013665676117)","('Supply_Chain_Management', 0.1376253068447113)","('NON-ESG', 0.3315920829772949)","('NON-ESG', 0.14258013665676117)","('NON-ESG', 0.1376253068447113)"
Line 132,"Examples  include standardizing care for patients with chronic  cardiovascular diseases and performance optimiza- tion solutions focused on patient flow.DEEPEST COLLABORATION Significant unmet needs for patient-centered   innovation remain, and the biggest advances are  made through collaboration between clinicians,  researchers, care providers, patients, regulators  and industry.
","('Access_And_Affordability', 0.5876209139823914)","('Customer_Welfare', 0.06516395509243011)","('Employee_Health_And_Safety', 0.03698685020208359)","(['Health Outcome Contribution'], 0.5876209139823914)","('NON-ESG', 0.06516395509243011)","('NON-ESG', 0.03698685020208359)"
Line 133,"We maintain a strong base of clinical  evidence to support the safety and efficacy of our  devices, with data gathered from bench testing,  randomized controlled trials and ongoing real-world  evidence.
","('Product_Quality_And_Safety', 0.6337441802024841)","('Selling_Practices_And_Product_Labeling', 0.11205124109983444)","('Customer_Welfare', 0.044172801077365875)","(['Product Quality & Recall Management'], 0.6337441802024841)","('NON-ESG', 0.11205124109983444)","('NON-ESG', 0.044172801077365875)"
Line 134,"To meet needs for localized training and  innovation, we have established 14 Institutes for  Advancing Science located in the Americas, Africa,  Asia and Europe.
","('Access_And_Affordability', 0.26713165640830994)","('Employee_Engagement_Inclusion_And_Diversity', 0.11222582310438156)","('Customer_Welfare', 0.06467340886592865)","('NON-ESG', 0.26713165640830994)","('NON-ESG', 0.11222582310438156)","('NON-ESG', 0.06467340886592865)"
Line 135,"We also take a global approach to  research and development at our four research and  development design centers, with work underway to  expand capabilities in India, Costa Rica and China.
","('Access_And_Affordability', 0.24345870316028595)","('Business_Model_Resilience', 0.12074890732765198)","('Employee_Engagement_Inclusion_And_Diversity', 0.0945129245519638)","('NON-ESG', 0.24345870316028595)","('NON-ESG', 0.12074890732765198)","('NON-ESG', 0.0945129245519638)"
Line 136,"Health Equity & Enriching Our Communities In 2018 we prioritized efforts to promote health  equity and make a sustainable impact through our  Close the Gap initiative.
","('Access_And_Affordability', 0.4993608891963959)","('Human_Rights_And_Community_Relations', 0.19200265407562256)","('Employee_Health_And_Safety', 0.05766496807336807)","('NON-ESG', 0.4993608891963959)","('NON-ESG', 0.19200265407562256)","('NON-ESG', 0.05766496807336807)"
Line 137,"Our primary focus in this  work was cardiovascular disease and treatment  disparities among women and minority populations.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9238751530647278)","('Employee_Health_And_Safety', 0.011079134419560432)","('Access_And_Affordability', 0.010690602473914623)","(['Human Capital Development'], 0.9238751530647278)","('NON-ESG', 0.011079134419560432)","('NON-ESG', 0.010690602473914623)"
Line 138,"In communities across the U.S. that have traditionally  A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p."" In all that we accomplished over the course of the year, there  is one common denominator that gave us a distinct edge:  the winning spirit of our people.
","('Human_Rights_And_Community_Relations', 0.4327819347381592)","('Business_Model_Resilience', 0.11876598745584488)","('Competitive_Behavior', 0.08306990563869476)","('NON-ESG', 0.4327819347381592)","('NON-ESG', 0.11876598745584488)","('NON-ESG', 0.08306990563869476)"
Line 139,"Our employees are the   talented and dedicated force behind every Boston Scientific  milestone.""  — Mike Mahoney             15 Boehmer JP, Hariharan R, Devecchi FG, et al.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4918312430381775)","('Employee_Health_And_Safety', 0.06024758145213127)","('Access_And_Affordability', 0.04389526695013046)","('NON-ESG', 0.4918312430381775)","('NON-ESG', 0.06024758145213127)","('NON-ESG', 0.04389526695013046)"
Line 140,"A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study.
","('Employee_Health_And_Safety', 0.5724717974662781)","('Critical_Incident_Risk_Management', 0.16115470230579376)","('Access_And_Affordability', 0.02695627696812153)","(['Operational Eco-Efficiency'], 0.5724717974662781)","('NON-ESG', 0.16115470230579376)","('NON-ESG', 0.02695627696812153)"
Line 141,"JACC Heart Fail .
","('Business_Ethics', 0.45626702904701233)","('Systemic_Risk_Management', 0.12038931995630264)","('Critical_Incident_Risk_Management', 0.0566781610250473)","('NON-ESG', 0.45626702904701233)","('NON-ESG', 0.12038931995630264)","('NON-ESG', 0.0566781610250473)"
Line 142,"2017 Mar;5(3):216-25    18 Device under development.
","('Management_Of_Legal_And_Regulatory_Framework', 0.18937943875789642)","('Product_Design_And_Lifecycle_Management', 0.13769184052944183)","('Business_Model_Resilience', 0.10325692594051361)","('NON-ESG', 0.18937943875789642)","('NON-ESG', 0.13769184052944183)","('NON-ESG', 0.10325692594051361)"
Line 143,"Not available for sale or use worldwide."" I think perhaps one of the  most important metrics in   a company beyond the   financials is employee   engagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9062976837158203)","('Employee_Health_And_Safety', 0.008678529411554337)","('Human_Rights_And_Community_Relations', 0.008615638129413128)","(['Human Capital Development'], 0.9062976837158203)","('NON-ESG', 0.008678529411554337)","('NON-ESG', 0.008615638129413128)"
Line 144,"I’m very proud  of the high engagement  levels we have across the  business, the extra effort our  employees make, and the  teamwork they demonstrate  to deliver for patients who  really need our solutions.""   — Mike Mahoney   levels we have across the business, the extra effort  our employees make, and the teamwork they  demonstrate to deliver for patients who really need  our solutions.
","('Access_And_Affordability', 0.35464298725128174)","('Employee_Health_And_Safety', 0.07203374058008194)","('Customer_Welfare', 0.06684897094964981)","('NON-ESG', 0.35464298725128174)","('NON-ESG', 0.07203374058008194)","('NON-ESG', 0.06684897094964981)"
Line 145,"All of us at Boston Scientific understand  that we need to continuously push ourselves to  make a greater contribution to patients around the  world.
","('Access_And_Affordability', 0.5362234115600586)","('Customer_Welfare', 0.06530401855707169)","('Management_Of_Legal_And_Regulatory_Framework', 0.05264591798186302)","(['Health Outcome Contribution'], 0.5362234115600586)","('NON-ESG', 0.06530401855707169)","('NON-ESG', 0.05264591798186302)"
Line 146,"Looking ahead, I know that the community and   culture we have built will equip us to adapt to the  needs of the rapidly evolving healthcare landscape.
","('Human_Rights_And_Community_Relations', 0.2629047930240631)","('Business_Model_Resilience', 0.2258015125989914)","('Employee_Engagement_Inclusion_And_Diversity', 0.19082897901535034)","('NON-ESG', 0.2629047930240631)","('NON-ESG', 0.2258015125989914)","('NON-ESG', 0.19082897901535034)"
Line 147,"Even after a year of so many accomplishments, I   can say with confidence that our most meaningful  and exciting work is yet to come.
","('Employee_Engagement_Inclusion_And_Diversity', 0.26759323477745056)","('Human_Rights_And_Community_Relations', 0.11392351984977722)","('Business_Model_Resilience', 0.10767128318548203)","('NON-ESG', 0.26759323477745056)","('NON-ESG', 0.11392351984977722)","('NON-ESG', 0.10767128318548203)"
Line 148,"I commend our employees for the passion they   bring to our mission every day.
","('Employee_Engagement_Inclusion_And_Diversity', 0.21387116611003876)","('Human_Rights_And_Community_Relations', 0.13377301394939423)","('Employee_Health_And_Safety', 0.09972517937421799)","('NON-ESG', 0.21387116611003876)","('NON-ESG', 0.13377301394939423)","('NON-ESG', 0.09972517937421799)"
Line 149,"On behalf of all of   us, I want to thank our Board of Directors for their  commitment and service to Boston Scientific.
","('Director_Removal', 0.6832588315010071)","('Management_Of_Legal_And_Regulatory_Framework', 0.03706732764840126)","('Business_Model_Resilience', 0.03483668342232704)","(['Anti-Crime Policy & Measures'], 0.6832588315010071)","('NON-ESG', 0.03706732764840126)","('NON-ESG', 0.03483668342232704)"
Line 150,"And I extend our sincere gratitude to you, our   shareholders, for your continued support.
","('Director_Removal', 0.19325660169124603)","('Business_Model_Resilience', 0.1387256234884262)","('Customer_Privacy', 0.09494487196207047)","('NON-ESG', 0.19325660169124603)","('NON-ESG', 0.1387256234884262)","('NON-ESG', 0.09494487196207047)"
Line 151,"I am  fortunate to lead this incredible company and I look  forward to all that we will accomplish in the year  ahead.
","('Business_Model_Resilience', 0.49980393052101135)","('Employee_Engagement_Inclusion_And_Diversity', 0.0805094987154007)","('Director_Removal', 0.07287517189979553)","('NON-ESG', 0.49980393052101135)","('NON-ESG', 0.0805094987154007)","('NON-ESG', 0.07287517189979553)"
Line 152,"Sincerely, Mike Mahoney Chairman and Chief Executive Officer March 15, 2019Our People In all that we accomplished over the course of   the year, there is one common denominator that  gave us a distinct edge: the winning spirit of our  people.
","('Business_Model_Resilience', 0.343652606010437)","('Employee_Engagement_Inclusion_And_Diversity', 0.16691994667053223)","('Director_Removal', 0.099676713347435)","('NON-ESG', 0.343652606010437)","('NON-ESG', 0.16691994667053223)","('NON-ESG', 0.099676713347435)"
Line 153,"Our employees are the talented and   dedicated force behind every Boston Scientific   milestone.
","('Employee_Engagement_Inclusion_And_Diversity', 0.801749050617218)","('Employee_Health_And_Safety', 0.027861181646585464)","('Product_Design_And_Lifecycle_Management', 0.015954388305544853)","(['Human Capital Development'], 0.801749050617218)","('NON-ESG', 0.027861181646585464)","('NON-ESG', 0.015954388305544853)"
Line 154,"Our top industry awards and rankings  include FORTUNE World’s Most Admired Companies,   Forbes’ Best Large Employer, Newsweek Green  Rankings, the Human Rights Campaign’s Corporate  Equality Index, Working Mother 100 Best Companies, NAFE Top Companies for Executive Women, and   the Diversity Best Practices Inclusion Index.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9388250112533569)","('Human_Rights_And_Community_Relations', 0.012343133799731731)","('Employee_Health_And_Safety', 0.007177991326898336)","(['Human Capital Development'], 0.9388250112533569)","('NON-ESG', 0.012343133799731731)","('NON-ESG', 0.007177991326898336)"
Line 155,"As a global company, it is important to have diverse  perspectives and people who reflect the patients,  customers and markets we serve.
","('Employee_Engagement_Inclusion_And_Diversity', 0.777097761631012)","('Business_Model_Resilience', 0.04119738191366196)","('Human_Rights_And_Community_Relations', 0.027352849021553993)","(['Human Capital Development'], 0.777097761631012)","('NON-ESG', 0.04119738191366196)","('NON-ESG', 0.027352849021553993)"
Line 156,"In addition to   driving growth, this leads to greater diversity of  thought, which fuels innovation, creates a more   rewarding place to work and helps us attract and  retain top talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9365077614784241)","('Business_Model_Resilience', 0.006853191647678614)","('Director_Removal', 0.004640806932002306)","(['Human Capital Development'], 0.9365077614784241)","('NON-ESG', 0.006853191647678614)","('NON-ESG', 0.004640806932002306)"
Line 157,"We announced an 18-month   initiative to strengthen the core of our organization  by 2020 through diversity and inclusion, including   a goal of increasing global representation of women  and people of color in supervisor and manager   roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9761402010917664)","('Employee_Health_And_Safety', 0.0016724101733416319)","('Human_Rights_And_Community_Relations', 0.0016502861399203539)","(['Human Capital Development'], 0.9761402010917664)","('NON-ESG', 0.0016724101733416319)","('NON-ESG', 0.0016502861399203539)"
Line 158,"We also launched initiatives to help us better  understand the needs of our employees in different  parts of the world and tailor benefits accordingly.
","('Labor_Practices', 0.3264855146408081)","('Employee_Engagement_Inclusion_And_Diversity', 0.20022934675216675)","('Employee_Health_And_Safety', 0.16942675411701202)","('NON-ESG', 0.3264855146408081)","('NON-ESG', 0.20022934675216675)","('NON-ESG', 0.16942675411701202)"
Line 159,"Our Benefits to Fit Your Life program launched   globally in 2018 as a comprehensive package   designed to meet employees at various stages   of work and life.
","('Employee_Health_And_Safety', 0.3457255959510803)","('Labor_Practices', 0.17119906842708588)","('Employee_Engagement_Inclusion_And_Diversity', 0.14430265128612518)","('NON-ESG', 0.3457255959510803)","('NON-ESG', 0.17119906842708588)","('NON-ESG', 0.14430265128612518)"
Line 160,"Examples of offerings in the   U.S. include expanded infertility treatment support,  maternal and paternal leave, a breast milk shipping  service, adult and child back-up care, and enhanced  planning programs for college assistance as well as  employees with aging parents.
","('Access_And_Affordability', 0.610216498374939)","('Employee_Health_And_Safety', 0.08696998655796051)","('Employee_Engagement_Inclusion_And_Diversity', 0.080768883228302)","(['Health Outcome Contribution'], 0.610216498374939)","('NON-ESG', 0.08696998655796051)","('NON-ESG', 0.080768883228302)"
Line 161,"LOOKING AHEAD I think perhaps one of the most important metrics   in a company beyond the financials is employee   engagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9487207531929016)","('Human_Rights_And_Community_Relations', 0.006134792696684599)","('Employee_Health_And_Safety', 0.005897643510252237)","(['Human Capital Development'], 0.9487207531929016)","('NON-ESG', 0.006134792696684599)","('NON-ESG', 0.005897643510252237)"
Line 162,"I’m very proud of the high engagement   A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.2018 SALES BY REGION  Reported Operational (DOLLARS IN MILLIONS)   Sales Growth1    U.S.  $ 5,538 7.3%   Europe, Middle East       and Africa (EMEA)† 2,176 9.0%    Asia-Pacific (APAC)† 1,727 7.5%   Latin America and Canada (LACA) 383 15.8%   $9,823 8.0%      2018 SALES BY PRODUCT CATEGORY  Reported Operational (DOLLARS IN MILLIONS)    Sales Growth1  MedSurg      Endoscopy $ 1,762 8.3%   Urology and Pelvic Health 1,245 10.6% Rhythm and Neuro     Cardiac Rhythm Management 1,951  2.1%    Electrophysiology 311 10.9%    Neuromodulation 779 22.5% Cardiovascular     Interventional Cardiology 2,590 6.6%    Peripheral Interventions 1,187 9.2%   $9,823 8.0% † Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments.
","('Product_Design_And_Lifecycle_Management', 0.7223357558250427)","('Customer_Welfare', 0.053122628480196)","('Business_Model_Resilience', 0.05110644921660423)","(['Product Stewardship'], 0.7223357558250427)","('NON-ESG', 0.053122628480196)","('NON-ESG', 0.05110644921660423)"
Line 163,"I’m very proud of the high engagement   A MESSAGE FROM OUR CHAIRMAN AND CEO BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.2018 SALES BY REGION  Reported Operational (DOLLARS IN MILLIONS)   Sales Growth1    U.S.  $ 5,538 7.3%   Europe, Middle East       and Africa (EMEA)† 2,176 9.0%    Asia-Pacific (APAC)† 1,727 7.5%   Latin America and Canada (LACA) 383 15.8%   $9,823 8.0%      2018 SALES BY PRODUCT CATEGORY  Reported Operational (DOLLARS IN MILLIONS)    Sales Growth1  MedSurg      Endoscopy $ 1,762 8.3%   Urology and Pelvic Health 1,245 10.6% Rhythm and Neuro     Cardiac Rhythm Management 1,951  2.1%    Electrophysiology 311 10.9%    Neuromodulation 779 22.5% Cardiovascular     Interventional Cardiology 2,590 6.6%    Peripheral Interventions 1,187 9.2%   $9,823 8.0% † Effective January 1, 2018, following organizational changes to align the structure of our business with our focus on active implantable devices, we revised our reportable segments.
","('Employee_Health_And_Safety', 0.2538401186466217)","('Access_And_Affordability', 0.16804608702659607)","('Customer_Welfare', 0.09038184583187103)","('NON-ESG', 0.2538401186466217)","('NON-ESG', 0.16804608702659607)","('NON-ESG', 0.09038184583187103)"
Line 164,"The revision reflects a reclassification of our Neuromodulation business from our Medical Surgical (MedSurg) segment to our newly  created Rhythm and Neuro segment, which includes Cardiac Rhythm Management (CRM), Electrophysiology and Neuromodulation.
","('Customer_Welfare', 0.13358162343502045)","('Employee_Health_And_Safety', 0.1101444661617279)","('Competitive_Behavior', 0.08332479745149612)","('NON-ESG', 0.13358162343502045)","('NON-ESG', 0.1101444661617279)","('NON-ESG', 0.08332479745149612)"
Line 165,"In addition, we reclassified the Middle East and Africa (MEA) regions from the former AMEA region with Europe to create the new EMEA region.
","('Business_Model_Resilience', 0.2115519791841507)","('Management_Of_Legal_And_Regulatory_Framework', 0.13475532829761505)","('Ecological_Impacts', 0.10872787982225418)","('NON-ESG', 0.2115519791841507)","('NON-ESG', 0.13475532829761505)","('NON-ESG', 0.10872787982225418)"
Line 166,"The new Asia-Pacific (APAC) region   was also previously part of the former AMEA region.
","('Business_Model_Resilience', 0.24135148525238037)","('Ecological_Impacts', 0.1615029275417328)","('Management_Of_Legal_And_Regulatory_Framework', 0.09355935454368591)","('NON-ESG', 0.24135148525238037)","('NON-ESG', 0.1615029275417328)","('NON-ESG', 0.09355935454368591)"
Line 167,"Prior year balances and year over year growth rates (denoted with “†”) have been revised accordingly.
","('Systemic_Risk_Management', 0.40920498967170715)","('Business_Model_Resilience', 0.2528781592845917)","('Physical_Impacts_Of_Climate_Change', 0.05489443242549896)","('NON-ESG', 0.40920498967170715)","('NON-ESG', 0.2528781592845917)","('NON-ESG', 0.05489443242549896)"
Line 168,"1 Operational revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations; see non-GAAP reconciliations on   pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5738473534584045)","('Systemic_Risk_Management', 0.22103282809257507)","('Competitive_Behavior', 0.030466703698039055)","(['Corporate Governance'], 0.5738473534584045)","('NON-ESG', 0.22103282809257507)","('NON-ESG', 0.030466703698039055)"
Line 169,"2 Organic revenue growth rates are non-GAAP measures that exclude the impact of foreign currency fluctuations and the first twelve months of sales from the acquisitions of the electrophysiology business of C.R. Bard Inc., the Interventional Division of Bayer AG, the American Medical Systems   male urology portfolio, EndoChoice Holdings, Inc., Symetis SA, NxThera, Inc., Claret Medical, Inc.
","('Systemic_Risk_Management', 0.42225438356399536)","('Competitive_Behavior', 0.19288752973079681)","('Business_Model_Resilience', 0.08221738785505295)","('NON-ESG', 0.42225438356399536)","('NON-ESG', 0.19288752973079681)","('NON-ESG', 0.08221738785505295)"
Line 170,"and Augmenix, Inc., since there are  no prior period related net sales; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.42149171233177185)","('Systemic_Risk_Management', 0.23259325325489044)","('Competitive_Behavior', 0.05646457150578499)","('NON-ESG', 0.42149171233177185)","('NON-ESG', 0.23259325325489044)","('NON-ESG', 0.05646457150578499)"
Line 171,"3 Adjusted operating margin, adjusted earnings per share and their related growth rates are   non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation related net charges and  credits, pension termination charges, certain debt extinguishment charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.
","('Business_Ethics', 0.41207361221313477)","('Management_Of_Legal_And_Regulatory_Framework', 0.26480966806411743)","('Systemic_Risk_Management', 0.09763120859861374)","('NON-ESG', 0.41207361221313477)","('NON-ESG', 0.26480966806411743)","('NON-ESG', 0.09763120859861374)"
Line 172,"3 Adjusted operating margin, adjusted earnings per share and their related growth rates are   non-GAAP measures that exclude the impacts of certain charges (credits) which may include amortization expense, goodwill and intangible asset impairment charges, acquisition-related net charges and credits, restructuring and restructuring-related net charges and credits, litigation related net charges and  credits, pension termination charges, certain debt extinguishment charges, certain investment impairment charges and/or certain discrete tax items; see non-GAAP reconciliations on pages 55-57.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9420791268348694)","('Energy_Management', 0.009964924305677414)","('Competitive_Behavior', 0.007050871849060059)","(['Corporate Governance'], 0.9420791268348694)","('NON-ESG', 0.009964924305677414)","('NON-ESG', 0.007050871849060059)"
Line 173,"BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.FINANCIAL HIGHLIGHTS OPERATIONAL    REVENUE   GROWTH1,2018:   8% 7% 2017:   8% 7% 2016:  12% 10%   Operational revenue growth   Organic revenue growthADJUSTED    EARNINGS PER   SHARE GROWTH2018:   17% 2017:   13% 2016:   20%   Adjusted EPS growth from prior year   includes $0.07 net tax benefit in 2018.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2966460883617401)","('Systemic_Risk_Management', 0.26179981231689453)","('Business_Model_Resilience', 0.12245649099349976)","('NON-ESG', 0.2966460883617401)","('NON-ESG', 0.26179981231689453)","('NON-ESG', 0.12245649099349976)"
Line 174,"Adjusted EPS growth from prior year,   excluding $0.07 net tax benefit in 2018,   increased 11% in 2018 as compared to   the prior year.ADJUSTED    OPERATING    MARGIN3  2018:  25.5% 2017:   25.0% 2016:  24.1% 16 17 16 17 16 17 18  BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.BOSTON SCIENTIFIC AT A GLANCE Boston Scientific transforms lives through innovative medical solutions that improve the health  of patients around the world.
","('Product_Design_And_Lifecycle_Management', 0.2659640312194824)","('Business_Model_Resilience', 0.16428802907466888)","('Access_And_Affordability', 0.11147391051054001)","('NON-ESG', 0.2659640312194824)","('NON-ESG', 0.16428802907466888)","('NON-ESG', 0.11147391051054001)"
Line 175,"As a global medical technology leader for nearly 40 years, we   advance science for life by providing a broad range of high-performance solutions that address  unmet patient needs and reduce the cost of healthcare.
","('Product_Design_And_Lifecycle_Management', 0.3832705020904541)","('Energy_Management', 0.21698124706745148)","('Access_And_Affordability', 0.062356751412153244)","('NON-ESG', 0.3832705020904541)","('NON-ESG', 0.21698124706745148)","('NON-ESG', 0.062356751412153244)"
Line 176,"ENDOSCOPY Industry leader in minimally invasive devices for diagnosing and treating    gastrointestinal and pulmonary conditions UROLOGY AND  Industry-leading solutions for urological, urogynecological and gynecological  PELVIC HEALTH conditions  CARDIAC RHYTHM  Groundbreaking technologies that treat irregular heart rhythms and heart  MANAGEMENT  failure and help protect against sudden cardiac arrest  ELECTROPHYSIOLOGY  A broad range of mapping and treatment technologies for diagnosing and  treating heart rhythm disorders NEUROMODULATION Electronic implantable technologies that help patients manage debilitating    chronic pain and neurological conditions INTERVENTIONAL  Minimally invasive innovations that help improve the lives of patients living  CARDIOLOGY with heart and vascular conditions  PERIPHERAL Minimally-invasive treatments of peripheral vascular disease and cancer   INTERVENTIONS Committed to   carbon neutrality   in manufacturing   and key distribution   sites for all products   by 2030  BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.BOSTON SCIENTIFIC BY THE NUMBERS 200+    STEM   events 32,000+    employees worldwide$9.8+ billion    in salesHelped improve   approximately 30 million   patient livesApproximately $1 billion   invested in   research and  developmentRecycled 9,600+   tonnes   of solid waste$81 million+    provided for medical   research, educational   and charitable giving Named to   the Forbes'   list of The  World’s Most   Innovative   CompaniesLaunched approximately   100 new product innovations   globally Reduced greenhouse gas emissions* by   75,000+ tonnes  *Compared to 2009 baseline.43,000+    employee volunteer hours   BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.MEANINGFUL INNOVATION SpyGlass™ DS Direct   Visualization System  The first minimally   invasive, single-use,   single-operator   digital scope used for   cholangiopancreatoscopy  procedures designed   to target biopsies and  stone fragments in the   bile, hepatic and   pancreatic ducts.ACURATE neo™ Aortic Valve System*   and LOTUS Edge™ Valve System**  Complementary transcatheter aortic valve   replacement (TAVR) devices that are designed   to enable implanting physicians to treat the   broadest range of patients and aortic valve   anatomies.Spectra WaveWriter™ Spinal Cord   Stimulator (SCS) System Designed to provide personalized, long-lasting   pain relief through combination therapy, novel  sub-perception algorithms and waveform   automation.Eluvia™ Drug-Eluting   Vascular Stent System The first peripheral   vascular interventional  technology approved in  the U.S. to offer sustained  release of antiproliferative  drug to treat patients with  peripheral artery disease.
","('Employee_Health_And_Safety', 0.3953740894794464)","('Critical_Incident_Risk_Management', 0.11482233554124832)","('Access_And_Affordability', 0.10173218697309494)","('NON-ESG', 0.3953740894794464)","('NON-ESG', 0.11482233554124832)","('NON-ESG', 0.10173218697309494)"
Line 177,"ENDOSCOPY Industry leader in minimally invasive devices for diagnosing and treating    gastrointestinal and pulmonary conditions UROLOGY AND  Industry-leading solutions for urological, urogynecological and gynecological  PELVIC HEALTH conditions  CARDIAC RHYTHM  Groundbreaking technologies that treat irregular heart rhythms and heart  MANAGEMENT  failure and help protect against sudden cardiac arrest  ELECTROPHYSIOLOGY  A broad range of mapping and treatment technologies for diagnosing and  treating heart rhythm disorders NEUROMODULATION Electronic implantable technologies that help patients manage debilitating    chronic pain and neurological conditions INTERVENTIONAL  Minimally invasive innovations that help improve the lives of patients living  CARDIOLOGY with heart and vascular conditions  PERIPHERAL Minimally-invasive treatments of peripheral vascular disease and cancer   INTERVENTIONS Committed to   carbon neutrality   in manufacturing   and key distribution   sites for all products   by 2030  BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.BOSTON SCIENTIFIC BY THE NUMBERS 200+    STEM   events 32,000+    employees worldwide$9.8+ billion    in salesHelped improve   approximately 30 million   patient livesApproximately $1 billion   invested in   research and  developmentRecycled 9,600+   tonnes   of solid waste$81 million+    provided for medical   research, educational   and charitable giving Named to   the Forbes'   list of The  World’s Most   Innovative   CompaniesLaunched approximately   100 new product innovations   globally Reduced greenhouse gas emissions* by   75,000+ tonnes  *Compared to 2009 baseline.43,000+    employee volunteer hours   BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.MEANINGFUL INNOVATION SpyGlass™ DS Direct   Visualization System  The first minimally   invasive, single-use,   single-operator   digital scope used for   cholangiopancreatoscopy  procedures designed   to target biopsies and  stone fragments in the   bile, hepatic and   pancreatic ducts.ACURATE neo™ Aortic Valve System*   and LOTUS Edge™ Valve System**  Complementary transcatheter aortic valve   replacement (TAVR) devices that are designed   to enable implanting physicians to treat the   broadest range of patients and aortic valve   anatomies.Spectra WaveWriter™ Spinal Cord   Stimulator (SCS) System Designed to provide personalized, long-lasting   pain relief through combination therapy, novel  sub-perception algorithms and waveform   automation.Eluvia™ Drug-Eluting   Vascular Stent System The first peripheral   vascular interventional  technology approved in  the U.S. to offer sustained  release of antiproliferative  drug to treat patients with  peripheral artery disease.
","('Employee_Health_And_Safety', 0.6027175784111023)","('Access_And_Affordability', 0.12455858290195465)","('Product_Quality_And_Safety', 0.03951556608080864)","(['Operational Eco-Efficiency'], 0.6027175784111023)","('NON-ESG', 0.12455858290195465)","('NON-ESG', 0.03951556608080864)"
Line 178,"ENDOSCOPY Industry leader in minimally invasive devices for diagnosing and treating    gastrointestinal and pulmonary conditions UROLOGY AND  Industry-leading solutions for urological, urogynecological and gynecological  PELVIC HEALTH conditions  CARDIAC RHYTHM  Groundbreaking technologies that treat irregular heart rhythms and heart  MANAGEMENT  failure and help protect against sudden cardiac arrest  ELECTROPHYSIOLOGY  A broad range of mapping and treatment technologies for diagnosing and  treating heart rhythm disorders NEUROMODULATION Electronic implantable technologies that help patients manage debilitating    chronic pain and neurological conditions INTERVENTIONAL  Minimally invasive innovations that help improve the lives of patients living  CARDIOLOGY with heart and vascular conditions  PERIPHERAL Minimally-invasive treatments of peripheral vascular disease and cancer   INTERVENTIONS Committed to   carbon neutrality   in manufacturing   and key distribution   sites for all products   by 2030  BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.BOSTON SCIENTIFIC BY THE NUMBERS 200+    STEM   events 32,000+    employees worldwide$9.8+ billion    in salesHelped improve   approximately 30 million   patient livesApproximately $1 billion   invested in   research and  developmentRecycled 9,600+   tonnes   of solid waste$81 million+    provided for medical   research, educational   and charitable giving Named to   the Forbes'   list of The  World’s Most   Innovative   CompaniesLaunched approximately   100 new product innovations   globally Reduced greenhouse gas emissions* by   75,000+ tonnes  *Compared to 2009 baseline.43,000+    employee volunteer hours   BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.MEANINGFUL INNOVATION SpyGlass™ DS Direct   Visualization System  The first minimally   invasive, single-use,   single-operator   digital scope used for   cholangiopancreatoscopy  procedures designed   to target biopsies and  stone fragments in the   bile, hepatic and   pancreatic ducts.ACURATE neo™ Aortic Valve System*   and LOTUS Edge™ Valve System**  Complementary transcatheter aortic valve   replacement (TAVR) devices that are designed   to enable implanting physicians to treat the   broadest range of patients and aortic valve   anatomies.Spectra WaveWriter™ Spinal Cord   Stimulator (SCS) System Designed to provide personalized, long-lasting   pain relief through combination therapy, novel  sub-perception algorithms and waveform   automation.Eluvia™ Drug-Eluting   Vascular Stent System The first peripheral   vascular interventional  technology approved in  the U.S. to offer sustained  release of antiproliferative  drug to treat patients with  peripheral artery disease.
","('Waste_And_Hazardous_Materials_Management', 0.9784603714942932)","('Water_And_Wastewater_Management', 0.0023313502315431833)","('Product_Design_And_Lifecycle_Management', 0.0015635847812518477)","(['Operational Eco-Efficiency'], 0.9784603714942932)","('NON-ESG', 0.0023313502315431833)","('NON-ESG', 0.0015635847812518477)"
Line 179,"ENDOSCOPY Industry leader in minimally invasive devices for diagnosing and treating    gastrointestinal and pulmonary conditions UROLOGY AND  Industry-leading solutions for urological, urogynecological and gynecological  PELVIC HEALTH conditions  CARDIAC RHYTHM  Groundbreaking technologies that treat irregular heart rhythms and heart  MANAGEMENT  failure and help protect against sudden cardiac arrest  ELECTROPHYSIOLOGY  A broad range of mapping and treatment technologies for diagnosing and  treating heart rhythm disorders NEUROMODULATION Electronic implantable technologies that help patients manage debilitating    chronic pain and neurological conditions INTERVENTIONAL  Minimally invasive innovations that help improve the lives of patients living  CARDIOLOGY with heart and vascular conditions  PERIPHERAL Minimally-invasive treatments of peripheral vascular disease and cancer   INTERVENTIONS Committed to   carbon neutrality   in manufacturing   and key distribution   sites for all products   by 2030  BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.BOSTON SCIENTIFIC BY THE NUMBERS 200+    STEM   events 32,000+    employees worldwide$9.8+ billion    in salesHelped improve   approximately 30 million   patient livesApproximately $1 billion   invested in   research and  developmentRecycled 9,600+   tonnes   of solid waste$81 million+    provided for medical   research, educational   and charitable giving Named to   the Forbes'   list of The  World’s Most   Innovative   CompaniesLaunched approximately   100 new product innovations   globally Reduced greenhouse gas emissions* by   75,000+ tonnes  *Compared to 2009 baseline.43,000+    employee volunteer hours   BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.MEANINGFUL INNOVATION SpyGlass™ DS Direct   Visualization System  The first minimally   invasive, single-use,   single-operator   digital scope used for   cholangiopancreatoscopy  procedures designed   to target biopsies and  stone fragments in the   bile, hepatic and   pancreatic ducts.ACURATE neo™ Aortic Valve System*   and LOTUS Edge™ Valve System**  Complementary transcatheter aortic valve   replacement (TAVR) devices that are designed   to enable implanting physicians to treat the   broadest range of patients and aortic valve   anatomies.Spectra WaveWriter™ Spinal Cord   Stimulator (SCS) System Designed to provide personalized, long-lasting   pain relief through combination therapy, novel  sub-perception algorithms and waveform   automation.Eluvia™ Drug-Eluting   Vascular Stent System The first peripheral   vascular interventional  technology approved in  the U.S. to offer sustained  release of antiproliferative  drug to treat patients with  peripheral artery disease.
","('GHG_Emissions', 0.9657923579216003)","('Air_Quality', 0.0042707729153335094)","('Ecological_Impacts', 0.003865693463012576)","(['Climate Change'], 0.9657923579216003)","('NON-ESG', 0.0042707729153335094)","('NON-ESG', 0.003865693463012576)"
Line 180,"ENDOSCOPY Industry leader in minimally invasive devices for diagnosing and treating    gastrointestinal and pulmonary conditions UROLOGY AND  Industry-leading solutions for urological, urogynecological and gynecological  PELVIC HEALTH conditions  CARDIAC RHYTHM  Groundbreaking technologies that treat irregular heart rhythms and heart  MANAGEMENT  failure and help protect against sudden cardiac arrest  ELECTROPHYSIOLOGY  A broad range of mapping and treatment technologies for diagnosing and  treating heart rhythm disorders NEUROMODULATION Electronic implantable technologies that help patients manage debilitating    chronic pain and neurological conditions INTERVENTIONAL  Minimally invasive innovations that help improve the lives of patients living  CARDIOLOGY with heart and vascular conditions  PERIPHERAL Minimally-invasive treatments of peripheral vascular disease and cancer   INTERVENTIONS Committed to   carbon neutrality   in manufacturing   and key distribution   sites for all products   by 2030  BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.BOSTON SCIENTIFIC BY THE NUMBERS 200+    STEM   events 32,000+    employees worldwide$9.8+ billion    in salesHelped improve   approximately 30 million   patient livesApproximately $1 billion   invested in   research and  developmentRecycled 9,600+   tonnes   of solid waste$81 million+    provided for medical   research, educational   and charitable giving Named to   the Forbes'   list of The  World’s Most   Innovative   CompaniesLaunched approximately   100 new product innovations   globally Reduced greenhouse gas emissions* by   75,000+ tonnes  *Compared to 2009 baseline.43,000+    employee volunteer hours   BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.MEANINGFUL INNOVATION SpyGlass™ DS Direct   Visualization System  The first minimally   invasive, single-use,   single-operator   digital scope used for   cholangiopancreatoscopy  procedures designed   to target biopsies and  stone fragments in the   bile, hepatic and   pancreatic ducts.ACURATE neo™ Aortic Valve System*   and LOTUS Edge™ Valve System**  Complementary transcatheter aortic valve   replacement (TAVR) devices that are designed   to enable implanting physicians to treat the   broadest range of patients and aortic valve   anatomies.Spectra WaveWriter™ Spinal Cord   Stimulator (SCS) System Designed to provide personalized, long-lasting   pain relief through combination therapy, novel  sub-perception algorithms and waveform   automation.Eluvia™ Drug-Eluting   Vascular Stent System The first peripheral   vascular interventional  technology approved in  the U.S. to offer sustained  release of antiproliferative  drug to treat patients with  peripheral artery disease.
","('Employee_Health_And_Safety', 0.5811625123023987)","('Access_And_Affordability', 0.12493778020143509)","('Product_Quality_And_Safety', 0.03536003455519676)","(['Operational Eco-Efficiency'], 0.5811625123023987)","('NON-ESG', 0.12493778020143509)","('NON-ESG', 0.03536003455519676)"
Line 181,"ENDOSCOPY Industry leader in minimally invasive devices for diagnosing and treating    gastrointestinal and pulmonary conditions UROLOGY AND  Industry-leading solutions for urological, urogynecological and gynecological  PELVIC HEALTH conditions  CARDIAC RHYTHM  Groundbreaking technologies that treat irregular heart rhythms and heart  MANAGEMENT  failure and help protect against sudden cardiac arrest  ELECTROPHYSIOLOGY  A broad range of mapping and treatment technologies for diagnosing and  treating heart rhythm disorders NEUROMODULATION Electronic implantable technologies that help patients manage debilitating    chronic pain and neurological conditions INTERVENTIONAL  Minimally invasive innovations that help improve the lives of patients living  CARDIOLOGY with heart and vascular conditions  PERIPHERAL Minimally-invasive treatments of peripheral vascular disease and cancer   INTERVENTIONS Committed to   carbon neutrality   in manufacturing   and key distribution   sites for all products   by 2030  BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.BOSTON SCIENTIFIC BY THE NUMBERS 200+    STEM   events 32,000+    employees worldwide$9.8+ billion    in salesHelped improve   approximately 30 million   patient livesApproximately $1 billion   invested in   research and  developmentRecycled 9,600+   tonnes   of solid waste$81 million+    provided for medical   research, educational   and charitable giving Named to   the Forbes'   list of The  World’s Most   Innovative   CompaniesLaunched approximately   100 new product innovations   globally Reduced greenhouse gas emissions* by   75,000+ tonnes  *Compared to 2009 baseline.43,000+    employee volunteer hours   BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.MEANINGFUL INNOVATION SpyGlass™ DS Direct   Visualization System  The first minimally   invasive, single-use,   single-operator   digital scope used for   cholangiopancreatoscopy  procedures designed   to target biopsies and  stone fragments in the   bile, hepatic and   pancreatic ducts.ACURATE neo™ Aortic Valve System*   and LOTUS Edge™ Valve System**  Complementary transcatheter aortic valve   replacement (TAVR) devices that are designed   to enable implanting physicians to treat the   broadest range of patients and aortic valve   anatomies.Spectra WaveWriter™ Spinal Cord   Stimulator (SCS) System Designed to provide personalized, long-lasting   pain relief through combination therapy, novel  sub-perception algorithms and waveform   automation.Eluvia™ Drug-Eluting   Vascular Stent System The first peripheral   vascular interventional  technology approved in  the U.S. to offer sustained  release of antiproliferative  drug to treat patients with  peripheral artery disease.
","('Access_And_Affordability', 0.2092900276184082)","('Customer_Welfare', 0.16647858917713165)","('Product_Quality_And_Safety', 0.08598880469799042)","('NON-ESG', 0.2092900276184082)","('NON-ESG', 0.16647858917713165)","('NON-ESG', 0.08598880469799042)"
Line 182,"*The ACURATE device is an investigational device and is not available for sale in the U.S. ACURATE CE Marked.
","('Customer_Welfare', 0.44174450635910034)","('Selling_Practices_And_Product_Labeling', 0.15936383605003357)","('Competitive_Behavior', 0.04765300825238228)","('NON-ESG', 0.44174450635910034)","('NON-ESG', 0.15936383605003357)","('NON-ESG', 0.04765300825238228)"
Line 183,"**The LOTUS device is an investigational device and is not available for sale.
","('Selling_Practices_And_Product_Labeling', 0.3940243721008301)","('Customer_Welfare', 0.1334356963634491)","('Product_Quality_And_Safety', 0.10657476633787155)","('NON-ESG', 0.3940243721008301)","('NON-ESG', 0.1334356963634491)","('NON-ESG', 0.10657476633787155)"
Line 184,"CE Marked.ACURATE neo™   Aortic Valve System* LOTUS Edge™   Valve System**   Rezu–m™ Water Vapor Therapy A minimally invasive treatment for benign prostatic  hyperplasia (BPH) that is typically performed in a  physician’s office to remove excess prostate tissue  and reduce BPH-related symptoms, such as pain  and a frequent need to urinate.
","('Employee_Health_And_Safety', 0.5226249098777771)","('Employee_Engagement_Inclusion_And_Diversity', 0.09518416970968246)","('Access_And_Affordability', 0.05463109910488129)","(['Operational Eco-Efficiency'], 0.5226249098777771)","('NON-ESG', 0.09518416970968246)","('NON-ESG', 0.05463109910488129)"
Line 185,"SpaceOAR™ Hydrogel System  An absorbable gel that is injected prior to   radiation therapy for prostate cancer treatment,  which temporarily increases the space between  the rectum and prostate, thereby reducing   rectal radiation dose and associated side effects.WATCHMAN Left Atrial   Appendage Closure Device The first and only  FDA-approved one-time  heart implant proven   to reduce stroke risk   in patients with non-  valvular atrial fibrillation  who need an alternative  to long-term blood  thinners.MEANINGFUL INNOVATION MEANINGFUL INNOVATION BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.15.Boehmer JP, Hariharan R, Devecchi FG, et al.
","('Access_And_Affordability', 0.19450527429580688)","('Employee_Health_And_Safety', 0.16067291796207428)","('Customer_Welfare', 0.11357338726520538)","('NON-ESG', 0.19450527429580688)","('NON-ESG', 0.16067291796207428)","('NON-ESG', 0.11357338726520538)"
Line 186,"SpaceOAR™ Hydrogel System  An absorbable gel that is injected prior to   radiation therapy for prostate cancer treatment,  which temporarily increases the space between  the rectum and prostate, thereby reducing   rectal radiation dose and associated side effects.WATCHMAN Left Atrial   Appendage Closure Device The first and only  FDA-approved one-time  heart implant proven   to reduce stroke risk   in patients with non-  valvular atrial fibrillation  who need an alternative  to long-term blood  thinners.MEANINGFUL INNOVATION MEANINGFUL INNOVATION BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.15.Boehmer JP, Hariharan R, Devecchi FG, et al.
","('Competitive_Behavior', 0.3174070119857788)","('Product_Design_And_Lifecycle_Management', 0.12383250147104263)","('Business_Model_Resilience', 0.10049706697463989)","('NON-ESG', 0.3174070119857788)","('NON-ESG', 0.12383250147104263)","('NON-ESG', 0.10049706697463989)"
Line 187,"A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study.
","('Employee_Health_And_Safety', 0.5724717974662781)","('Critical_Incident_Risk_Management', 0.16115470230579376)","('Access_And_Affordability', 0.02695627696812153)","(['Operational Eco-Efficiency'], 0.5724717974662781)","('NON-ESG', 0.16115470230579376)","('NON-ESG', 0.02695627696812153)"
Line 188,"JACC Heart Fail .
","('Business_Ethics', 0.45626702904701233)","('Systemic_Risk_Management', 0.12038931995630264)","('Critical_Incident_Risk_Management', 0.0566781610250473)","('NON-ESG', 0.45626702904701233)","('NON-ESG', 0.12038931995630264)","('NON-ESG', 0.0566781610250473)"
Line 189,"2017 Mar;5(3):216-25.HeartLogic™ Heart   Failure Diagnostic The first and only heart   failure diagnostic tool   proven to detect 70   percent of heart failure  events several weeks   in advance, potentially   reducing further hospital- ization for patients with  heart failure.15 Featured   in the Boston Scientific  Resonate™ family of   cardiac resynchronization  therapy defibrillator   (CRT-D) and implantable  cardioverter defibrillator   (ICD) devices.
","('Employee_Health_And_Safety', 0.6812984347343445)","('Critical_Incident_Risk_Management', 0.1555003672838211)","('Product_Quality_And_Safety', 0.014852526597678661)","(['Operational Eco-Efficiency'], 0.6812984347343445)","('NON-ESG', 0.1555003672838211)","('NON-ESG', 0.014852526597678661)"
Line 190,"Symbols representing   sensors from the   HeartLogic diagnostic tool.
","('Product_Design_And_Lifecycle_Management', 0.11052561551332474)","('Customer_Welfare', 0.09808478504419327)","('Access_And_Affordability', 0.07939022034406662)","('NON-ESG', 0.11052561551332474)","('NON-ESG', 0.09808478504419327)","('NON-ESG', 0.07939022034406662)"
Line 191,"A Boston Scientific employee participating in   volunteer day near our Marlborough, Massachusetts  headquarters.CORPORATE SOCIAL RESPONSIBILITY AT BOSTON SCIENTIFIC MANAGING CORPORATE    SOCIAL RESPONSIBILITY   Our CSR Council is composed of subject matter  experts from across the company and charged with  defining our strategy and driving accountability   across the organization by setting clear targets   and measuring progress.
","('Human_Rights_And_Community_Relations', 0.932548463344574)","('Access_And_Affordability', 0.007326675113290548)","('Management_Of_Legal_And_Regulatory_Framework', 0.006144764367491007)","(['Community Relations'], 0.932548463344574)","('NON-ESG', 0.007326675113290548)","('NON-ESG', 0.006144764367491007)"
Line 192,"An Executive Steering   Committee sponsors the priorities and goals set   by the Council and supports efforts to further   embed responsible practices into the business.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6382408142089844)","('Human_Rights_And_Community_Relations', 0.15182805061340332)","('Director_Removal', 0.02376621589064598)","(['Corporate Governance'], 0.6382408142089844)","('NON-ESG', 0.15182805061340332)","('NON-ESG', 0.02376621589064598)"
Line 193,"OUR APPROACH: MATERIALITY   To focus our CSR efforts where we can have   the greatest impact, we must understand the   changing healthcare landscape, what matters   to our stakeholders and what most affects our   business across key markets.
","('Business_Model_Resilience', 0.7252070903778076)","('Systemic_Risk_Management', 0.07068432122468948)","('Physical_Impacts_Of_Climate_Change', 0.025756550952792168)","(['Codes of Business Conduct'], 0.7252070903778076)","('NON-ESG', 0.07068432122468948)","('NON-ESG', 0.025756550952792168)"
Line 194,"In 2017, we completed   a materiality assessment to identify the CSR issues   of greatest importance to Boston Scientific and   our stakeholders, including employees, customers,  investors and communities where we live and   work.
","('Human_Rights_And_Community_Relations', 0.9395900964736938)","('Business_Model_Resilience', 0.00596140930429101)","('Access_And_Affordability', 0.005364961456507444)","(['Community Relations'], 0.9395900964736938)","('NON-ESG', 0.00596140930429101)","('NON-ESG', 0.005364961456507444)"
Line 195,"The assessment was performed in accordance  with the internationally accredited Global Reporting  Initiative (GRI) guidelines and evaluated topics related  to our business strategy and stakeholder interests.
","('Business_Model_Resilience', 0.43975380063056946)","('Management_Of_Legal_And_Regulatory_Framework', 0.14960859715938568)","('Human_Rights_And_Community_Relations', 0.09353246539831161)","('NON-ESG', 0.43975380063056946)","('NON-ESG', 0.14960859715938568)","('NON-ESG', 0.09353246539831161)"
Line 196,"The assessment identified our material aspects,   the highest priority issues to our stakeholders for  social, economic and environmental impact.The actions we take today   can shape a better future   for our patients, customers,  employees, communities and  the world we share.
","('Human_Rights_And_Community_Relations', 0.9491504430770874)","('Ecological_Impacts', 0.004968909081071615)","('Access_And_Affordability', 0.0042141517624258995)","(['Community Relations'], 0.9491504430770874)","('NON-ESG', 0.004968909081071615)","('NON-ESG', 0.0042141517624258995)"
Line 197,"Our approach to corporate social responsibility (CSR)  is based on assessments of social, environmental  and governance issues that guide our policies and  day-to-day practices.
","('Human_Rights_And_Community_Relations', 0.8858901262283325)","('Management_Of_Legal_And_Regulatory_Framework', 0.021393822506070137)","('Business_Model_Resilience', 0.013125737197697163)","(['Community Relations'], 0.8858901262283325)","('NON-ESG', 0.021393822506070137)","('NON-ESG', 0.013125737197697163)"
Line 198,"This work is supported by our  cross-functional CSR Council, Environmental Health  and Safety (EH&S) policies and programs, a Global  Council for Inclusion as well as employee and   community programs.
","('Human_Rights_And_Community_Relations', 0.5532165765762329)","('Employee_Health_And_Safety', 0.16714933514595032)","('Employee_Engagement_Inclusion_And_Diversity', 0.12432979047298431)","(['Community Relations'], 0.5532165765762329)","('NON-ESG', 0.16714933514595032)","('NON-ESG', 0.12432979047298431)"
Line 199,"ENGAGING WITH STAKEHOLDERS At Boston Scientific, we engage with stakeholder  groups at the global, national and local levels to  inform our corporate responsibility strategy.
","('Human_Rights_And_Community_Relations', 0.5589683055877686)","('Management_Of_Legal_And_Regulatory_Framework', 0.16221924126148224)","('Business_Model_Resilience', 0.05777602270245552)","(['Community Relations'], 0.5589683055877686)","('NON-ESG', 0.16221924126148224)","('NON-ESG', 0.05777602270245552)"
Line 200,"This   engagement occurs at all levels of the organization,  from employees at our manufacturing sites and  research facilities to senior management in our  divisions and Executive Committee leaders.
","('Director_Removal', 0.3843275308609009)","('Employee_Engagement_Inclusion_And_Diversity', 0.2869260907173157)","('Business_Model_Resilience', 0.052609555423259735)","('NON-ESG', 0.3843275308609009)","('NON-ESG', 0.2869260907173157)","('NON-ESG', 0.052609555423259735)"
Line 201,"We  value the opportunity to learn about the concerns  and priorities of the communities and stakeholder  groups we serve as we work to anticipate and better  understand emerging environmental, social and  governance topics.
","('Human_Rights_And_Community_Relations', 0.9273287057876587)","('Management_Of_Legal_And_Regulatory_Framework', 0.00949165690690279)","('Ecological_Impacts', 0.006714177317917347)","(['Community Relations'], 0.9273287057876587)","('NON-ESG', 0.00949165690690279)","('NON-ESG', 0.006714177317917347)"
Line 202,"CORPORATE SOCIAL RESPONSIBILITY AT BOSTON SCIENTIFIC BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.15In 2018, we aligned the outcomes of this assessment  to the United Nations Sustainable Development  Goals (SDGs), which address key global challenges  to create a better and more sustainable future for  everyone.
","('Human_Rights_And_Community_Relations', 0.8285301327705383)","('Business_Model_Resilience', 0.03181158006191254)","('Management_Of_Legal_And_Regulatory_Framework', 0.012734574265778065)","(['Community Relations'], 0.8285301327705383)","('NON-ESG', 0.03181158006191254)","('NON-ESG', 0.012734574265778065)"
Line 203,"Though the United Nation’s 17 SDGs are  interconnected, our material aspects align to 10   goals where we believe we can make the most  meaningful contributions to critical issues.
","('Business_Model_Resilience', 0.2748396098613739)","('Human_Rights_And_Community_Relations', 0.16298331320285797)","('Management_Of_Legal_And_Regulatory_Framework', 0.12418539077043533)","('NON-ESG', 0.2748396098613739)","('NON-ESG', 0.16298331320285797)","('NON-ESG', 0.12418539077043533)"
Line 204,"A focus   on positively influencing these goals will continue   to guide our CSR programs in 2019 and beyond.
","('Management_Of_Legal_And_Regulatory_Framework', 0.731656551361084)","('Human_Rights_And_Community_Relations', 0.09482591599225998)","('Access_And_Affordability', 0.020534291863441467)","(['Corporate Governance'], 0.731656551361084)","('NON-ESG', 0.09482591599225998)","('NON-ESG', 0.020534291863441467)"
Line 205,"OUR CSR PERFORMANCE We hold ourselves accountable for providing updates  and data related to our corporate social responsibility  performance, and we share this information through  several communication channels, including this   report.
","('Human_Rights_And_Community_Relations', 0.9134666323661804)","('Management_Of_Legal_And_Regulatory_Framework', 0.01095602847635746)","('Business_Model_Resilience', 0.008900115266442299)","(['Community Relations'], 0.9134666323661804)","('NON-ESG', 0.01095602847635746)","('NON-ESG', 0.008900115266442299)"
Line 206,"Each year, we report the company’s impact on  the environment as defined by the Carbon Disclosure  Project (CDP), and we actively participate in several  important environment, social and governance   rating surveys.
","('Human_Rights_And_Community_Relations', 0.4837265610694885)","('Management_Of_Legal_And_Regulatory_Framework', 0.15445689857006073)","('Ecological_Impacts', 0.07046489417552948)","('NON-ESG', 0.4837265610694885)","('NON-ESG', 0.15445689857006073)","('NON-ESG', 0.07046489417552948)"
Line 207,"This report has been prepared by referencing the  Global Reporting Initiative (GRI) guidelines.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6916120052337646)","('Access_And_Affordability', 0.05469168350100517)","('Human_Rights_And_Community_Relations', 0.046175405383110046)","(['Corporate Governance'], 0.6916120052337646)","('NON-ESG', 0.05469168350100517)","('NON-ESG', 0.046175405383110046)"
Line 208,"Data in  this report covers the period between January 1, 2018  and December 31, 2018, unless otherwise indicated.Boston Scientific Supports the SDGs Our Planet  Climate Change  Environmental ImpactOur People   Diversity and Inclusion   Culture and Career   Community    Stakeholder EngagementOur Practices  Innovative Products  Governance and Ethics  Compliance  Sustainable Supply ChainOf the seventeen United Nations Sustainable Development  Goals (SDGs), our material aspects align with ten, which will  continue to guide our corporate social responsibility programs  in 2019 and beyond.
","('Supply_Chain_Management', 0.4289993643760681)","('Physical_Impacts_Of_Climate_Change', 0.24087248742580414)","('Business_Model_Resilience', 0.11729227751493454)","('NON-ESG', 0.4289993643760681)","('NON-ESG', 0.24087248742580414)","('NON-ESG', 0.11729227751493454)"
Line 209,"Data in  this report covers the period between January 1, 2018  and December 31, 2018, unless otherwise indicated.Boston Scientific Supports the SDGs Our Planet  Climate Change  Environmental ImpactOur People   Diversity and Inclusion   Culture and Career   Community    Stakeholder EngagementOur Practices  Innovative Products  Governance and Ethics  Compliance  Sustainable Supply ChainOf the seventeen United Nations Sustainable Development  Goals (SDGs), our material aspects align with ten, which will  continue to guide our corporate social responsibility programs  in 2019 and beyond.
","('Human_Rights_And_Community_Relations', 0.9051642417907715)","('Access_And_Affordability', 0.011955165304243565)","('Business_Model_Resilience', 0.011199126951396465)","(['Community Relations'], 0.9051642417907715)","('NON-ESG', 0.011955165304243565)","('NON-ESG', 0.011199126951396465)"
Line 210,"CORPORATE SOCIAL RESPONSIBILITY AT BOSTON SCIENTIFIC BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.
","('Human_Rights_And_Community_Relations', 0.8880396485328674)","('Management_Of_Legal_And_Regulatory_Framework', 0.013315132819116116)","('Business_Model_Resilience', 0.010146020911633968)","(['Community Relations'], 0.8880396485328674)","('NON-ESG', 0.013315132819116116)","('NON-ESG', 0.010146020911633968)"
Line 211,"BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.OUR PLANET OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.In all established operations and distribution   locations, we proactively pursue environmental   standards that deliver exceptional ISO14001:2015   performance.
","('Product_Quality_And_Safety', 0.6397094130516052)","('Management_Of_Legal_And_Regulatory_Framework', 0.10099732130765915)","('Product_Design_And_Lifecycle_Management', 0.03180532157421112)","(['Product Quality & Recall Management'], 0.6397094130516052)","('NON-ESG', 0.10099732130765915)","('NON-ESG', 0.03180532157421112)"
Line 212,"During the 2018 audit cycle, we  achieved zero non-conformances globally.
","('Product_Quality_And_Safety', 0.3418048620223999)","('Business_Ethics', 0.3053901195526123)","('Management_Of_Legal_And_Regulatory_Framework', 0.054714661091566086)","('NON-ESG', 0.3418048620223999)","('NON-ESG', 0.3053901195526123)","('NON-ESG', 0.054714661091566086)"
Line 213,"We also received zero regulatory environmental  noncompliance notices or fines.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9202218651771545)","('Business_Ethics', 0.03411930426955223)","('Director_Removal', 0.004945083055645227)","(['Corporate Governance'], 0.9202218651771545)","('NON-ESG', 0.03411930426955223)","('NON-ESG', 0.004945083055645227)"
Line 214,"Our Global Energy Management System (GEMS),   developed in collaboration with the National   University of Ireland, Galway, helps ensure that   we meet our energy reduction commitment globally.
","('Energy_Management', 0.9770797491073608)","('Air_Quality', 0.003241576487198472)","('Management_Of_Legal_And_Regulatory_Framework', 0.0023580631241202354)","(['Operational Eco-Efficiency'], 0.9770797491073608)","('NON-ESG', 0.003241576487198472)","('NON-ESG', 0.0023580631241202354)"
Line 215,"Using the C3 strategy (Cut, Convert, Compensate),  GEMS focuses on cutting energy use, converting   to renewable energy sources instead of fossil fuels  and compensating with carbon offset projects   where needed.
","('Energy_Management', 0.9769743084907532)","('Management_Of_Legal_And_Regulatory_Framework', 0.0038756204303354025)","('Product_Design_And_Lifecycle_Management', 0.0018583489581942558)","(['Operational Eco-Efficiency'], 0.9769743084907532)","('NON-ESG', 0.0038756204303354025)","('NON-ESG', 0.0018583489581942558)"
Line 216,"Across our global manufacturing and distribution  locations, we have established the following targets  and are continually monitoring progress through  GEMS:   50% renewable electricity by   100% renewable electricity by 2024    90% renewable energy (all sources) by 2027    Carbon neutral by 2030  As a global medical device  manufacturer, we understand  that our planet is facing   challenges that affect the  well-being of patients,   customers, employees,   communities and investors.
","('Energy_Management', 0.9376406669616699)","('Access_And_Affordability', 0.010941945016384125)","('Product_Design_And_Lifecycle_Management', 0.00811154767870903)","(['Operational Eco-Efficiency'], 0.9376406669616699)","('NON-ESG', 0.010941945016384125)","('NON-ESG', 0.00811154767870903)"
Line 217,"By proactively addressing   energy consumption, carbon  output, waste management  and water use, we are   making measurable progress  toward shaping a better   future for our planet.
","('Energy_Management', 0.9422775506973267)","('Water_And_Wastewater_Management', 0.01859601028263569)","('Air_Quality', 0.004425970371812582)","(['Operational Eco-Efficiency'], 0.9422775506973267)","('NON-ESG', 0.01859601028263569)","('NON-ESG', 0.004425970371812582)"
Line 218,"Our Environment, Health and Safety (EHS) Policy   outlines our high standards as we pursue   environmental excellence.
","('Employee_Health_And_Safety', 0.33262455463409424)","('Critical_Incident_Risk_Management', 0.12200786918401718)","('Human_Rights_And_Community_Relations', 0.10998202115297318)","('NON-ESG', 0.33262455463409424)","('NON-ESG', 0.12200786918401718)","('NON-ESG', 0.10998202115297318)"
Line 219,"We take a global   approach to prioritizing, executing and monitoring  efforts to achieve EHS goals and measure progress   to deliver sustainable development.
","('Human_Rights_And_Community_Relations', 0.3157680332660675)","('Business_Model_Resilience', 0.2094825804233551)","('Ecological_Impacts', 0.08561326563358307)","('NON-ESG', 0.3157680332660675)","('NON-ESG', 0.2094825804233551)","('NON-ESG', 0.08561326563358307)"
Line 220,"The newest Boston Scientific   manufacturing site in Penang,   Malaysia, was granted LEED Silver   certification in 2018.CARING FOR OUR PLANET Boston Scientific has 13  LEED-certified buildings  around the globe.
","('Product_Design_And_Lifecycle_Management', 0.31958505511283875)","('Product_Quality_And_Safety', 0.13019703328609467)","('Management_Of_Legal_And_Regulatory_Framework', 0.08144138753414154)","('NON-ESG', 0.31958505511283875)","('NON-ESG', 0.13019703328609467)","('NON-ESG', 0.08144138753414154)"
Line 221,"OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.KPI DEFINITION Carbon  Total amount of Scope 1 and Scope 2 greenhouse  Footprint gas emissions emitted into the atmosphere from   (MT CO2eq) manufacturing and distribution sites.
","('GHG_Emissions', 0.9686001539230347)","('Air_Quality', 0.004422961268573999)","('Ecological_Impacts', 0.0037677688524127007)","(['Climate Change'], 0.9686001539230347)","('NON-ESG', 0.004422961268573999)","('NON-ESG', 0.0037677688524127007)"
Line 222,"Measured    in tonnes of carbon equivalent.
","('GHG_Emissions', 0.3903656005859375)","('Energy_Management', 0.21882733702659607)","('Management_Of_Legal_And_Regulatory_Framework', 0.09669296443462372)","('NON-ESG', 0.3903656005859375)","('NON-ESG', 0.21882733702659607)","('NON-ESG', 0.09669296443462372)"
Line 223,"Energy Use  Total energy Boston Scientific consumes annually  (kWh) to manufacture our products.
","('Energy_Management', 0.9457167983055115)","('Product_Design_And_Lifecycle_Management', 0.01832444593310356)","('Management_Of_Legal_And_Regulatory_Framework', 0.002747535239905119)","(['Operational Eco-Efficiency'], 0.9457167983055115)","('NON-ESG', 0.01832444593310356)","('NON-ESG', 0.002747535239905119)"
Line 224,"EM3  An energy management maturity model to establish  (% change  where in the “energy journey” each manufacturing  in score)  site resides on a scale from 1 to 5 (Minimal >   Emerging > Developing > Advancing > Leading) Green Real  Percentage of Boston Scientific real estate that is  Estate independently certified for energy efficiency by  (% of total) industry-leading programs such as LEED for design    and Energy Star or ISO50001 for building operations.
","('Energy_Management', 0.9796711802482605)","('Air_Quality', 0.002261615823954344)","('Water_And_Wastewater_Management', 0.0016296366229653358)","(['Operational Eco-Efficiency'], 0.9796711802482605)","('NON-ESG', 0.002261615823954344)","('NON-ESG', 0.0016296366229653358)"
Line 225,"Renewable  Percentage of total energy consumed, generated  Energy from renewable energy sources, with Boston Scientific   (% of total) owning the renewable attributes.
","('Energy_Management', 0.9796382188796997)","('Management_Of_Legal_And_Regulatory_Framework', 0.0021425799932330847)","('Product_Design_And_Lifecycle_Management', 0.0016105835093185306)","(['Operational Eco-Efficiency'], 0.9796382188796997)","('NON-ESG', 0.0021425799932330847)","('NON-ESG', 0.0016105835093185306)"
Line 226,"Cleaner Energy Energy produced from fossil fuels, but based on   (% of total) high-efficiency technologies such as combined heat    and power (CHP) in comparison to conventional    power generation.
","('Energy_Management', 0.9796252250671387)","('Management_Of_Legal_And_Regulatory_Framework', 0.0019860968459397554)","('Air_Quality', 0.001694446080364287)","(['Operational Eco-Efficiency'], 0.9796252250671387)","('NON-ESG', 0.0019860968459397554)","('NON-ESG', 0.001694446080364287)"
Line 227,"The GEMS methodology is implemented through our global energy team, including representatives from each of our manufacturing and key distribution sites.
","('Supply_Chain_Management', 0.39335402846336365)","('Product_Design_And_Lifecycle_Management', 0.1555328518152237)","('Customer_Welfare', 0.08549808710813522)","('NON-ESG', 0.39335402846336365)","('NON-ESG', 0.1555328518152237)","('NON-ESG', 0.08549808710813522)"
Line 228,"Our performance is continually measured through our GEMS key performance indicators (KPIs):   118,370,083,    2.
","('Systemic_Risk_Management', 0.5032650232315063)","('Business_Model_Resilience', 0.17755170166492462)","('Supply_Chain_Management', 0.033695969730615616)","(['Risk & Crisis Management'], 0.5032650232315063)","('NON-ESG', 0.17755170166492462)","('NON-ESG', 0.033695969730615616)"
Line 229,"27%       —       6%108,694  367,102,    3.
","('Employee_Engagement_Inclusion_And_Diversity', 0.21637608110904694)","('Competitive_Behavior', 0.1364985853433609)","('Management_Of_Legal_And_Regulatory_Framework', 0.07756389677524567)","('NON-ESG', 0.21637608110904694)","('NON-ESG', 0.1364985853433609)","('NON-ESG', 0.07756389677524567)"
Line 230,"28%       —       7%94,363,684,542*     3.
","('Employee_Engagement_Inclusion_And_Diversity', 0.14765900373458862)","('Director_Removal', 0.1334751397371292)","('Competitive_Behavior', 0.08295206725597382)","('NON-ESG', 0.14765900373458862)","('NON-ESG', 0.1334751397371292)","('NON-ESG', 0.08295206725597382)"
Line 231,"32%       —       9%*85,  352M   3.7   37%   5%   9% *2017 kilowatt hour figures corrected due to conversion factor error for diesel fuel use.CLIMATE CHANGE Striving for Carbon Neutrality As a medical device manufacturer with facilities and   employees around the world, we recognize we have  an important role in addressing climate change.
","('Physical_Impacts_Of_Climate_Change', 0.9499608278274536)","('Business_Model_Resilience', 0.008206452243030071)","('GHG_Emissions', 0.005990676116198301)","(['Climate Change'], 0.9499608278274536)","('NON-ESG', 0.008206452243030071)","('NON-ESG', 0.005990676116198301)"
Line 232,"Our  commitment is to achieve carbon neutrality across   Boston Scientific manufacturing and key distribution  sites by 2030.
","('GHG_Emissions', 0.4913252890110016)","('Energy_Management', 0.12873093783855438)","('Management_Of_Legal_And_Regulatory_Framework', 0.09400691092014313)","('NON-ESG', 0.4913252890110016)","('NON-ESG', 0.12873093783855438)","('NON-ESG', 0.09400691092014313)"
Line 233,"Carbon neutrality means achieving  net zero carbon emissions associated with manufac - turing operations and energy use by balancing the  amount of carbon released with an equal amount   removed or compensated.
","('GHG_Emissions', 0.8593149185180664)","('Air_Quality', 0.026509800925850868)","('Management_Of_Legal_And_Regulatory_Framework', 0.02021891437470913)","(['Climate Change'], 0.8593149185180664)","('NON-ESG', 0.026509800925850868)","('NON-ESG', 0.02021891437470913)"
Line 234,"As increased levels of  carbon dioxide and other greenhouse gases in  our atmosphere are closely tied to climate change,  achieving carbon neutrality will greatly reduce our  contribution to this pressing global issue.
","('GHG_Emissions', 0.9472442865371704)","('Physical_Impacts_Of_Climate_Change', 0.012541517615318298)","('Air_Quality', 0.007028883323073387)","(['Climate Change'], 0.9472442865371704)","('NON-ESG', 0.012541517615318298)","('NON-ESG', 0.007028883323073387)"
Line 235,"Leading in Energy Certification A critical part of our sustainability effort includes  ongoing improvement of existing facilities   and development of new construction in an   environmentally responsible manner.
","('Product_Design_And_Lifecycle_Management', 0.5470763444900513)","('Energy_Management', 0.1713690459728241)","('Product_Quality_And_Safety', 0.04232816398143768)","(['Product Stewardship'], 0.5470763444900513)","('NON-ESG', 0.1713690459728241)","('NON-ESG', 0.04232816398143768)"
Line 236,"Leadership in Energy and Environmental Design  (LEED) is an internationally recognized certification  program for the environmental performance and  sustainable design of buildings.
","('Product_Design_And_Lifecycle_Management', 0.7869633436203003)","('Product_Quality_And_Safety', 0.03297395631670952)","('Energy_Management', 0.03131403028964996)","(['Product Stewardship'], 0.7869633436203003)","('NON-ESG', 0.03297395631670952)","('NON-ESG', 0.03131403028964996)"
Line 237,"Boston Scientific  now has 13 LEED-certified buildings around the   globe (37 percent of total) – including our newest  manufacturing site in Penang, Malaysia, which was  granted LEED Silver certification in March 2018.
","('Product_Design_And_Lifecycle_Management', 0.3292267918586731)","('Product_Quality_And_Safety', 0.1822320967912674)","('Energy_Management', 0.08554061502218246)","('NON-ESG', 0.3292267918586731)","('NON-ESG', 0.1822320967912674)","('NON-ESG', 0.08554061502218246)"
Line 238,"Our two sites in Costa Rica, Coyol and Heredia,   have both received ISO 50001:2011 Energy   Management System certification.
","('Energy_Management', 0.9606855511665344)","('Product_Design_And_Lifecycle_Management', 0.007578695192933083)","('Management_Of_Legal_And_Regulatory_Framework', 0.0031119040213525295)","(['Operational Eco-Efficiency'], 0.9606855511665344)","('NON-ESG', 0.007578695192933083)","('NON-ESG', 0.0031119040213525295)"
Line 239,"ISO 50001 is   an energy management system standard that   provides a framework for all aspects of energy,   including procurement and use.
","('Energy_Management', 0.9796444177627563)","('Management_Of_Legal_And_Regulatory_Framework', 0.002074489602819085)","('Air_Quality', 0.001994427526369691)","(['Operational Eco-Efficiency'], 0.9796444177627563)","('NON-ESG', 0.002074489602819085)","('NON-ESG', 0.001994427526369691)"
Line 240,"In 2018, our   distribution center in Kerkrade, Netherlands,   received a third star from Lean and Green, Europe’s  leading program for sustainable logistics.
","('Product_Design_And_Lifecycle_Management', 0.7186548709869385)","('Supply_Chain_Management', 0.11155284196138382)","('Energy_Management', 0.02436460554599762)","(['Product Stewardship'], 0.7186548709869385)","('NON-ESG', 0.11155284196138382)","('NON-ESG', 0.02436460554599762)"
Line 241,"We are   one of only six companies in Europe to receive this  highest-level award for carbon output reduction.
","('Energy_Management', 0.4736343324184418)","('GHG_Emissions', 0.15446048974990845)","('Management_Of_Legal_And_Regulatory_Framework', 0.15322986245155334)","('NON-ESG', 0.4736343324184418)","('NON-ESG', 0.15446048974990845)","('NON-ESG', 0.15322986245155334)"
Line 242,"In total, Boston Scientific operates nearly 3.3 million   square feet of independently certified Green Real  Estate that supports our energy efficiency and   sustainability goals, representing 37 percent of   our global footprint.
","('Energy_Management', 0.9645799994468689)","('Product_Design_And_Lifecycle_Management', 0.00762984761968255)","('Management_Of_Legal_And_Regulatory_Framework', 0.002691442146897316)","(['Operational Eco-Efficiency'], 0.9645799994468689)","('NON-ESG', 0.00762984761968255)","('NON-ESG', 0.002691442146897316)"
Line 243,"OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.We have committed to  achieving carbon neutrality   in all of our manufacturing  and key distribution sites   by 2030.
","('GHG_Emissions', 0.6733422875404358)","('Energy_Management', 0.055210717022418976)","('Management_Of_Legal_And_Regulatory_Framework', 0.04638223350048065)","(['Climate Change'], 0.6733422875404358)","('NON-ESG', 0.055210717022418976)","('NON-ESG', 0.04638223350048065)"
Line 244,"LEEDing Locations  United States:  A Maple Grove, Minnesota LEED Silver     LEED Certified   B Marlborough, Massachusetts  LEED Gold   LEED Certified  C Quincy, Massachusetts LEED Silver      LEED Certified Central America:  D Coyol, Costa Rica LEED Silver      ISO 50001    E Heredia, Costa Rica ISO Europe:  F Kerkrade, Netherlands LEED Silver      Lean and Green Asia:  G Penang, Malaysia LEED Silver  H Singapore LEED Silver  I Beijing, China LEED Silver     LEED Certified  J Shanghai, China LEED SilverA BC DEF G HI JInvesting in Energy Efficiency Increased use of renewable energy is another way  that we are reducing GHG emissions.
","('Product_Quality_And_Safety', 0.33258458971977234)","('Management_Of_Legal_And_Regulatory_Framework', 0.13959194719791412)","('Product_Design_And_Lifecycle_Management', 0.08588853478431702)","('NON-ESG', 0.33258458971977234)","('NON-ESG', 0.13959194719791412)","('NON-ESG', 0.08588853478431702)"
Line 245,"LEEDing Locations  United States:  A Maple Grove, Minnesota LEED Silver     LEED Certified   B Marlborough, Massachusetts  LEED Gold   LEED Certified  C Quincy, Massachusetts LEED Silver      LEED Certified Central America:  D Coyol, Costa Rica LEED Silver      ISO 50001    E Heredia, Costa Rica ISO Europe:  F Kerkrade, Netherlands LEED Silver      Lean and Green Asia:  G Penang, Malaysia LEED Silver  H Singapore LEED Silver  I Beijing, China LEED Silver     LEED Certified  J Shanghai, China LEED SilverA BC DEF G HI JInvesting in Energy Efficiency Increased use of renewable energy is another way  that we are reducing GHG emissions.
","('GHG_Emissions', 0.9517675638198853)","('Energy_Management', 0.00836118496954441)","('Air_Quality', 0.005068215541541576)","(['Climate Change'], 0.9517675638198853)","('NON-ESG', 0.00836118496954441)","('NON-ESG', 0.005068215541541576)"
Line 246,"Two Boston  Scientific locations in Massachusetts each have solar  installments: our Marlborough headquarters site  generates 31 percent of its required electricity and  the Quincy distribution center generates 26 percent   of its required electricity, resulting in cumulative savings   of about 1,000 tonnes of GHG emissions.
","('GHG_Emissions', 0.9584112763404846)","('Air_Quality', 0.006050466559827328)","('Energy_Management', 0.005505372304469347)","(['Climate Change'], 0.9584112763404846)","('NON-ESG', 0.006050466559827328)","('NON-ESG', 0.005505372304469347)"
Line 247,"In June  2018, our facility in Dorado, Puerto Rico, joined a  Power Purchase Agreement (PPA) to purchase   electricity generated from solar panels to be installed  on-site.
","('Energy_Management', 0.9740711450576782)","('Management_Of_Legal_And_Regulatory_Framework', 0.0046446667984128)","('Air_Quality', 0.0018475658725947142)","(['Operational Eco-Efficiency'], 0.9740711450576782)","('NON-ESG', 0.0046446667984128)","('NON-ESG', 0.0018475658725947142)"
Line 248,"We are making progress toward our goal of purchasing  100 percent renewable energy by 2024 by purchasing   only renewable electricity for our three sites in Ireland,   installing on-site solar at certain facilities and pursuing  a virtual power purchase agreement for renewable  electricity for our U.S. energy needs.
","('Energy_Management', 0.9775426387786865)","('Management_Of_Legal_And_Regulatory_Framework', 0.003921507857739925)","('Air_Quality', 0.0016083164373412728)","(['Operational Eco-Efficiency'], 0.9775426387786865)","('NON-ESG', 0.003921507857739925)","('NON-ESG', 0.0016083164373412728)"
Line 249,"We will continue  to implement a combination of on-site and off-site  projects to achieve our renewable energy goals.
","('Energy_Management', 0.9753605723381042)","('Management_Of_Legal_And_Regulatory_Framework', 0.003709543263539672)","('Product_Design_And_Lifecycle_Management', 0.0019570321310311556)","(['Operational Eco-Efficiency'], 0.9753605723381042)","('NON-ESG', 0.003709543263539672)","('NON-ESG', 0.0019570321310311556)"
Line 250,"Renewable electricity accounted for 5 percent of   our energy purchased globally in 2018.
","('Energy_Management', 0.9774295091629028)","('Management_Of_Legal_And_Regulatory_Framework', 0.0033771777525544167)","('Water_And_Wastewater_Management', 0.0016643308335915208)","(['Operational Eco-Efficiency'], 0.9774295091629028)","('NON-ESG', 0.0033771777525544167)","('NON-ESG', 0.0016643308335915208)"
Line 251,"ENVIRONMENTAL IMPACT As a company with a global footprint and global  impact, we have a responsibility to manage how   we consume resources and reduce waste.
","('Waste_And_Hazardous_Materials_Management', 0.852859616279602)","('Product_Design_And_Lifecycle_Management', 0.02646886743605137)","('Supply_Chain_Management', 0.017267437651753426)","(['Operational Eco-Efficiency'], 0.852859616279602)","('NON-ESG', 0.02646886743605137)","('NON-ESG', 0.017267437651753426)"
Line 252,"We   carefully measure waste generation and water use  at our major manufacturing and distribution facilities  using ISO 14001:2015, a globally recognized standard CorkIRELANDfor environmental management systems (EMS).
","('Waste_And_Hazardous_Materials_Management', 0.9568208456039429)","('Water_And_Wastewater_Management', 0.013238459825515747)","('Air_Quality', 0.0033126589842140675)","(['Operational Eco-Efficiency'], 0.9568208456039429)","('NON-ESG', 0.013238459825515747)","('NON-ESG', 0.0033126589842140675)"
Line 253,"The  system ensures that throughout our operations we  respond to changing environmental conditions, meet  compliance obligations, enhance environmental   performance and deliver sustainable development.
","('Business_Model_Resilience', 0.20679181814193726)","('Ecological_Impacts', 0.19309204816818237)","('Human_Rights_And_Community_Relations', 0.1422063410282135)","('NON-ESG', 0.20679181814193726)","('NON-ESG', 0.19309204816818237)","('NON-ESG', 0.1422063410282135)"
Line 254,"As of 2018, 15 of our sites achieved third-party   certifications to this standard.
","('Product_Quality_And_Safety', 0.4717351794242859)","('Management_Of_Legal_And_Regulatory_Framework', 0.13962842524051666)","('Product_Design_And_Lifecycle_Management', 0.04722665250301361)","('NON-ESG', 0.4717351794242859)","('NON-ESG', 0.13962842524051666)","('NON-ESG', 0.04722665250301361)"
Line 255,"Reducing Waste We approach waste-reduction systematically,  through the adoption of international best practices  and research-backed protocols.
","('Waste_And_Hazardous_Materials_Management', 0.9835439324378967)","('Air_Quality', 0.0013505774550139904)","('Water_And_Wastewater_Management', 0.0012965283822268248)","(['Operational Eco-Efficiency'], 0.9835439324378967)","('NON-ESG', 0.0013505774550139904)","('NON-ESG', 0.0012965283822268248)"
Line 256,"In 2017, we met   our ambitious goal to achieve a recycling index of   81 percent for solid waste generated by our major  manufacturing and distribution facilities.
","('Waste_And_Hazardous_Materials_Management', 0.9827409386634827)","('Water_And_Wastewater_Management', 0.0016726880567148328)","('Product_Design_And_Lifecycle_Management', 0.001183573273010552)","(['Operational Eco-Efficiency'], 0.9827409386634827)","('NON-ESG', 0.0016726880567148328)","('NON-ESG', 0.001183573273010552)"
Line 257,"Striving to  do even better, we further improved our recycling   index and achieved 83 percent in 2018.
","('Energy_Management', 0.35156282782554626)","('Product_Design_And_Lifecycle_Management', 0.16119414567947388)","('Management_Of_Legal_And_Regulatory_Framework', 0.13264615833759308)","('NON-ESG', 0.35156282782554626)","('NON-ESG', 0.16119414567947388)","('NON-ESG', 0.13264615833759308)"
Line 258,"Of the  remaining non-recycled solid waste, we divert the  majority away from landfills.
","('Waste_And_Hazardous_Materials_Management', 0.9838984608650208)","('Water_And_Wastewater_Management', 0.0015079048462212086)","('Data_Security', 0.001291522872634232)","(['Operational Eco-Efficiency'], 0.9838984608650208)","('NON-ESG', 0.0015079048462212086)","('NON-ESG', 0.001291522872634232)"
Line 259,"OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Sustainability at our Ireland Facilities Beginning in October of 2018, the three Boston   Scientific manufacturing sites in Ireland, located in  Galway, Cork and Clonmel, began purchasing certified  100 percent renewable electricity.
","('Energy_Management', 0.968228280544281)","('Management_Of_Legal_And_Regulatory_Framework', 0.0045969984494149685)","('Product_Design_And_Lifecycle_Management', 0.003813627175986767)","(['Operational Eco-Efficiency'], 0.968228280544281)","('NON-ESG', 0.0045969984494149685)","('NON-ESG', 0.003813627175986767)"
Line 260,"This represents  12 percent of our total purchased electricity and  delivers a 9 percent overall reduction in carbon  emissions.
","('GHG_Emissions', 0.4959643483161926)","('Energy_Management', 0.2301046997308731)","('Air_Quality', 0.12219856679439545)","('NON-ESG', 0.4959643483161926)","('NON-ESG', 0.2301046997308731)","('NON-ESG', 0.12219856679439545)"
Line 261,"In November 2018, Boston Scientific joined other   businesses in Ireland and signed the Business in   The Community (BITC) Low Carbon Pledge.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31729668378829956)","('GHG_Emissions', 0.2208055555820465)","('Physical_Impacts_Of_Climate_Change', 0.06041978299617767)","('NON-ESG', 0.31729668378829956)","('NON-ESG', 0.2208055555820465)","('NON-ESG', 0.06041978299617767)"
Line 262,"These companies pledge to reduce scope 1 and   scope 2 greenhouse gas (GHG) emission intensity   50 percent by 2030.
","('GHG_Emissions', 0.969017505645752)","('Air_Quality', 0.004073114600032568)","('Ecological_Impacts', 0.003741553518921137)","(['Climate Change'], 0.969017505645752)","('NON-ESG', 0.004073114600032568)","('NON-ESG', 0.003741553518921137)"
Line 263,"Scope 1 GHGs are those   produced by Boston Scientific facilities directly,   and scope 2 GHGs are those generated by the   purchased electricity we consume.
","('GHG_Emissions', 0.9646697640419006)","('Air_Quality', 0.00442354753613472)","('Ecological_Impacts', 0.0035180607810616493)","(['Climate Change'], 0.9646697640419006)","('NON-ESG', 0.00442354753613472)","('NON-ESG', 0.0035180607810616493)"
Line 264,"We plan to   surpass this goal with our carbon neutrality pledge.GOAL SET IN 2009: 35% reduction in   greenhouse gas (GHG)   emissions* by 2019.
","('GHG_Emissions', 0.9693319201469421)","('Ecological_Impacts', 0.004270365461707115)","('Management_Of_Legal_And_Regulatory_Framework', 0.002744921250268817)","(['Climate Change'], 0.9693319201469421)","('NON-ESG', 0.004270365461707115)","('NON-ESG', 0.002744921250268817)"
Line 265,"2018 RESULT: 47%   reduction  (75,711 tonnes)** *Using market-based emissions calculations.
","('GHG_Emissions', 0.6055465936660767)","('Air_Quality', 0.22816529870033264)","('Energy_Management', 0.04617252200841904)","(['Climate Change'], 0.6055465936660767)","('NON-ESG', 0.22816529870033264)","('NON-ESG', 0.04617252200841904)"
Line 266,"**Compared to the 2009 manufacturing operations baseline.Galway ClonmelConserving Water While Boston Scientific operations are not water-  intensive, we understand the importance of water  as a shared resource.
","('Water_And_Wastewater_Management', 0.974521279335022)","('GHG_Emissions', 0.0031859129667282104)","('Ecological_Impacts', 0.002384838182479143)","(['Operational Eco-Efficiency'], 0.974521279335022)","('NON-ESG', 0.0031859129667282104)","('NON-ESG', 0.002384838182479143)"
Line 267,"We strive to minimize our  consumption and plan for environmental challenges  such as water scarcity.
","('Water_And_Wastewater_Management', 0.951130747795105)","('Energy_Management', 0.007887677289545536)","('GHG_Emissions', 0.0064513664692640305)","(['Operational Eco-Efficiency'], 0.951130747795105)","('NON-ESG', 0.007887677289545536)","('NON-ESG', 0.0064513664692640305)"
Line 268,"In 2018, we further decreased  water usage by 5 percent, representing a total   reduction of more than 30 percent since 2009.
","('Water_And_Wastewater_Management', 0.9714362025260925)","('Energy_Management', 0.004355256911367178)","('GHG_Emissions', 0.002934943651780486)","(['Operational Eco-Efficiency'], 0.9714362025260925)","('NON-ESG', 0.004355256911367178)","('NON-ESG', 0.002934943651780486)"
Line 269,"RECOGNITIONS FOR    SUSTAINABILITY LEADERSHIP   Received a Third Star for our facility in Kerkrade,  Netherlands, from Lean & Green, Europe’s leading  program for sustainable logistics   Confirmed a FTSE4Good Index Series constituent,  designed to measure the performance of   companies demonstrating strong Environmental,  Social and Governance (ESG) practices   Awarded the Ecological Blue Flag Award with five  stars by the Costa Rican government, the highest  ranking in the climate change category    OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Recognition for Solid Waste Reduction Achievement In April 2018, the Boston Scientific site in Maple  Grove, Minnesota, received the Chelsea Santucci  Greenovation Award from Kimberly-Clark   Professional for diverting 39,920 pounds of waste  from landfills.
","('Physical_Impacts_Of_Climate_Change', 0.9166494011878967)","('Business_Model_Resilience', 0.020459095016121864)","('Human_Rights_And_Community_Relations', 0.008440366946160793)","(['Climate Change'], 0.9166494011878967)","('NON-ESG', 0.020459095016121864)","('NON-ESG', 0.008440366946160793)"
Line 270,"RECOGNITIONS FOR    SUSTAINABILITY LEADERSHIP   Received a Third Star for our facility in Kerkrade,  Netherlands, from Lean & Green, Europe’s leading  program for sustainable logistics   Confirmed a FTSE4Good Index Series constituent,  designed to measure the performance of   companies demonstrating strong Environmental,  Social and Governance (ESG) practices   Awarded the Ecological Blue Flag Award with five  stars by the Costa Rican government, the highest  ranking in the climate change category    OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Recognition for Solid Waste Reduction Achievement In April 2018, the Boston Scientific site in Maple  Grove, Minnesota, received the Chelsea Santucci  Greenovation Award from Kimberly-Clark   Professional for diverting 39,920 pounds of waste  from landfills.
","('Waste_And_Hazardous_Materials_Management', 0.9835981726646423)","('Water_And_Wastewater_Management', 0.0015142345800995827)","('Air_Quality', 0.001470515038818121)","(['Operational Eco-Efficiency'], 0.9835981726646423)","('NON-ESG', 0.0015142345800995827)","('NON-ESG', 0.001470515038818121)"
Line 271,"We participate in The RightCycle  Program, the first large-scale recycling program  for non-hazardous lab, cleanroom and industrial  waste.
","('Waste_And_Hazardous_Materials_Management', 0.9842872619628906)","('Water_And_Wastewater_Management', 0.001270007574930787)","('Employee_Health_And_Safety', 0.0010753823444247246)","(['Operational Eco-Efficiency'], 0.9842872619628906)","('NON-ESG', 0.001270007574930787)","('NON-ESG', 0.0010753823444247246)"
Line 272,"RightCycle is designed to help pharmaceutical  companies, research laboratories and manufacturing  facilities reduce solid waste streams by recycling   nontraditional waste such as garments, gloves,  hoods, boot covers, masks and safety eyewear.
","('Waste_And_Hazardous_Materials_Management', 0.982223629951477)","('Employee_Health_And_Safety', 0.001368192839436233)","('Product_Design_And_Lifecycle_Management', 0.0013405482750386)","(['Operational Eco-Efficiency'], 0.982223629951477)","('NON-ESG', 0.001368192839436233)","('NON-ESG', 0.0013405482750386)"
Line 273,"Participants in the program have diverted more   than 600 tons of waste from landfills since 2011.
","('Waste_And_Hazardous_Materials_Management', 0.983360767364502)","('Water_And_Wastewater_Management', 0.001529813394881785)","('Air_Quality', 0.0013518115738406777)","(['Operational Eco-Efficiency'], 0.983360767364502)","('NON-ESG', 0.001529813394881785)","('NON-ESG', 0.0013518115738406777)"
Line 274,"Above: Boston Scientific employees in Maple Grove,  Minnesota, commemorate Earth Day 2018 with their  award.2018 ACHIEVEMENTS: 83%  increase* in   solid waste recycle index,   or 9,660+ tonnes.
","('Waste_And_Hazardous_Materials_Management', 0.9838656783103943)","('Data_Security', 0.0012855746317654848)","('Air_Quality', 0.0012482922757044435)","(['Operational Eco-Efficiency'], 0.9838656783103943)","('NON-ESG', 0.0012855746317654848)","('NON-ESG', 0.0012482922757044435)"
Line 275,"30%  water use   reduction*.
","('Water_And_Wastewater_Management', 0.9747153520584106)","('GHG_Emissions', 0.0025993867311626673)","('Waste_And_Hazardous_Materials_Management', 0.002302614040672779)","(['Operational Eco-Efficiency'], 0.9747153520584106)","('NON-ESG', 0.0025993867311626673)","('NON-ESG', 0.002302614040672779)"
Line 276,"equal to   301,571 cubic meters.
","('Water_And_Wastewater_Management', 0.2685111165046692)","('Waste_And_Hazardous_Materials_Management', 0.1527274250984192)","('Energy_Management', 0.14745739102363586)","('NON-ESG', 0.2685111165046692)","('NON-ESG', 0.1527274250984192)","('NON-ESG', 0.14745739102363586)"
Line 277,"1,332 tonnes   of non-recycled solid waste  was diverted away from  landfills, achieving 95%  avoidance.
","('Waste_And_Hazardous_Materials_Management', 0.982864499092102)","('Water_And_Wastewater_Management', 0.001787478686310351)","('Air_Quality', 0.0014311793493106961)","(['Operational Eco-Efficiency'], 0.982864499092102)","('NON-ESG', 0.001787478686310351)","('NON-ESG', 0.0014311793493106961)"
Line 278,"*Compared to 2009 baseline.
","('Management_Of_Legal_And_Regulatory_Framework', 0.19285424053668976)","('Systemic_Risk_Management', 0.15896470844745636)","('GHG_Emissions', 0.0771256536245346)","('NON-ESG', 0.19285424053668976)","('NON-ESG', 0.15896470844745636)","('NON-ESG', 0.0771256536245346)"
Line 279,"The blue flag at the Coyol, Costa Rica office symbolizes  our commitment to sustainability.
","('Business_Model_Resilience', 0.3353250324726105)","('Product_Design_And_Lifecycle_Management', 0.15809153020381927)","('Human_Rights_And_Community_Relations', 0.07253769040107727)","('NON-ESG', 0.3353250324726105)","('NON-ESG', 0.15809153020381927)","('NON-ESG', 0.07253769040107727)"
Line 280,"OUR PLANET BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Beach Clean-up in Costa Rica In Coyol, Costa Rica, more than 100 Boston   Scientific employees, and their families and friends,  gathered at Guacalillo Beach for a clean-up initiative  in April 2018.
","('Waste_And_Hazardous_Materials_Management', 0.3274948298931122)","('Water_And_Wastewater_Management', 0.2681741416454315)","('Ecological_Impacts', 0.08769510686397552)","('NON-ESG', 0.3274948298931122)","('NON-ESG', 0.2681741416454315)","('NON-ESG', 0.08769510686397552)"
Line 281,"The event was organized in conjunction  with the local community, government, Red Cross  organization and local foundations, Operation   Rich Coast and Algo por la Tierra.
","('Human_Rights_And_Community_Relations', 0.91093510389328)","('Management_Of_Legal_And_Regulatory_Framework', 0.017327429726719856)","('Access_And_Affordability', 0.015461561270058155)","(['Community Relations'], 0.91093510389328)","('NON-ESG', 0.017327429726719856)","('NON-ESG', 0.015461561270058155)"
Line 282,"This effort resulted   in the collection of approximately one ton of  waste and litter, including more than 70 used car  tires.
","('Waste_And_Hazardous_Materials_Management', 0.9831334948539734)","('Water_And_Wastewater_Management', 0.0016781664453446865)","('Air_Quality', 0.0012046658666804433)","(['Operational Eco-Efficiency'], 0.9831334948539734)","('NON-ESG', 0.0016781664453446865)","('NON-ESG', 0.0012046658666804433)"
Line 283,"This demonstration in caring for our planet is  an important reminder of why we strive to meet   ambitious waste reduction and recycling goals.River Stewardship in California In Valencia, California, Boston Scientific employee  volunteers partnered with the Community Hiking  Club, the California Wilderness Coalition and outdoor  retail co-op REI to clean along Piru Creek, a part of  the protected National Wild & Scenic Rivers System.
","('Waste_And_Hazardous_Materials_Management', 0.9721320271492004)","('Water_And_Wastewater_Management', 0.004682435188442469)","('Ecological_Impacts', 0.002043510088697076)","(['Operational Eco-Efficiency'], 0.9721320271492004)","('NON-ESG', 0.004682435188442469)","('NON-ESG', 0.002043510088697076)"
Line 284,"During October 2018, volunteers worked to help  preserve the habitat by removing impediments  to endangered migrating fish and collecting more  than 500 pounds of trash.GREEN TEAM ENVIRONMENTAL    SUSTAINABILITY INITIATIVES Our employee-led Green Teams present new ideas  and implement projects that reduce the company’s  environmental footprint globally, improve the   communities in which we do business and   strengthen our business practices.
","('Ecological_Impacts', 0.9728302359580994)","('Human_Rights_And_Community_Relations', 0.003937150817364454)","('GHG_Emissions', 0.0033530662767589092)","(['Natural Capital'], 0.9728302359580994)","('NON-ESG', 0.003937150817364454)","('NON-ESG', 0.0033530662767589092)"
Line 285,"In 2018, we  worked with many community partners to make   a positive impact and raise environmental   awareness.
","('Human_Rights_And_Community_Relations', 0.8555513024330139)","('Ecological_Impacts', 0.02477785386145115)","('Access_And_Affordability', 0.013733637519180775)","(['Community Relations'], 0.8555513024330139)","('NON-ESG', 0.02477785386145115)","('NON-ESG', 0.013733637519180775)"
Line 286,"Keeping our Planet Clean Beyond maintaining our facilities, our employees  around the globe participated in efforts to preserve  beaches and habitats in surrounding communities,  helping to ensure that local ecosystems remain   intact as wildlife habitats and for future generations  to enjoy.BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.OUR PEOPLE OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.At Boston Scientific, our work has purpose – it results in lives  changed, and lives saved.
","('Ecological_Impacts', 0.9725151062011719)","('Human_Rights_And_Community_Relations', 0.003470371477305889)","('GHG_Emissions', 0.0031069638207554817)","(['Natural Capital'], 0.9725151062011719)","('NON-ESG', 0.003470371477305889)","('NON-ESG', 0.0031069638207554817)"
Line 287,"Together, our employees strive   to solve healthcare challenges that matter most, with an   unwavering focus on the needs of patients, physicians and  healthcare systems.
","('Access_And_Affordability', 0.30194905400276184)","('Employee_Health_And_Safety', 0.09807401895523071)","('Critical_Incident_Risk_Management', 0.08415553718805313)","('NON-ESG', 0.30194905400276184)","('NON-ESG', 0.09807401895523071)","('NON-ESG', 0.08415553718805313)"
Line 288,"Our team of more than 32,000 employees  around the globe are collaborators, explorers and problem-  solvers, united by a focus on advancing science for life.
","('Systemic_Risk_Management', 0.14450223743915558)","('Business_Model_Resilience', 0.0994432345032692)","('Competitive_Behavior', 0.07806238532066345)","('NON-ESG', 0.14450223743915558)","('NON-ESG', 0.0994432345032692)","('NON-ESG', 0.07806238532066345)"
Line 289,"We understand that choosing the right place to   work is an important decision, and that people join  companies to find meaningful purpose and a place  to grow.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4307861030101776)","('Business_Model_Resilience', 0.11008229106664658)","('Human_Rights_And_Community_Relations', 0.09354972839355469)","('NON-ESG', 0.4307861030101776)","('NON-ESG', 0.11008229106664658)","('NON-ESG', 0.09354972839355469)"
Line 290,"We recognize that the aspirations and goals  of each employee are personal.
","('Human_Rights_And_Community_Relations', 0.7384957671165466)","('Employee_Engagement_Inclusion_And_Diversity', 0.053680047392845154)","('Employee_Health_And_Safety', 0.029782075434923172)","(['Community Relations'], 0.7384957671165466)","('NON-ESG', 0.053680047392845154)","('NON-ESG', 0.029782075434923172)"
Line 291,"Boston Scientific  global talent management practices support a   workplace where individuals can:   Build a career with global impact — truly make   a difference to people both around the world   and around the corner   Be empowered with opportunities to grow —   thrive in a culture that prioritizes learning,   development and progression    Meaningfully contribute in a collaborative   environment — build lasting relationships with  colleagues and global thought leaders   Embrace a culture with “winning spirit”  — be   part of a culture that takes measured risks   and challenges the status quo   Be rewarded — enjoy a workplace that recognizes  success and rewards individual and team   performance    Choose from diverse career options — explore   careers that suit varying backgrounds and   ambitions    Experience mobility with global opportunities —  expand personal reach and contribute to business  imperatives through international assignments  and programs  The talent of our teams and individuals creates a  competitive advantage for the company.
","('Employee_Engagement_Inclusion_And_Diversity', 0.930692732334137)","('Business_Model_Resilience', 0.00772908004000783)","('Human_Rights_And_Community_Relations', 0.006013119593262672)","(['Human Capital Development'], 0.930692732334137)","('NON-ESG', 0.00772908004000783)","('NON-ESG', 0.006013119593262672)"
Line 292,"Boston Scientific  global talent management practices support a   workplace where individuals can:   Build a career with global impact — truly make   a difference to people both around the world   and around the corner   Be empowered with opportunities to grow —   thrive in a culture that prioritizes learning,   development and progression    Meaningfully contribute in a collaborative   environment — build lasting relationships with  colleagues and global thought leaders   Embrace a culture with “winning spirit”  — be   part of a culture that takes measured risks   and challenges the status quo   Be rewarded — enjoy a workplace that recognizes  success and rewards individual and team   performance    Choose from diverse career options — explore   careers that suit varying backgrounds and   ambitions    Experience mobility with global opportunities —  expand personal reach and contribute to business  imperatives through international assignments  and programs  The talent of our teams and individuals creates a  competitive advantage for the company.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9491633772850037)","('Employee_Health_And_Safety', 0.006547640543431044)","('Business_Model_Resilience', 0.00385290733538568)","(['Human Capital Development'], 0.9491633772850037)","('NON-ESG', 0.006547640543431044)","('NON-ESG', 0.00385290733538568)"
Line 293,"Boston Scientific  global talent management practices support a   workplace where individuals can:   Build a career with global impact — truly make   a difference to people both around the world   and around the corner   Be empowered with opportunities to grow —   thrive in a culture that prioritizes learning,   development and progression    Meaningfully contribute in a collaborative   environment — build lasting relationships with  colleagues and global thought leaders   Embrace a culture with “winning spirit”  — be   part of a culture that takes measured risks   and challenges the status quo   Be rewarded — enjoy a workplace that recognizes  success and rewards individual and team   performance    Choose from diverse career options — explore   careers that suit varying backgrounds and   ambitions    Experience mobility with global opportunities —  expand personal reach and contribute to business  imperatives through international assignments  and programs  The talent of our teams and individuals creates a  competitive advantage for the company.
","('Competitive_Behavior', 0.9575072526931763)","('Business_Model_Resilience', 0.0034358850680291653)","('Business_Ethics', 0.0031291907653212547)","(['Business Ethics'], 0.9575072526931763)","('NON-ESG', 0.0034358850680291653)","('NON-ESG', 0.0031291907653212547)"
Line 294,"That’s   why we work hard to attract diverse talent, enable   a culture of engagement and inclusion and enhance  our organizational capabilities to build the workforce  of the future.
","('Employee_Engagement_Inclusion_And_Diversity', 0.975307285785675)","('Human_Rights_And_Community_Relations', 0.0019181645475327969)","('Employee_Health_And_Safety', 0.0018295061308890581)","(['Human Capital Development'], 0.975307285785675)","('NON-ESG', 0.0019181645475327969)","('NON-ESG', 0.0018295061308890581)"
Line 295,"The Boston Scientific Women’s Network worked  with the Girls on the Run organization to help  young girls develop essential skills to establish   a lifetime of health and fitness.OUR PEOPLE OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.ACCELERATING DIVERSITY    AND INCLUSION At Boston Scientific, our diversity value stands for  inclusion, equality and opportunity for all, and guides  our work to advance science and improve patient  health.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9681108593940735)","('Employee_Health_And_Safety', 0.004224914591759443)","('Human_Rights_And_Community_Relations', 0.002663241932168603)","(['Human Capital Development'], 0.9681108593940735)","('NON-ESG', 0.004224914591759443)","('NON-ESG', 0.002663241932168603)"
Line 296,"By embracing unique backgrounds and   perspectives, we create a more rewarding place to  work that better reflects the patients, customers and  communities we serve.
","('Employee_Engagement_Inclusion_And_Diversity', 0.920112133026123)","('Human_Rights_And_Community_Relations', 0.014534475281834602)","('Access_And_Affordability', 0.007266326807439327)","(['Human Capital Development'], 0.920112133026123)","('NON-ESG', 0.014534475281834602)","('NON-ESG', 0.007266326807439327)"
Line 297,"Our Diversity and Inclusion efforts are focused on  four strategic pillars:    Career   Culture   Commerce    Community ATTRACTING AND ENGAGING    DIVERSE TALENT In 2018, we launched “10/20/40 by 2020” goals to  accelerate our diversity and inclusion efforts.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9755231142044067)","('Employee_Health_And_Safety', 0.0020630082581192255)","('Human_Rights_And_Community_Relations', 0.0014953683130443096)","(['Human Capital Development'], 0.9755231142044067)","('NON-ESG', 0.0020630082581192255)","('NON-ESG', 0.0014953683130443096)"
Line 298,"These  goals are aimed at reshaping the company’s core  mid-level employee base to move beyond traditional   diversity recruiting efforts that tend to target the  entry-level pipeline or focus on top-down change.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9743121266365051)","('Business_Model_Resilience', 0.001815451425500214)","('Employee_Health_And_Safety', 0.001603942597284913)","(['Human Capital Development'], 0.9743121266365051)","('NON-ESG', 0.001815451425500214)","('NON-ESG', 0.001603942597284913)"
Line 299,"Transparent reporting is an important part of how   we hold ourselves accountable.
","('Business_Ethics', 0.9464115500450134)","('Management_Of_Legal_And_Regulatory_Framework', 0.011009338311851025)","('Competitive_Behavior', 0.004021493252366781)","(['Business Ethics'], 0.9464115500450134)","('NON-ESG', 0.011009338311851025)","('NON-ESG', 0.004021493252366781)"
Line 300,"By the end of 2018,   we achieved the following progress toward our  goals: By 2020, our goals are to: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Women Global46.5%  45.5 %2017 |People of Color U.S./Puerto Rico31.7%  30.7 %2017 |2018All Levels 38.4% 37.4% Supervisors & Managers429.5% 27.3% Senior Management318.8 % 12.5 % Executive Officers230.0 % 30.0 % Board of Directors2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level44.3%43.6 % 56.2% 50.5% 45.5% 40.6 %57.7% 43.6 % 45.5% 43.3%US/PR Latin America Canada Europe, Middle East & Africa Asia Pacific2017 |2018By region American Indian / Alaskan Asian Black / African American Hispanic / Latino Multiracial Native Hawaiian / Other Pacific Islander13.7% 13.4% 5.1% 10.1% 9.5% 1.2% 0.3%1.6% 0.3%6.5%0.3% 0.3%2017 |2018By ethnic groupRepresentation of Women Around the GlobeRepresentation of People of Color in the U.S. and Puerto Rico*Based on individuals' voluntary self-identification    1 Gender: Gender information is collected uniformly for global reporting purposes.
","('Director_Removal', 0.38287273049354553)","('Employee_Engagement_Inclusion_And_Diversity', 0.28945159912109375)","('Business_Model_Resilience', 0.049524642527103424)","('NON-ESG', 0.38287273049354553)","('NON-ESG', 0.28945159912109375)","('NON-ESG', 0.049524642527103424)"
Line 301,"By the end of 2018,   we achieved the following progress toward our  goals: By 2020, our goals are to: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Women Global46.5%  45.5 %2017 |People of Color U.S./Puerto Rico31.7%  30.7 %2017 |2018All Levels 38.4% 37.4% Supervisors & Managers429.5% 27.3% Senior Management318.8 % 12.5 % Executive Officers230.0 % 30.0 % Board of Directors2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level44.3%43.6 % 56.2% 50.5% 45.5% 40.6 %57.7% 43.6 % 45.5% 43.3%US/PR Latin America Canada Europe, Middle East & Africa Asia Pacific2017 |2018By region American Indian / Alaskan Asian Black / African American Hispanic / Latino Multiracial Native Hawaiian / Other Pacific Islander13.7% 13.4% 5.1% 10.1% 9.5% 1.2% 0.3%1.6% 0.3%6.5%0.3% 0.3%2017 |2018By ethnic groupRepresentation of Women Around the GlobeRepresentation of People of Color in the U.S. and Puerto Rico*Based on individuals' voluntary self-identification    1 Gender: Gender information is collected uniformly for global reporting purposes.
","('Employee_Engagement_Inclusion_And_Diversity', 0.969363272190094)","('Business_Model_Resilience', 0.0026420203503221273)","('Human_Rights_And_Community_Relations', 0.002091397764161229)","(['Human Capital Development'], 0.969363272190094)","('NON-ESG', 0.0026420203503221273)","('NON-ESG', 0.002091397764161229)"
Line 302,"By the end of 2018,   we achieved the following progress toward our  goals: By 2020, our goals are to: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Women Global46.5%  45.5 %2017 |People of Color U.S./Puerto Rico31.7%  30.7 %2017 |2018All Levels 38.4% 37.4% Supervisors & Managers429.5% 27.3% Senior Management318.8 % 12.5 % Executive Officers230.0 % 30.0 % Board of Directors2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level 17.8%19.6% Supervisors & Managers11.5 %13.1% Senior Management2017 |2018By level44.3%43.6 % 56.2% 50.5% 45.5% 40.6 %57.7% 43.6 % 45.5% 43.3%US/PR Latin America Canada Europe, Middle East & Africa Asia Pacific2017 |2018By region American Indian / Alaskan Asian Black / African American Hispanic / Latino Multiracial Native Hawaiian / Other Pacific Islander13.7% 13.4% 5.1% 10.1% 9.5% 1.2% 0.3%1.6% 0.3%6.5%0.3% 0.3%2017 |2018By ethnic groupRepresentation of Women Around the GlobeRepresentation of People of Color in the U.S. and Puerto Rico*Based on individuals' voluntary self-identification    1 Gender: Gender information is collected uniformly for global reporting purposes.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9691339135169983)","('Customer_Privacy', 0.003694753395393491)","('Employee_Health_And_Safety', 0.0024567467626184225)","(['Human Capital Development'], 0.9691339135169983)","('NON-ESG', 0.003694753395393491)","('NON-ESG', 0.0024567467626184225)"
Line 303,"2 Executive Officers includes all executive committee members listed in the company's Annual Report.
","('Director_Removal', 0.7556074857711792)","('Management_Of_Legal_And_Regulatory_Framework', 0.02835102006793022)","('Labor_Practices', 0.022498441860079765)","(['Anti-Crime Policy & Measures'], 0.7556074857711792)","('NON-ESG', 0.02835102006793022)","('NON-ESG', 0.022498441860079765)"
Line 304,"3  Senior Management includes all levels that are  director, vice president, senior vice president, executive vice president and CEO    4 Supervisors and Managers includes all levels that are supervisor, manager I and manager II.
","('Director_Removal', 0.5791951417922974)","('Employee_Engagement_Inclusion_And_Diversity', 0.10103789716959)","('Labor_Practices', 0.035930510610342026)","(['Anti-Crime Policy & Measures'], 0.5791951417922974)","('NON-ESG', 0.10103789716959)","('NON-ESG', 0.035930510610342026)"
Line 305,"5 People of Color (PoC): Each country has specific requirements and legal considerations regarding how PoC data can be  used and reported.
","('Employee_Engagement_Inclusion_And_Diversity', 0.953050971031189)","('Customer_Privacy', 0.006614872720092535)","('Employee_Health_And_Safety', 0.00379132735542953)","(['Human Capital Development'], 0.953050971031189)","('NON-ESG', 0.006614872720092535)","('NON-ESG', 0.00379132735542953)"
Line 306,"Our reporting focuses on our US/PR PoC populations as it is uniform in definition, reporting and use.THE PEOPLE OF BOSTON SCIENTIFIC* OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.LEADERSHIP COMMITMENT Fostering a more inclusive environment starts at the  top.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7996924519538879)","('Human_Rights_And_Community_Relations', 0.05576087161898613)","('Business_Model_Resilience', 0.01919897086918354)","(['Human Capital Development'], 0.7996924519538879)","('NON-ESG', 0.05576087161898613)","('NON-ESG', 0.01919897086918354)"
Line 307,"Chairman and CEO Mike Mahoney, along with  chief executives of the world’s leading companies,  are part of the CEO Action for Diversity and Inclusion  Pledge , the largest CEO-driven business commitment   to advance workplace diversity and inclusion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9747198820114136)","('Employee_Health_And_Safety', 0.0027501992881298065)","('Human_Rights_And_Community_Relations', 0.001580495503731072)","(['Human Capital Development'], 0.9747198820114136)","('NON-ESG', 0.0027501992881298065)","('NON-ESG', 0.001580495503731072)"
Line 308,"Since  signing the pledge in 2017, Boston Scientific and   other participating companies have shared best  practices for creating a work environment where  complex and sometimes difficult conversations  about diversity and inclusion can occur, including  holding a Day of Understanding to provide a forum  for employees to engage in meaningful dialogue   on inclusion barriers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9762256145477295)","('Employee_Health_And_Safety', 0.0022932826541364193)","('Human_Rights_And_Community_Relations', 0.0017997563118115067)","(['Human Capital Development'], 0.9762256145477295)","('NON-ESG', 0.0022932826541364193)","('NON-ESG', 0.0017997563118115067)"
Line 309,"To achieve our 10/20/40 goals, each business,   regional and functional leadership team has   established plans to increase representation of  women, people of color and globalization within  their organizations.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9740020036697388)","('Human_Rights_And_Community_Relations', 0.00218327809125185)","('Employee_Health_And_Safety', 0.0019249372417107224)","(['Human Capital Development'], 0.9740020036697388)","('NON-ESG', 0.00218327809125185)","('NON-ESG', 0.0019249372417107224)"
Line 310,"Examples of plan initiatives   include mandatory consideration of a diverse   slate of qualified candidates for all manager and  above roles, required unconscious bias training   for all those who manage people and programs   that promote diversity awareness and inclusive   competency skills.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9739437699317932)","('Human_Rights_And_Community_Relations', 0.001905030570924282)","('Employee_Health_And_Safety', 0.001808783388696611)","(['Human Capital Development'], 0.9739437699317932)","('NON-ESG', 0.001905030570924282)","('NON-ESG', 0.001808783388696611)"
Line 311,"Additionally, we audit key   talent management practices such as interview  questions and high-potential leadership program   requirements to ensure support of an inclusive  culture.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9707499146461487)","('Employee_Health_And_Safety', 0.0022295869421213865)","('Business_Model_Resilience', 0.001988939242437482)","(['Human Capital Development'], 0.9707499146461487)","('NON-ESG', 0.0022295869421213865)","('NON-ESG', 0.001988939242437482)"
Line 312,"Collaborating for Change We proudly partner with leading organizations   that promote and support the development of   women, people of color, people with disabilities   and LGBTQ talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9674060344696045)","('Human_Rights_And_Community_Relations', 0.0034904221538454294)","('Employee_Health_And_Safety', 0.002669108333066106)","(['Human Capital Development'], 0.9674060344696045)","('NON-ESG', 0.0034904221538454294)","('NON-ESG', 0.002669108333066106)"
Line 313,"In the United States, these   partnerships include Advancing Minorities’ Interests  in Engineering, Disability:IN, Hiring Our Heroes,   the Human Rights Campaign, the National Society   of Black Engineers, National Action Council for   Minorities in Engineering, reacHIRE, the Society   of Hispanic Professional Engineers and the Society   of Women Engineers, among others.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9552602171897888)","('Employee_Health_And_Safety', 0.008013584651052952)","('Human_Rights_And_Community_Relations', 0.005975135136395693)","(['Human Capital Development'], 0.9552602171897888)","('NON-ESG', 0.008013584651052952)","('NON-ESG', 0.005975135136395693)"
Line 314,"We are building similar collaborations in other   parts of the world.
","('Business_Model_Resilience', 0.13786987960338593)","('Employee_Engagement_Inclusion_And_Diversity', 0.12771651148796082)","('Product_Design_And_Lifecycle_Management', 0.07124500721693039)","('NON-ESG', 0.13786987960338593)","('NON-ESG', 0.12771651148796082)","('NON-ESG', 0.07124500721693039)"
Line 315,"In 2018, we hosted 100 members  of the Japan Women’s Innovative Network (J-Win)  organization at our corporate headquarters as part  of the organization’s Annual Overseas Study Tour.
","('Employee_Engagement_Inclusion_And_Diversity', 0.38043835759162903)","('Business_Model_Resilience', 0.1185741052031517)","('Human_Rights_And_Community_Relations', 0.05750172957777977)","('NON-ESG', 0.38043835759162903)","('NON-ESG', 0.1185741052031517)","('NON-ESG', 0.05750172957777977)"
Line 316,"During their visit, J-WIN members learned more  about the medical device industry and participated   in an interactive career experience session with   Boston Scientific leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.16610237956047058)","('Supply_Chain_Management', 0.1622297167778015)","('Business_Model_Resilience', 0.12268722057342529)","('NON-ESG', 0.16610237956047058)","('NON-ESG', 0.1622297167778015)","('NON-ESG', 0.12268722057342529)"
Line 317,"As a founding member of Disability:IN’s Inclusion  Works Program (formerly Going for the Gold), we  are advancing programs to support the hiring and  inclusion of people with disabilities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9447893500328064)","('Employee_Health_And_Safety', 0.013633767142891884)","('Human_Rights_And_Community_Relations', 0.005143463145941496)","(['Human Capital Development'], 0.9447893500328064)","('NON-ESG', 0.013633767142891884)","('NON-ESG', 0.005143463145941496)"
Line 318,"Through this  collaboration, we conducted disability awareness  training globally, increased understanding and   adoption of the reasonable accommodations   process and expanded the availability of on-site   resources.
","('Employee_Health_And_Safety', 0.38698092103004456)","('Employee_Engagement_Inclusion_And_Diversity', 0.32264336943626404)","('Access_And_Affordability', 0.09799359738826752)","('NON-ESG', 0.38698092103004456)","('NON-ESG', 0.32264336943626404)","('NON-ESG', 0.09799359738826752)"
Line 319,"Also in 2018, our fulfillment center in   Quincy, Massachusetts, launched a program to   assist people with disabilities seeking customer   service and distribution center employment.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8277119994163513)","('Employee_Health_And_Safety', 0.03925113007426262)","('Access_And_Affordability', 0.038028210401535034)","(['Human Capital Development'], 0.8277119994163513)","('NON-ESG', 0.03925113007426262)","('NON-ESG', 0.038028210401535034)"
Line 320,"Boston Scientific has been recognized for three   consecutive years as a Disability Equality Index®   (DEI) Best Place to Work.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8721762895584106)","('Employee_Health_And_Safety', 0.04947914555668831)","('Labor_Practices', 0.013674034737050533)","(['Human Capital Development'], 0.8721762895584106)","('NON-ESG', 0.04947914555668831)","('NON-ESG', 0.013674034737050533)"
Line 321,"In 2018, our Europe, Middle East and Africa region established a regional D&I Council that includes D&I champions  who set regional goals and address the needs of employees located across 35 countries and three continents.51.2 % 50.5% Women Global2017 |42.6% 40.7% People of Color U.S./Puerto Rico2017 |2018Boston Scientific New Hires OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Targeted development/retention programs  We continue to increase focus on developing   women and people of color through specific   development initiatives that include executive   sponsorship, deliberate job movement and   leadership development programs.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9696885347366333)","('Employee_Health_And_Safety', 0.003027936676517129)","('Human_Rights_And_Community_Relations', 0.0026161049026995897)","(['Human Capital Development'], 0.9696885347366333)","('NON-ESG', 0.003027936676517129)","('NON-ESG', 0.0026161049026995897)"
Line 322,"In 2018, our Europe, Middle East and Africa region established a regional D&I Council that includes D&I champions  who set regional goals and address the needs of employees located across 35 countries and three continents.51.2 % 50.5% Women Global2017 |42.6% 40.7% People of Color U.S./Puerto Rico2017 |2018Boston Scientific New Hires OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Targeted development/retention programs  We continue to increase focus on developing   women and people of color through specific   development initiatives that include executive   sponsorship, deliberate job movement and   leadership development programs.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7917045950889587)","('Human_Rights_And_Community_Relations', 0.03013986349105835)","('Employee_Health_And_Safety', 0.021131295710802078)","(['Human Capital Development'], 0.7917045950889587)","('NON-ESG', 0.03013986349105835)","('NON-ESG', 0.021131295710802078)"
Line 323,"One example   of this work is the Boston Scientific EXCELerate   program, a multi-year sponsorship focused on   the career development of female talent in a   range of technical fields, including R&D,   manufacturing, supply chain, clinical, quality,   information technology, global business systems   and security.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6407639384269714)","('Supply_Chain_Management', 0.07879520207643509)","('Product_Design_And_Lifecycle_Management', 0.042234741151332855)","(['Human Capital Development'], 0.6407639384269714)","('NON-ESG', 0.07879520207643509)","('NON-ESG', 0.042234741151332855)"
Line 324,"In 2018, 93 women from seven   countries participated in the program and   were matched with Boston Scientific executive   sponsors who serve as advisors, mentors and   career advocates.In addition, our Women’s Network Employee   Resource Group chapters across local markets   support the personal and professional development  of women through formal mentoring programs.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8735097050666809)","('Human_Rights_And_Community_Relations', 0.022995315492153168)","('Access_And_Affordability', 0.0191100612282753)","(['Human Capital Development'], 0.8735097050666809)","('NON-ESG', 0.022995315492153168)","('NON-ESG', 0.0191100612282753)"
Line 325,"These programs are designed to help participants  develop leadership skills, set realistic career goals   and plans to achieve them, while expanding their  network within Boston Scientific.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8988135457038879)","('Business_Model_Resilience', 0.011517085134983063)","('Employee_Health_And_Safety', 0.008009734563529491)","(['Human Capital Development'], 0.8988135457038879)","('NON-ESG', 0.011517085134983063)","('NON-ESG', 0.008009734563529491)"
Line 326,"For instance, our  Women’s Network chapter in Japan held its annual  PRISM congress in 2018 with all female employees  and their managers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3747863173484802)","('Labor_Practices', 0.3117196559906006)","('Director_Removal', 0.08809717744588852)","('NON-ESG', 0.3747863173484802)","('NON-ESG', 0.3117196559906006)","('NON-ESG', 0.08809717744588852)"
Line 327,"The event focused on the state  of diversity and inclusion in Japan and how to further  address cultural barriers that impact the representa- tion of women in sales and leadership positions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9756671786308289)","('Human_Rights_And_Community_Relations', 0.001902507501654327)","('Employee_Health_And_Safety', 0.0017977432580664754)","(['Human Capital Development'], 0.9756671786308289)","('NON-ESG', 0.001902507501654327)","('NON-ESG', 0.0017977432580664754)"
Line 328,"LISTENING TO SUPPORT    AN INCLUSIVE CULTURE Our best ideas come from our people, including   how to continuously improve our workplace   and culture to attract and retain top talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.963648796081543)","('Employee_Health_And_Safety', 0.003426711540669203)","('Human_Rights_And_Community_Relations', 0.0032963540870696306)","(['Human Capital Development'], 0.963648796081543)","('NON-ESG', 0.003426711540669203)","('NON-ESG', 0.0032963540870696306)"
Line 329,"Employee Surveys  We regularly conduct a global Employee   Engagement survey to better understand our   cultural and organizational strengths and areas   for improvement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.926669716835022)","('Human_Rights_And_Community_Relations', 0.010802007280290127)","('Employee_Health_And_Safety', 0.009199257008731365)","(['Human Capital Development'], 0.926669716835022)","('NON-ESG', 0.010802007280290127)","('NON-ESG', 0.009199257008731365)"
Line 330,"Results from the latest global  survey include an overall engagement score of 79  percent, positioning Boston Scientific eight points  above the global benchmark for high performing  companies across industries.* The company also   exceeded the global high performing norm in four  out of the five benchmarked categories (engagement,   * Source: Corporate Executive Boardimmediate manager, senior leadership, talent and  performance management and total rewards).
","('Employee_Engagement_Inclusion_And_Diversity', 0.7406829595565796)","('Business_Model_Resilience', 0.05504422262310982)","('Director_Removal', 0.020179137587547302)","(['Human Capital Development'], 0.7406829595565796)","('NON-ESG', 0.05504422262310982)","('NON-ESG', 0.020179137587547302)"
Line 331,"Leaders, working with employees, reviewed these  results to create measurable multi-year action plans  to refine and improve on results at the corporate   and local level.
","('Management_Of_Legal_And_Regulatory_Framework', 0.44204333424568176)","('Human_Rights_And_Community_Relations', 0.22523599863052368)","('Access_And_Affordability', 0.040721677243709564)","('NON-ESG', 0.44204333424568176)","('NON-ESG', 0.22523599863052368)","('NON-ESG', 0.040721677243709564)"
Line 332,"We also conducted a 2018 qualitative study with a  global cross-representation of employees to better  understand engagement differences in employee  perceptions of career development opportunities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.969691812992096)","('Employee_Health_And_Safety', 0.003313038730993867)","('Labor_Practices', 0.002736448310315609)","(['Human Capital Development'], 0.969691812992096)","('NON-ESG', 0.003313038730993867)","('NON-ESG', 0.002736448310315609)"
Line 333,"As a result of this effort, as well as best-practice  benchmarking, we expanded manager skill-building  programs and drove greater transparency of our  diversity data, initiatives and goals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9723244905471802)","('Customer_Privacy', 0.0021586911752820015)","('Human_Rights_And_Community_Relations', 0.0018352670595049858)","(['Human Capital Development'], 0.9723244905471802)","('NON-ESG', 0.0021586911752820015)","('NON-ESG', 0.0018352670595049858)"
Line 334,"Several of these  initiatives were launched in 2018 and will continue  into the next year and beyond.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3864220082759857)","('Human_Rights_And_Community_Relations', 0.1804996132850647)","('Access_And_Affordability', 0.10483569651842117)","('NON-ESG', 0.3864220082759857)","('NON-ESG', 0.1804996132850647)","('NON-ESG', 0.10483569651842117)"
Line 335,"Self-ID Survey As a U.S. federal contractor doing business with   the U.S. government, Boston Scientific is required  to regularly survey employees about their disability  status.
","('Employee_Health_And_Safety', 0.5076665282249451)","('Employee_Engagement_Inclusion_And_Diversity', 0.3821544647216797)","('Labor_Practices', 0.02392084151506424)","(['Operational Eco-Efficiency'], 0.5076665282249451)","('NON-ESG', 0.3821544647216797)","('NON-ESG', 0.02392084151506424)"
Line 336,"In response to employee feedback, our   2018 survey included questions related to self-  identification in the categories of military, gender,  LGBTQ and ethnicity/race.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9739599823951721)","('Customer_Privacy', 0.0023359761107712984)","('Employee_Health_And_Safety', 0.0021875605452805758)","(['Human Capital Development'], 0.9739599823951721)","('NON-ESG', 0.0023359761107712984)","('NON-ESG', 0.0021875605452805758)"
Line 337,"Nearly 30 percent of   the company’s U.S. and Puerto Rico employee   population completed the questionnaire.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8878915905952454)","('Labor_Practices', 0.02763848565518856)","('Employee_Health_And_Safety', 0.01374158263206482)","(['Human Capital Development'], 0.8878915905952454)","('NON-ESG', 0.02763848565518856)","('NON-ESG', 0.01374158263206482)"
Line 338,"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Our Employee Resource Groups (ERGs) help create thriving  communities for our diverse employees to connect and   succeed, while impacting communities around the world.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7465981245040894)","('Human_Rights_And_Community_Relations', 0.14776232838630676)","('Employee_Health_And_Safety', 0.010702523402869701)","(['Human Capital Development'], 0.7465981245040894)","('NON-ESG', 0.14776232838630676)","('NON-ESG', 0.010702523402869701)"
Line 339,"Here are a few examples of their achievements in 2018: Bridge to the Future The Valencia, California, BRIDGE  chapter hosts an annual Bridge   to the Future program that helps   introduce students of color to   STEM education.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9183891415596008)","('Access_And_Affordability', 0.012055246159434319)","('Product_Design_And_Lifecycle_Management', 0.005785927176475525)","(['Human Capital Development'], 0.9183891415596008)","('NON-ESG', 0.012055246159434319)","('NON-ESG', 0.005785927176475525)"
Line 340,"The nine-month  experience for 10th through   12th graders includes sessions   such as this one focused on   programming, coding and   robotics and professional skills.
","('Employee_Engagement_Inclusion_And_Diversity', 0.48260605335235596)","('Access_And_Affordability', 0.20028255879878998)","('Product_Quality_And_Safety', 0.031176019459962845)","('NON-ESG', 0.48260605335235596)","('NON-ESG', 0.20028255879878998)","('NON-ESG', 0.031176019459962845)"
Line 341,"In April 2018, BRIDGE hosted   their seventh graduation,   celebrating the growth and   development of 27 students.New ERGs in Ireland Our Clonmel, Cork and Galway   sites in Ireland coordinated the  launch of three new LEAD   chapters in 2018, while also   coordinating site-specific   disability inclusion training.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8996925354003906)","('Employee_Health_And_Safety', 0.032543882727622986)","('Access_And_Affordability', 0.008198421448469162)","(['Human Capital Development'], 0.8996925354003906)","('NON-ESG', 0.032543882727622986)","('NON-ESG', 0.008198421448469162)"
Line 342,"The sites collaborated to   develop programs dedicated   to supporting people with   disabilities in the workplace.Operation Gratitude In 2018, our VETS chapters   collaborated with Operation   Gratitude to collect more than   700 pounds of requested   supplies across Boston Scientific  locations.
","('Employee_Health_And_Safety', 0.5930339097976685)","('Access_And_Affordability', 0.15037068724632263)","('Employee_Engagement_Inclusion_And_Diversity', 0.09266599267721176)","(['Operational Eco-Efficiency'], 0.5930339097976685)","('NON-ESG', 0.15037068724632263)","('NON-ESG', 0.09266599267721176)"
Line 343,"Operation Gratitude   supports U.S. troops and their   families by sending care   packages to all who bravely   serve and delivering items   needed by their families   at home.
","('Access_And_Affordability', 0.5799285173416138)","('Employee_Health_And_Safety', 0.17912347614765167)","('Critical_Incident_Risk_Management', 0.050995174795389175)","(['Health Outcome Contribution'], 0.5799285173416138)","('NON-ESG', 0.17912347614765167)","('NON-ESG', 0.050995174795389175)"
Line 344,"EMPLOYEE RESOURCE GROUPS Our ERGs are at the heart of our culture of diversity,   collaborating across the business at all levels to  promote awareness in a wide range of areas.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9738361239433289)","('Employee_Health_And_Safety', 0.0021674507297575474)","('Human_Rights_And_Community_Relations', 0.001983165042474866)","(['Human Capital Development'], 0.9738361239433289)","('NON-ESG', 0.0021674507297575474)","('NON-ESG', 0.001983165042474866)"
Line 345,"When  people join and contribute to these groups, they   take on valuable new experiences and opportunities  to handle new responsibilities.
","('Human_Rights_And_Community_Relations', 0.528095006942749)","('Employee_Engagement_Inclusion_And_Diversity', 0.21191464364528656)","('Access_And_Affordability', 0.03934494033455849)","(['Community Relations'], 0.528095006942749)","('NON-ESG', 0.21191464364528656)","('NON-ESG', 0.03934494033455849)"
Line 346,"More than 4,400    Boston Scientific employees  are active in 9 ERGs with 85  chapters around the world:     BRIDGE: Developing a Community of Black  Leaders   HOLA: Hispanic Organization for Leadership  and Achievement   LEAD: Leadership, Education and Allies for   Disabilities   PACE: People Accepting and Celebrating   Equality   PEARL: Pacific East Asian Resources in   Leadership   SAIL: South Asians in Leadership   VETS: Veterans & Employees Together in   Service (Military)   Women’s Network: Promoting Professional   Development of Women   YPN: Young Professionals Network OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Global Council for Inclusion  Our leaders are important role models for driving  change.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9681853652000427)","('Employee_Health_And_Safety', 0.0039058392867445946)","('Human_Rights_And_Community_Relations', 0.0031366213224828243)","(['Human Capital Development'], 0.9681853652000427)","('NON-ESG', 0.0039058392867445946)","('NON-ESG', 0.0031366213224828243)"
Line 347,"More than 4,400    Boston Scientific employees  are active in 9 ERGs with 85  chapters around the world:     BRIDGE: Developing a Community of Black  Leaders   HOLA: Hispanic Organization for Leadership  and Achievement   LEAD: Leadership, Education and Allies for   Disabilities   PACE: People Accepting and Celebrating   Equality   PEARL: Pacific East Asian Resources in   Leadership   SAIL: South Asians in Leadership   VETS: Veterans & Employees Together in   Service (Military)   Women’s Network: Promoting Professional   Development of Women   YPN: Young Professionals Network OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Global Council for Inclusion  Our leaders are important role models for driving  change.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9331075549125671)","('Human_Rights_And_Community_Relations', 0.014369702897965908)","('Access_And_Affordability', 0.004541411530226469)","(['Human Capital Development'], 0.9331075549125671)","('NON-ESG', 0.014369702897965908)","('NON-ESG', 0.004541411530226469)"
Line 348,"The Boston Scientific Global Council for  Inclusion guides the implementation of our D&I   strategies.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8529831171035767)","('Human_Rights_And_Community_Relations', 0.02005317248404026)","('Business_Model_Resilience', 0.017350267618894577)","(['Human Capital Development'], 0.8529831171035767)","('NON-ESG', 0.02005317248404026)","('NON-ESG', 0.017350267618894577)"
Line 349,"The council is chaired by Chief Financial   Officer Dan Brennan and its members include   Chairman and CEO Mike Mahoney, the Executive  Committee, our global D&I team and all global   ERG leaders.
","('Director_Removal', 0.29253914952278137)","('Business_Model_Resilience', 0.22707755863666534)","('Systemic_Risk_Management', 0.09528574347496033)","('NON-ESG', 0.29253914952278137)","('NON-ESG', 0.22707755863666534)","('NON-ESG', 0.09528574347496033)"
Line 350,"The council meets quarterly to assess   diversity and inclusion progress and engage in  candid conversations on issues that our employee  groups may be facing.
","('Employee_Engagement_Inclusion_And_Diversity', 0.975590705871582)","('Employee_Health_And_Safety', 0.0020082718692719936)","('Human_Rights_And_Community_Relations', 0.001937835942953825)","(['Human Capital Development'], 0.975590705871582)","('NON-ESG', 0.0020082718692719936)","('NON-ESG', 0.001937835942953825)"
Line 351,"Each of our nine ERGs are   also sponsored by an Executive Committee member.
","('Director_Removal', 0.5877659320831299)","('Management_Of_Legal_And_Regulatory_Framework', 0.08902618288993835)","('Employee_Engagement_Inclusion_And_Diversity', 0.031049411743879318)","(['Anti-Crime Policy & Measures'], 0.5877659320831299)","('NON-ESG', 0.08902618288993835)","('NON-ESG', 0.031049411743879318)"
Line 352,"Recognizing that our businesses, functions and   regions experience D&I challenges differently,   we have also established local inclusion councils   to support these unique opportunities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9590632915496826)","('Human_Rights_And_Community_Relations', 0.005369431339204311)","('Employee_Health_And_Safety', 0.0033148734364658594)","(['Human Capital Development'], 0.9590632915496826)","('NON-ESG', 0.005369431339204311)","('NON-ESG', 0.0033148734364658594)"
Line 353,"SETTING THE BAR HIGHER   Boston Scientific participates in several external  benchmark index surveys that enable us to   compare and assess our progress and practices   for continued improvement.
","('Management_Of_Legal_And_Regulatory_Framework', 0.32778507471084595)","('Systemic_Risk_Management', 0.1398283839225769)","('Competitive_Behavior', 0.0844409242272377)","('NON-ESG', 0.32778507471084595)","('NON-ESG', 0.1398283839225769)","('NON-ESG', 0.0844409242272377)"
Line 354,"With a D&I goal   focused on achieving Top 10 workplace inclusion  leadership in key focus areas (women, people of  color, disabilities and LGBTQ), we are committed   to driving practices that promote an inclusive   culture and enable us to be an employer of   choice for globally diverse talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9761770963668823)","('Employee_Health_And_Safety', 0.0018868217011913657)","('Human_Rights_And_Community_Relations', 0.0017061920370906591)","(['Human Capital Development'], 0.9761770963668823)","('NON-ESG', 0.0018868217011913657)","('NON-ESG', 0.0017061920370906591)"
Line 355,"We are proud   to have been recognized by the following   organizations in 2018 for our work:2018 Awards    LATINA Style’s 50 Best Companies for   Latinas (2015-2018)      Disability Equality Index (DEI) (2016 - 2018)    Fatherly Top 50 Places to Work for New   Dads (2018)      Forbes list of Best Employers for Women  (2018)      Forbes list of Best Employers for Diversity  (2018)      Glassdoor Employees' Choice Best Places   to Work (2018)      Historically Black Colleges and Universities  (HBCU) Top Supporter (2016-2018)      Human Rights Campaign’s Corporate   Equality Index (2015–2018)      Leading Diversity Best Practices Inclusion  Index Organization (2018)   National Association for Female Executives  Top Companies for Executive Women (2018)    Working Mother ""100 Best Companies""   (2017-2018)Equal Employment Opportunity Policy Boston Scientific has been, and will continue to   be, an equal opportunity employer.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9640414714813232)","('Employee_Health_And_Safety', 0.005072932690382004)","('Labor_Practices', 0.004026560112833977)","(['Human Capital Development'], 0.9640414714813232)","('NON-ESG', 0.005072932690382004)","('NON-ESG', 0.004026560112833977)"
Line 356,"We are proud   to have been recognized by the following   organizations in 2018 for our work:2018 Awards    LATINA Style’s 50 Best Companies for   Latinas (2015-2018)      Disability Equality Index (DEI) (2016 - 2018)    Fatherly Top 50 Places to Work for New   Dads (2018)      Forbes list of Best Employers for Women  (2018)      Forbes list of Best Employers for Diversity  (2018)      Glassdoor Employees' Choice Best Places   to Work (2018)      Historically Black Colleges and Universities  (HBCU) Top Supporter (2016-2018)      Human Rights Campaign’s Corporate   Equality Index (2015–2018)      Leading Diversity Best Practices Inclusion  Index Organization (2018)   National Association for Female Executives  Top Companies for Executive Women (2018)    Working Mother ""100 Best Companies""   (2017-2018)Equal Employment Opportunity Policy Boston Scientific has been, and will continue to   be, an equal opportunity employer.
","('Employee_Engagement_Inclusion_And_Diversity', 0.960800290107727)","('Human_Rights_And_Community_Relations', 0.005227136425673962)","('Labor_Practices', 0.004820779897272587)","(['Human Capital Development'], 0.960800290107727)","('NON-ESG', 0.005227136425673962)","('NON-ESG', 0.004820779897272587)"
Line 357,"To ensure   full implementation of the company’s equal   employment policy, we continue to work to ensure  that recruitment, hiring, assignment, promotion,  compensation and all other personnel decisions   are made and administered without regard to   race, religion, color, national origin, citizenship,   sex, sexual orientation, gender identity, gender   expression, veteran’s status, age, mental or   physical disability, genetic information or any   other protected class.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9747649431228638)","('Employee_Health_And_Safety', 0.002553350757807493)","('Labor_Practices', 0.0022059024777263403)","(['Human Capital Development'], 0.9747649431228638)","('NON-ESG', 0.002553350757807493)","('NON-ESG', 0.0022059024777263403)"
Line 358,"We draw strength from   the unique talents and abilities inherent in a   diverse workforce and we believe that the best   and most innovative products come from an   inclusive workplace where varied viewpoints   are welcomed and encouraged.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9617992043495178)","('Employee_Health_And_Safety', 0.0035234419628977776)","('Business_Model_Resilience', 0.0029205498285591602)","(['Human Capital Development'], 0.9617992043495178)","('NON-ESG', 0.0035234419628977776)","('NON-ESG', 0.0029205498285591602)"
Line 359,"We also have   a strict policy against harassment that is   reinforced through training and other ongoing   communication.
","('Employee_Health_And_Safety', 0.322890967130661)","('Employee_Engagement_Inclusion_And_Diversity', 0.21402482688426971)","('Business_Ethics', 0.15677258372306824)","('NON-ESG', 0.322890967130661)","('NON-ESG', 0.21402482688426971)","('NON-ESG', 0.15677258372306824)"
Line 360,"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.EMPLOYEE GROWTH AND DEVELOPMENT Growing and developing our people is essential   to growing our company.
","('Employee_Engagement_Inclusion_And_Diversity', 0.38624823093414307)","('Business_Model_Resilience', 0.1582375466823578)","('Human_Rights_And_Community_Relations', 0.10468903928995132)","('NON-ESG', 0.38624823093414307)","('NON-ESG', 0.1582375466823578)","('NON-ESG', 0.10468903928995132)"
Line 361,"Employees at every   level have access to a variety of programs, training  and tools to advance their skills and career so   they can meaningfully contribute to our mission   of transforming lives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7976850867271423)","('Access_And_Affordability', 0.04470621421933174)","('Employee_Health_And_Safety', 0.02372840791940689)","(['Human Capital Development'], 0.7976850867271423)","('NON-ESG', 0.04470621421933174)","('NON-ESG', 0.02372840791940689)"
Line 362,"Coaching and Development  Creating an environment where coaching and   development are valued and prioritized will   accelerate our company performance.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3125464618206024)","('Access_And_Affordability', 0.20254555344581604)","('Employee_Health_And_Safety', 0.08520219475030899)","('NON-ESG', 0.3125464618206024)","('NON-ESG', 0.20254555344581604)","('NON-ESG', 0.08520219475030899)"
Line 363,"To ensure   the growth and success of our leaders as coaches,  we have invested in tools and training to support  their continued development and expand measures   for accountability, including:     Management Development Program (MDP):   The MDP features tools and coaching for our  employees who manage people.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6562679409980774)","('Human_Rights_And_Community_Relations', 0.0473606251180172)","('Access_And_Affordability', 0.043536923825740814)","(['Human Capital Development'], 0.6562679409980774)","('NON-ESG', 0.0473606251180172)","('NON-ESG', 0.043536923825740814)"
Line 364,"The mandatory  18-month curriculum focuses on enhancing   skills ranging from hiring talent to managing   performance, unconscious bias training and   situational leadership.
","('Employee_Engagement_Inclusion_And_Diversity', 0.895037829875946)","('Employee_Health_And_Safety', 0.013832367956638336)","('Access_And_Affordability', 0.013480163179337978)","(['Human Capital Development'], 0.895037829875946)","('NON-ESG', 0.013832367956638336)","('NON-ESG', 0.013480163179337978)"
Line 365,"Upon completion, leaders  are provided with several tools and resources   that help put this training into practice.
","('Access_And_Affordability', 0.30735260248184204)","('Employee_Engagement_Inclusion_And_Diversity', 0.22274631261825562)","('Product_Quality_And_Safety', 0.0848073661327362)","('NON-ESG', 0.30735260248184204)","('NON-ESG', 0.22274631261825562)","('NON-ESG', 0.0848073661327362)"
Line 366,"In 2018,  more than 2,000 managers globally completed  more than 6,000 MDP sessions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.13076040148735046)","('Management_Of_Legal_And_Regulatory_Framework', 0.12343110889196396)","('Access_And_Affordability', 0.10812082141637802)","('NON-ESG', 0.13076040148735046)","('NON-ESG', 0.12343110889196396)","('NON-ESG', 0.10812082141637802)"
Line 367,"Employee feedback: To provide leaders valuable  feedback on their coaching performance from  those who interact with them most in this role —  their employees — we provide a number of tools  to help initiate dialogue and inform our leaders’  individual development plans.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5134192705154419)","('Human_Rights_And_Community_Relations', 0.12520821392536163)","('Access_And_Affordability', 0.05342359468340874)","(['Human Capital Development'], 0.5134192705154419)","('NON-ESG', 0.12520821392536163)","('NON-ESG', 0.05342359468340874)"
Line 368,"These tools include employee input on annual performance reviews,  360-degree surveys and an employee leadership  assessment survey – SPARK – that gives employees  an opportunity to rate their manager’s performance   against the behaviors that define a people leader  at Boston Scientific.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8984969854354858)","('Human_Rights_And_Community_Relations', 0.014850111678242683)","('Employee_Health_And_Safety', 0.009270554408431053)","(['Human Capital Development'], 0.8984969854354858)","('NON-ESG', 0.014850111678242683)","('NON-ESG', 0.009270554408431053)"
Line 369,"Empowering Leaders of Today and Tomorrow Boston Scientific offers learning and development  programs that help employees achieve their unique  career goals and aspirations.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8659341335296631)","('Human_Rights_And_Community_Relations', 0.013585618697106838)","('Employee_Health_And_Safety', 0.012684183195233345)","(['Human Capital Development'], 0.8659341335296631)","('NON-ESG', 0.013585618697106838)","('NON-ESG', 0.012684183195233345)"
Line 370,"These programs range  from on-the-job training and skills-based learning to  focused leadership programs aimed at accelerating  the growth and development of our talent who have  the potential to hold leadership roles in our business  in the future.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9230715036392212)","('Human_Rights_And_Community_Relations', 0.007486239541321993)","('Employee_Health_And_Safety', 0.006704980041831732)","(['Human Capital Development'], 0.9230715036392212)","('NON-ESG', 0.007486239541321993)","('NON-ESG', 0.006704980041831732)"
Line 371,"In addition to offering more than 150 professional and technical skills courses to all global  employees each year, we also offer several specific  leadership development programs:    Building Managerial Potential (BMP): The BMP is  for employees who nominate themselves to build  the skills they need to prepare for management  roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9002926349639893)","('Employee_Health_And_Safety', 0.018725240603089333)","('Labor_Practices', 0.007318925578147173)","(['Human Capital Development'], 0.9002926349639893)","('NON-ESG', 0.018725240603089333)","('NON-ESG', 0.007318925578147173)"
Line 372,"Since its launch in 2016, approximately 500  employees have graduated from the program,  including more than 200 in 2018.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7502825260162354)","('Labor_Practices', 0.05859246104955673)","('Employee_Health_And_Safety', 0.021670790389180183)","(['Human Capital Development'], 0.7502825260162354)","('NON-ESG', 0.05859246104955673)","('NON-ESG', 0.021670790389180183)"
Line 373,"Advanced Manager Development Program  (AMDP): The AMDP helps middle managers with  several years of experience strengthen key compe- tencies such as strategic thinking, communication  and managing across cultures.
","('Employee_Engagement_Inclusion_And_Diversity', 0.29225659370422363)","('Business_Model_Resilience', 0.24803045392036438)","('Human_Rights_And_Community_Relations', 0.056493427604436874)","('NON-ESG', 0.29225659370422363)","('NON-ESG', 0.24803045392036438)","('NON-ESG', 0.056493427604436874)"
Line 374,"In 2018, 91   managers participated in the program; more   than 500 have completed the course since 2016.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4305203855037689)","('Access_And_Affordability', 0.121119424700737)","('Management_Of_Legal_And_Regulatory_Framework', 0.04081791266798973)","('NON-ESG', 0.4305203855037689)","('NON-ESG', 0.121119424700737)","('NON-ESG', 0.04081791266798973)"
Line 375,"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.
","('Business_Model_Resilience', 0.24181583523750305)","('Human_Rights_And_Community_Relations', 0.08483568578958511)","('Employee_Engagement_Inclusion_And_Diversity', 0.08020741492509842)","('NON-ESG', 0.24181583523750305)","('NON-ESG', 0.08483568578958511)","('NON-ESG', 0.08020741492509842)"
Line 376,"Leadership Development Program (LDP): Director-  level and above employees are nominated to  participate in LDP to prepare for their next level of  growth by enhancing skills in personal and team  leadership through interactive sessions and busi- ness simulation, while providing opportunities for  networking and interaction with global peers and  senior leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6645140647888184)","('Human_Rights_And_Community_Relations', 0.058916687965393066)","('Director_Removal', 0.030183587223291397)","(['Human Capital Development'], 0.6645140647888184)","('NON-ESG', 0.058916687965393066)","('NON-ESG', 0.030183587223291397)"
Line 377,"In 2018, the LDP had 62 participants  from 13 countries.
","('Management_Of_Legal_And_Regulatory_Framework', 0.35664746165275574)","('Human_Rights_And_Community_Relations', 0.11569799482822418)","('Competitive_Behavior', 0.07595112919807434)","('NON-ESG', 0.35664746165275574)","('NON-ESG', 0.11569799482822418)","('NON-ESG', 0.07595112919807434)"
Line 378,"More than 490 leaders have   participated since the first offering in 2013.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2224389761686325)","('Business_Ethics', 0.12471604347229004)","('Management_Of_Legal_And_Regulatory_Framework', 0.07869898527860641)","('NON-ESG', 0.2224389761686325)","('NON-ESG', 0.12471604347229004)","('NON-ESG', 0.07869898527860641)"
Line 379,"Accelerated Leadership Development Program  (ALDP): Senior leaders act as facilitators for ALDP,  which is designed to accelerate the readiness  of high potentials and key successors to take on  more complex roles in the organization.
","('Employee_Engagement_Inclusion_And_Diversity', 0.39039355516433716)","('Business_Model_Resilience', 0.14695216715335846)","('Director_Removal', 0.11436912417411804)","('NON-ESG', 0.39039355516433716)","('NON-ESG', 0.14695216715335846)","('NON-ESG', 0.11436912417411804)"
Line 380,"A series  of one-week classroom sessions provides simula- tions, case studies and networking opportunities  with peers across the company and members of  the Executive Committee.
","('Access_And_Affordability', 0.29972198605537415)","('Employee_Engagement_Inclusion_And_Diversity', 0.28505393862724304)","('Human_Rights_And_Community_Relations', 0.05642919987440109)","('NON-ESG', 0.29972198605537415)","('NON-ESG', 0.28505393862724304)","('NON-ESG', 0.05642919987440109)"
Line 381,"During the sessions,  each participant is assigned a coach to support  continued feedback and development.
","('Access_And_Affordability', 0.33047008514404297)","('Employee_Engagement_Inclusion_And_Diversity', 0.26976820826530457)","('Human_Rights_And_Community_Relations', 0.04868841543793678)","('NON-ESG', 0.33047008514404297)","('NON-ESG', 0.26976820826530457)","('NON-ESG', 0.04868841543793678)"
Line 382,"Nearly 330  leaders have completed the program since its  inception in 2010, with 27 participants in 2018.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4845559298992157)","('Director_Removal', 0.05986469238996506)","('Human_Rights_And_Community_Relations', 0.05726908892393112)","('NON-ESG', 0.4845559298992157)","('NON-ESG', 0.05986469238996506)","('NON-ESG', 0.05726908892393112)"
Line 383,"Leadership Development Within Regions and   Across Cultures  Boston Scientific has also created targeted leadership  development programs to complement corporate  programs and support the development of talent  across the organization.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9436903595924377)","('Human_Rights_And_Community_Relations', 0.004710951820015907)","('Employee_Health_And_Safety', 0.004605310969054699)","(['Human Capital Development'], 0.9436903595924377)","('NON-ESG', 0.004710951820015907)","('NON-ESG', 0.004605310969054699)"
Line 384,"Some examples of regional  development programs include:    Through a combination of challenging interna- tional work experiences and business projects,  the Asia Pacific Global Leadership Development  Program (GLDP) is a tailored program that aims   to systematically develop talented, diverse and  global leaders who are capable of leading the  organization into the future.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7949433326721191)","('Human_Rights_And_Community_Relations', 0.04023439437150955)","('Business_Model_Resilience', 0.03280428424477577)","(['Human Capital Development'], 0.7949433326721191)","('NON-ESG', 0.04023439437150955)","('NON-ESG', 0.03280428424477577)"
Line 385,"In Latin America, regional leadership development  programs are facilitated by senior leaders and  program alumni to support the development of  competencies and capabilities that address the  region’s unique health ecosystem and emerging  market challenges.
","('Business_Model_Resilience', 0.5611714720726013)","('Competitive_Behavior', 0.110738605260849)","('Systemic_Risk_Management', 0.10317601263523102)","(['Codes of Business Conduct'], 0.5611714720726013)","('NON-ESG', 0.110738605260849)","('NON-ESG', 0.10317601263523102)"
Line 386,"The Europe, Middle East and Africa region’s   Key Talent Program provides high potential   senior managers and directors with opportunities,   experiences and leadership exposure to accelerate  their development and deepen the region’s   leadership pipeline.
","('Employee_Engagement_Inclusion_And_Diversity', 0.896331250667572)","('Business_Model_Resilience', 0.015264006331562996)","('Director_Removal', 0.009747507981956005)","(['Human Capital Development'], 0.896331250667572)","('NON-ESG', 0.015264006331562996)","('NON-ESG', 0.009747507981956005)"
Line 387,"Cross Cultural Learning As a global company operating around the world,  employees have an opportunity to interact routinely  with peers, customers and patients from a variety  of cultures and countries.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7864959239959717)","('Human_Rights_And_Community_Relations', 0.0393996462225914)","('Competitive_Behavior', 0.02347150817513466)","(['Human Capital Development'], 0.7864959239959717)","('NON-ESG', 0.0393996462225914)","('NON-ESG', 0.02347150817513466)"
Line 388,"To support cross-cultural  learning and awareness among all employees, the  company offers a portfolio of on-demand training  and resources.COMPENSATION AND BENEFITS We are committed to delivering compensation and  benefit programs that support overall well-being   and health, while providing flexibility to meet our  employees’ unique needs and expectations.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7914538383483887)","('Labor_Practices', 0.06603597849607468)","('Employee_Health_And_Safety', 0.03797275573015213)","(['Human Capital Development'], 0.7914538383483887)","('NON-ESG', 0.06603597849607468)","('NON-ESG', 0.03797275573015213)"
Line 389,"We   embrace our multigenerational workforce, with   programs that go beyond best-practice and focus   on best-fit.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9552559852600098)","('Employee_Health_And_Safety', 0.004183963872492313)","('Access_And_Affordability', 0.0041203428991138935)","(['Human Capital Development'], 0.9552559852600098)","('NON-ESG', 0.004183963872492313)","('NON-ESG', 0.0041203428991138935)"
Line 390,"Equal Pay for Equal Work Paying our employees equally for equal work is  consistent with our values and is at the heart of  our global compensation practices.
","('Labor_Practices', 0.9750070571899414)","('Employee_Engagement_Inclusion_And_Diversity', 0.002507987665012479)","('Director_Removal', 0.002057120203971863)","(['Labor Practice Indicators'], 0.9750070571899414)","('NON-ESG', 0.002507987665012479)","('NON-ESG', 0.002057120203971863)"
Line 391,"Our approach  to monitoring and maintaining pay equity includes  regularly benchmarking global salaries, conducting  rigorous internal and external parity audits and   reviewing pay recommendations across the company  as part of our annual compensation process.
","('Labor_Practices', 0.9198125004768372)","('Business_Ethics', 0.019874339923262596)","('Management_Of_Legal_And_Regulatory_Framework', 0.009278695099055767)","(['Labor Practice Indicators'], 0.9198125004768372)","('NON-ESG', 0.019874339923262596)","('NON-ESG', 0.009278695099055767)"
Line 392,"Boston Scientific works with an independent, third  party to annually assess pay equity across global  salaried and sales populations.
","('Competitive_Behavior', 0.29047074913978577)","('Management_Of_Legal_And_Regulatory_Framework', 0.2831924557685852)","('Labor_Practices', 0.08958480507135391)","('NON-ESG', 0.29047074913978577)","('NON-ESG', 0.2831924557685852)","('NON-ESG', 0.08958480507135391)"
Line 393,"In 2018, we expanded  our focus to include hourly employees.
","('Labor_Practices', 0.9224418997764587)","('Employee_Engagement_Inclusion_And_Diversity', 0.013579747639596462)","('Employee_Health_And_Safety', 0.009159085340797901)","(['Labor Practice Indicators'], 0.9224418997764587)","('NON-ESG', 0.013579747639596462)","('NON-ESG', 0.009159085340797901)"
Line 394,"We check   for pay equality using regression analysis — an  approach to analyzing data that controls for variables  that appropriately influence pay such as job, tenure,  years of experience and location.
","('Labor_Practices', 0.9593900442123413)","('Director_Removal', 0.004694875795394182)","('Employee_Engagement_Inclusion_And_Diversity', 0.0030233461875468493)","(['Labor Practice Indicators'], 0.9593900442123413)","('NON-ESG', 0.004694875795394182)","('NON-ESG', 0.0030233461875468493)"
Line 395,"We then look for  differences in pay between genders and, in the   U.S. and Puerto Rico, individuals of different races/ ethnicities.More than 2,000    people leaders around the  globe completed over   6,000 MDP sessions.2018 ACHIEVEMENT: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Consistent with our previously published findings, our  2018 analyses found less than a 1 percent statistical  difference in pay along gender lines for our global  salaried, hourly and sales employees.
","('Labor_Practices', 0.9048284292221069)","('Employee_Engagement_Inclusion_And_Diversity', 0.0428382009267807)","('Employee_Health_And_Safety', 0.006026660557836294)","(['Labor Practice Indicators'], 0.9048284292221069)","('NON-ESG', 0.0428382009267807)","('NON-ESG', 0.006026660557836294)"
Line 396,"For hourly   employees, we identified less than a 1.1 percent   statistical difference for race/ethnicity in the U.S.   and Puerto Rico*, and no disparities for salaried   and sales employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9641348719596863)","('Labor_Practices', 0.005225251894444227)","('Employee_Health_And_Safety', 0.0029180715791881084)","(['Human Capital Development'], 0.9641348719596863)","('NON-ESG', 0.005225251894444227)","('NON-ESG', 0.0029180715791881084)"
Line 397,"In the few instances where   we identified a gender disparity — which occurred   in positions involving both men and women —   we examined the circumstances and acted to   increase pay where appropriate.
","('Labor_Practices', 0.9605501890182495)","('Employee_Engagement_Inclusion_And_Diversity', 0.00557553768157959)","('Director_Removal', 0.004001084715127945)","(['Labor Practice Indicators'], 0.9605501890182495)","('NON-ESG', 0.00557553768157959)","('NON-ESG', 0.004001084715127945)"
Line 398,"We will continue to evolve our practices to maintain  and improve on our results.
","('Management_Of_Legal_And_Regulatory_Framework', 0.36176571249961853)","('Competitive_Behavior', 0.19790908694267273)","('Business_Model_Resilience', 0.08547325432300568)","('NON-ESG', 0.36176571249961853)","('NON-ESG', 0.19790908694267273)","('NON-ESG', 0.08547325432300568)"
Line 399,"For example, to further  reduce potential for biases in our hiring practices,  in 2018, we prohibited the request of salary history  from all U.S. job applicants.
","('Employee_Engagement_Inclusion_And_Diversity', 0.889470636844635)","('Labor_Practices', 0.02955363690853119)","('Competitive_Behavior', 0.008986860513687134)","(['Human Capital Development'], 0.889470636844635)","('NON-ESG', 0.02955363690853119)","('NON-ESG', 0.008986860513687134)"
Line 400,"The range of our jobs are  based on the skill set, experience required and what  the market demands, not on what candidates have  earned before.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7360593676567078)","('Labor_Practices', 0.12793079018592834)","('Employee_Health_And_Safety', 0.023568158969283104)","(['Human Capital Development'], 0.7360593676567078)","('NON-ESG', 0.12793079018592834)","('NON-ESG', 0.023568158969283104)"
Line 401,"We are evaluating similar hiring  practices for global locations in concert with local  laws and regulations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9487738609313965)","('Business_Ethics', 0.006162382662296295)","('Director_Removal', 0.004435037728399038)","(['Corporate Governance'], 0.9487738609313965)","('NON-ESG', 0.006162382662296295)","('NON-ESG', 0.004435037728399038)"
Line 402,"Analysis and reporting of   pay equity results are completed annually.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6900304555892944)","('Systemic_Risk_Management', 0.07000965625047684)","('Competitive_Behavior', 0.04875587671995163)","(['Corporate Governance'], 0.6900304555892944)","('NON-ESG', 0.07000965625047684)","('NON-ESG', 0.04875587671995163)"
Line 403,"Benefits Good health, financial wellness and security are   critical to a productive workforce.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7899577021598816)","('Employee_Health_And_Safety', 0.0386383980512619)","('Labor_Practices', 0.02608460746705532)","(['Human Capital Development'], 0.7899577021598816)","('NON-ESG', 0.0386383980512619)","('NON-ESG', 0.02608460746705532)"
Line 404,"We support a   culture of health by providing comprehensive   benefits to our employees.
","('Employee_Health_And_Safety', 0.7732336521148682)","('Access_And_Affordability', 0.08001621067523956)","('Employee_Engagement_Inclusion_And_Diversity', 0.030544208362698555)","(['Operational Eco-Efficiency'], 0.7732336521148682)","('NON-ESG', 0.08001621067523956)","('NON-ESG', 0.030544208362698555)"
Line 405,"The following principles govern our benefit plans   on a global basis:    Enable High Performing Talent — As part of a  broader rewards portfolio, we offer market   competitive benefits that are flexible and   affordable to meet the individual needs of   our increasingly diverse talent base   Support Life/Work Integration — We strive to   offer programs that acknowledge, respect and  support an individual’s life and work choices Sales100 % Hourly99.5% Salaried99.9%2018 Gender Globally Sales100 % 100 %   Hourly98.9 % Salaried 2018 Race / Ethnicity: U.S. / Puerto Rico   Promote Well-being — Our holistic programs   are intended to support and encourage physical,   emotional, financial and social well-being.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9444190859794617)","('Employee_Health_And_Safety', 0.005694774445146322)","('Customer_Welfare', 0.004279618617147207)","(['Human Capital Development'], 0.9444190859794617)","('NON-ESG', 0.005694774445146322)","('NON-ESG', 0.004279618617147207)"
Line 406,"The following principles govern our benefit plans   on a global basis:    Enable High Performing Talent — As part of a  broader rewards portfolio, we offer market   competitive benefits that are flexible and   affordable to meet the individual needs of   our increasingly diverse talent base   Support Life/Work Integration — We strive to   offer programs that acknowledge, respect and  support an individual’s life and work choices Sales100 % Hourly99.5% Salaried99.9%2018 Gender Globally Sales100 % 100 %   Hourly98.9 % Salaried 2018 Race / Ethnicity: U.S. / Puerto Rico   Promote Well-being — Our holistic programs   are intended to support and encourage physical,   emotional, financial and social well-being.
","('Employee_Engagement_Inclusion_And_Diversity', 0.899864673614502)","('Human_Rights_And_Community_Relations', 0.024041777476668358)","('Employee_Health_And_Safety', 0.013911984860897064)","(['Human Capital Development'], 0.899864673614502)","('NON-ESG', 0.024041777476668358)","('NON-ESG', 0.013911984860897064)"
Line 407,"Empowering employee well-being leads to   improved performance for the individual and   the organization    Value and Cultural Fit — We strive to offer benefits  that are valued by our employees, differentiated   by our culture when appropriate, and supportive   of an inclusive work environment    Communication and Tools — We aim to   communicate in a manner that makes our   plans easy to understand and use, and enables  employees to take action to achieve well-being.
","('Human_Rights_And_Community_Relations', 0.39699089527130127)","('Employee_Engagement_Inclusion_And_Diversity', 0.3323071002960205)","('Employee_Health_And_Safety', 0.05812246724963188)","('NON-ESG', 0.39699089527130127)","('NON-ESG', 0.3323071002960205)","('NON-ESG', 0.05812246724963188)"
Line 408,"For a comprehensive look at Boston Scientific   benefits package, please visit: https://secure.
","('Data_Security', 0.5452062487602234)","('Management_Of_Legal_And_Regulatory_Framework', 0.0817629024386406)","('Systemic_Risk_Management', 0.05950305610895157)","(['Information Security/Cybersecurity & System Availability'], 0.5452062487602234)","('NON-ESG', 0.0817629024386406)","('NON-ESG', 0.05950305610895157)"
Line 409,"bscbenefitsconnect.com/home/index.html Global Sabbaticals Policy In 2018, Boston Scientific began offering sabbaticals  to employees with more than seven years of service  to recognize their tenure and enable a planned   time of renewal for development or enrichment.
","('Labor_Practices', 0.41495978832244873)","('Employee_Engagement_Inclusion_And_Diversity', 0.10310962051153183)","('Management_Of_Legal_And_Regulatory_Framework', 0.0841442123055458)","('NON-ESG', 0.41495978832244873)","('NON-ESG', 0.10310962051153183)","('NON-ESG', 0.0841442123055458)"
Line 410,"For those countries where national laws mandate  that companies allow employees to apply for a  sabbatical leave with less than seven years of service,  the local tenure threshold is used.
","('Labor_Practices', 0.8698185086250305)","('Director_Removal', 0.02294335328042507)","('Employee_Engagement_Inclusion_And_Diversity', 0.021622419357299805)","(['Labor Practice Indicators'], 0.8698185086250305)","('NON-ESG', 0.02294335328042507)","('NON-ESG', 0.021622419357299805)"
Line 411,"We believe   employees return from time away revitalized, with  new perspectives that enable them to be more  productive and engaged.
","('Employee_Engagement_Inclusion_And_Diversity', 0.28457415103912354)","('Employee_Health_And_Safety', 0.21992887556552887)","('Labor_Practices', 0.11829618364572525)","('NON-ESG', 0.28457415103912354)","('NON-ESG', 0.21992887556552887)","('NON-ESG', 0.11829618364572525)"
Line 412,"Sabbaticals also represent  interim opportunities for others within the   organization to build skills and capabilities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4196208715438843)","('Labor_Practices', 0.10146849602460861)","('Management_Of_Legal_And_Regulatory_Framework', 0.060553234070539474)","('NON-ESG', 0.4196208715438843)","('NON-ESG', 0.10146849602460861)","('NON-ESG', 0.060553234070539474)"
Line 413,"*Each country has specific requirements and legal considerations regarding how race/ethnicity data can be used and reported.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9647248983383179)","('Customer_Privacy', 0.004716760944575071)","('Human_Rights_And_Community_Relations', 0.002783220959827304)","(['Human Capital Development'], 0.9647248983383179)","('NON-ESG', 0.004716760944575071)","('NON-ESG', 0.002783220959827304)"
Line 414,"Our reporting focuses on our US/PR populations as it is uniform in definition, reporting and use.Equal Pay For Equal Work Percentage of employees who showed no statistically significant pay disparity: OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Global Employee Assistance Program Global Employee Assistance programs provide a   network of support and valuable resources that  encourages overall well-being, including help with  finances, family life, elder/child care and mental  health.
","('Labor_Practices', 0.949353039264679)","('Employee_Engagement_Inclusion_And_Diversity', 0.010535739362239838)","('Employee_Health_And_Safety', 0.006271678023040295)","(['Labor Practice Indicators'], 0.949353039264679)","('NON-ESG', 0.010535739362239838)","('NON-ESG', 0.006271678023040295)"
Line 415,"In 2018, we expanded the availability of   the programs to include coverage in all countries  where Boston Scientific has a concentration of   employees.
","('Labor_Practices', 0.3672467768192291)","('Employee_Engagement_Inclusion_And_Diversity', 0.35530391335487366)","('Director_Removal', 0.038938503712415695)","('NON-ESG', 0.3672467768192291)","('NON-ESG', 0.35530391335487366)","('NON-ESG', 0.038938503712415695)"
Line 416,"EMBRACING NEW LIFE-WORK NEEDS   Our Benefits to Fit Your Life program provides a  range of benefits and services for different stages   of life that reflect what our employees want and  need to be happy, productive and engaged in   their roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.34263017773628235)","('Employee_Health_And_Safety', 0.21139873564243317)","('Human_Rights_And_Community_Relations', 0.06837082654237747)","('NON-ESG', 0.34263017773628235)","('NON-ESG', 0.21139873564243317)","('NON-ESG', 0.06837082654237747)"
Line 417,"In the U.S., the program includes enhanced   infertility treatment support and expanded   maternal and paternal leave, as well as breast   milk shipping service and increased assistance   for working parents to find and pay for child care.
","('Access_And_Affordability', 0.5917274951934814)","('Employee_Health_And_Safety', 0.08609452098608017)","('Employee_Engagement_Inclusion_And_Diversity', 0.07325418293476105)","(['Health Outcome Contribution'], 0.5917274951934814)","('NON-ESG', 0.08609452098608017)","('NON-ESG', 0.07325418293476105)"
Line 418,"We also added telehealth services and a new   meal planning service, while expanding programs   for college planning and caring for aging parents.
","('Access_And_Affordability', 0.8732969164848328)","('Employee_Engagement_Inclusion_And_Diversity', 0.012940260581672192)","('Employee_Health_And_Safety', 0.012861893512308598)","(['Health Outcome Contribution'], 0.8732969164848328)","('NON-ESG', 0.012940260581672192)","('NON-ESG', 0.012861893512308598)"
Line 419,"We will continue to evolve these programs with   a focus on paid time off, employee needs   resulting from the impact of delaying a family   for a career, fertility in all family units, and tuition   and educational support that includes remote   learning and non-degree education.
","('Access_And_Affordability', 0.6591810584068298)","('Employee_Engagement_Inclusion_And_Diversity', 0.10222336649894714)","('Employee_Health_And_Safety', 0.0386899933218956)","(['Health Outcome Contribution'], 0.6591810584068298)","('NON-ESG', 0.10222336649894714)","('NON-ESG', 0.0386899933218956)"
Line 420,"In 2018, we expanded the Benefits to Fit Your Life  program globally with programs developed in direct  response to regional employee input.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6266913414001465)","('Employee_Health_And_Safety', 0.10442753881216049)","('Access_And_Affordability', 0.056234780699014664)","(['Human Capital Development'], 0.6266913414001465)","('NON-ESG', 0.10442753881216049)","('NON-ESG', 0.056234780699014664)"
Line 421,"Examples of  our new offerings include:    Ireland – Alignment of maternity and paternity   pay and job-sharing for direct labor employees   as well as career staff    Japan – Programs to expand flexibility and   family support options for employees, including  improved work-from-home policies    Hong Kong – Flexible fitness, engagement,   personal development, child care and dental  benefits    China – New family-friendly options for working  parents such as flexible hours on the first day   of the school term     India and Korea – Child care subsidies for   working parents as well as new education   support options Employee Health and Safety A commitment to employee health and safety   is a prerequisite to our pursuit of patient care.
","('Labor_Practices', 0.9543257355690002)","('Employee_Health_And_Safety', 0.007534255273640156)","('Employee_Engagement_Inclusion_And_Diversity', 0.00753163592889905)","(['Labor Practice Indicators'], 0.9543257355690002)","('NON-ESG', 0.007534255273640156)","('NON-ESG', 0.00753163592889905)"
Line 422,"Examples of  our new offerings include:    Ireland – Alignment of maternity and paternity   pay and job-sharing for direct labor employees   as well as career staff    Japan – Programs to expand flexibility and   family support options for employees, including  improved work-from-home policies    Hong Kong – Flexible fitness, engagement,   personal development, child care and dental  benefits    China – New family-friendly options for working  parents such as flexible hours on the first day   of the school term     India and Korea – Child care subsidies for   working parents as well as new education   support options Employee Health and Safety A commitment to employee health and safety   is a prerequisite to our pursuit of patient care.
","('Employee_Health_And_Safety', 0.8122416138648987)","('Access_And_Affordability', 0.0917876735329628)","('Critical_Incident_Risk_Management', 0.012147900648415089)","(['Operational Eco-Efficiency'], 0.8122416138648987)","('NON-ESG', 0.0917876735329628)","('NON-ESG', 0.012147900648415089)"
Line 423,"A shared culture of ensuring the safety of our   employees enables meaningful innovation and  business success.
","('Employee_Health_And_Safety', 0.969290018081665)","('Employee_Engagement_Inclusion_And_Diversity', 0.004881874192506075)","('Product_Quality_And_Safety', 0.0030116133857518435)","(['Operational Eco-Efficiency'], 0.969290018081665)","('NON-ESG', 0.004881874192506075)","('NON-ESG', 0.0030116133857518435)"
Line 424,"Our strong health and safety performance   contributes to competitive strength and benefits   for not only our employees, but also our   customers, communities and shareholders.
","('Competitive_Behavior', 0.30954813957214355)","('Human_Rights_And_Community_Relations', 0.23079073429107666)","('Business_Model_Resilience', 0.08852683007717133)","('NON-ESG', 0.30954813957214355)","('NON-ESG', 0.23079073429107666)","('NON-ESG', 0.08852683007717133)"
Line 425,"To deliver on our goals in accordance with the   Boston Scientific Environmental, Health and  Safety (EHS) policy, we integrate safety metrics in   our overall monitoring systems at the local and  global levels.
","('Employee_Health_And_Safety', 0.9461966753005981)","('Product_Quality_And_Safety', 0.015975499525666237)","('Critical_Incident_Risk_Management', 0.0040867212228477)","(['Operational Eco-Efficiency'], 0.9461966753005981)","('NON-ESG', 0.015975499525666237)","('NON-ESG', 0.0040867212228477)"
Line 426,"Boston Scientific teams review these  metrics daily in local groups, weekly in management  meetings and monthly with global leadership, with  a focus on adverse trends or significant incidents to  ensure effective responses.
","('Systemic_Risk_Management', 0.3123595118522644)","('Management_Of_Legal_And_Regulatory_Framework', 0.1848779171705246)","('Physical_Impacts_Of_Climate_Change', 0.10618919879198074)","('NON-ESG', 0.3123595118522644)","('NON-ESG', 0.1848779171705246)","('NON-ESG', 0.10618919879198074)"
Line 427,"We set measurable safety goals called Total   Recordable Incident Rate (TRIR) targets for every   Boston Scientific site, with lower targets at our   less complex locations.
","('Employee_Health_And_Safety', 0.8753545880317688)","('Critical_Incident_Risk_Management', 0.07878987491130829)","('Air_Quality', 0.005069343373179436)","(['Operational Eco-Efficiency'], 0.8753545880317688)","('NON-ESG', 0.07878987491130829)","('NON-ESG', 0.005069343373179436)"
Line 428,"Our EHS Operations   Council assesses performance monthly to   discuss trending and improvement opportunities,  including global company leadership reviews.2018 ACHIEVEMENT: 0.5/100    We maintained our target  safety goal of 0.5 injuries  per 100 employees, which  we achieved in 2017.
","('Employee_Health_And_Safety', 0.9837259650230408)","('Employee_Engagement_Inclusion_And_Diversity', 0.001961818663403392)","('Critical_Incident_Risk_Management', 0.001897644717246294)","(['Operational Eco-Efficiency'], 0.9837259650230408)","('NON-ESG', 0.001961818663403392)","('NON-ESG', 0.001897644717246294)"
Line 429,"two years ahead of our   2019 target.
","('Business_Model_Resilience', 0.2675723433494568)","('Systemic_Risk_Management', 0.10404932498931885)","('GHG_Emissions', 0.0902523547410965)","('NON-ESG', 0.2675723433494568)","('NON-ESG', 0.10404932498931885)","('NON-ESG', 0.0902523547410965)"
Line 430,"*Safety goal specific to Boston Scientific major manufacturing and distribution facilities.
","('Product_Quality_And_Safety', 0.8395980596542358)","('Employee_Health_And_Safety', 0.04364391788840294)","('Product_Design_And_Lifecycle_Management', 0.014378590509295464)","(['Product Quality & Recall Management'], 0.8395980596542358)","('NON-ESG', 0.04364391788840294)","('NON-ESG', 0.014378590509295464)"
Line 431,"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.2018 renovations in our   Galway, Ireland, facility   focused around biophilic   design, an emerging field   with the goal of connecting   people more closely to   nature.
","('Employee_Engagement_Inclusion_And_Diversity', 0.17467918992042542)","('Human_Rights_And_Community_Relations', 0.12501071393489838)","('Ecological_Impacts', 0.10175613313913345)","('NON-ESG', 0.17467918992042542)","('NON-ESG', 0.12501071393489838)","('NON-ESG', 0.10175613313913345)"
Line 432,"2018 was the first full year of  operations in our expanded  Heredia, Costa Rica, facility,  featuring bright and open  collaboration spaces and new  amenities.Our new Hong Kong office,  which opened in February  2018, offers modern,   collaborative equipment   and plenty of natural light   in a location convenient to  public transportation.Renovations to our San Jose  – Baytech, California, facility  included adding more than  20,000 square feet of state- of-the-art R&D lab and open  office space, as well as a new  on-site fitness center.The Arden Hills, Minnesota,   office was renovated in 2018   to include a state-of-the-art  employee café and multi-use  space.Boston Scientific WorkspacesOccupational Health and Well-being Our employees are our most important resource   and a comprehensive employee well-being program  is an integral part of our employee support system.
","('Business_Model_Resilience', 0.24801290035247803)","('Product_Design_And_Lifecycle_Management', 0.12108022719621658)","('Employee_Engagement_Inclusion_And_Diversity', 0.08422952890396118)","('NON-ESG', 0.24801290035247803)","('NON-ESG', 0.12108022719621658)","('NON-ESG', 0.08422952890396118)"
Line 433,"2018 was the first full year of  operations in our expanded  Heredia, Costa Rica, facility,  featuring bright and open  collaboration spaces and new  amenities.Our new Hong Kong office,  which opened in February  2018, offers modern,   collaborative equipment   and plenty of natural light   in a location convenient to  public transportation.Renovations to our San Jose  – Baytech, California, facility  included adding more than  20,000 square feet of state- of-the-art R&D lab and open  office space, as well as a new  on-site fitness center.The Arden Hills, Minnesota,   office was renovated in 2018   to include a state-of-the-art  employee café and multi-use  space.Boston Scientific WorkspacesOccupational Health and Well-being Our employees are our most important resource   and a comprehensive employee well-being program  is an integral part of our employee support system.
","('Employee_Health_And_Safety', 0.8761680126190186)","('Access_And_Affordability', 0.027426186949014664)","('Employee_Engagement_Inclusion_And_Diversity', 0.017824597656726837)","(['Operational Eco-Efficiency'], 0.8761680126190186)","('NON-ESG', 0.027426186949014664)","('NON-ESG', 0.017824597656726837)"
Line 434,"To ensure stronger and more focused programs, we   launched a new Occupation Health Council in 2017  and saw promising results from its first full year of  work in 2018.Health and wellness programs provided in 2018  included employee nutrition, yoga, weight   management support, smoking cessation,   mindfulness and organized team sports events.
","('Employee_Health_And_Safety', 0.23922494053840637)","('Access_And_Affordability', 0.1610584408044815)","('Customer_Welfare', 0.15877053141593933)","('NON-ESG', 0.23922494053840637)","('NON-ESG', 0.1610584408044815)","('NON-ESG', 0.15877053141593933)"
Line 435,"In addition, we maintain global facilities at a   high standard to ensure our physical workspaces   promote optimal physical health and overall   well-being.
","('Employee_Health_And_Safety', 0.9161874055862427)","('Product_Design_And_Lifecycle_Management', 0.012399756349623203)","('Access_And_Affordability', 0.008619322441518307)","(['Operational Eco-Efficiency'], 0.9161874055862427)","('NON-ESG', 0.012399756349623203)","('NON-ESG', 0.008619322441518307)"
Line 436,"We continue to invest in Boston  Scientific workspaces worldwide to provide   energy-filled, creative environments that allow   innovation to thrive and employees to feel   included, valued and engaged.
","('Product_Design_And_Lifecycle_Management', 0.2705458402633667)","('Business_Model_Resilience', 0.12665601074695587)","('Employee_Engagement_Inclusion_And_Diversity', 0.11100421845912933)","('NON-ESG', 0.2705458402633667)","('NON-ESG', 0.12665601074695587)","('NON-ESG', 0.11100421845912933)"
Line 437,"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.CARING FOR OUR COMMUNITIES Boston Scientific employees volunteer at a variety   of organizations in communities where we operate,  including this event during our annual Week of   Caring to support a homeless shelter in California.
","('Access_And_Affordability', 0.3037087917327881)","('Employee_Health_And_Safety', 0.23200808465480804)","('Human_Rights_And_Community_Relations', 0.2153748720884323)","('NON-ESG', 0.3037087917327881)","('NON-ESG', 0.23200808465480804)","('NON-ESG', 0.2153748720884323)"
Line 438,"Our caring value guides us in how we engage with patients,  how we work together as colleagues and how we invest in the  well-being of communities.
","('Human_Rights_And_Community_Relations', 0.5241944789886475)","('Access_And_Affordability', 0.251894474029541)","('Employee_Health_And_Safety', 0.03624848648905754)","(['Community Relations'], 0.5241944789886475)","('NON-ESG', 0.251894474029541)","('NON-ESG', 0.03624848648905754)"
Line 439,"Around the world, our employees  participate in and influence the way we care for people in local  communities.
","('Human_Rights_And_Community_Relations', 0.9518088102340698)","('Access_And_Affordability', 0.01022309996187687)","('Critical_Incident_Risk_Management', 0.002877061488106847)","(['Community Relations'], 0.9518088102340698)","('NON-ESG', 0.01022309996187687)","('NON-ESG', 0.002877061488106847)"
Line 440,"We focus our community engagement efforts on three key areas:  Health We aim to decrease health  disparities for the underserved  by providing access to quality  care, supporting prevention  and awareness programs and  helping to prepare children for a  healthy journey into adulthood.Education By supporting education and  STEM (Science, Technology,   Engineering and Math)   programming for K-12 students  around the globe, we are  helping to develop the diverse  future talent that will enable   us to create health solutions   for generations to come.Community Through engagement and  recognition programs,  we are  empowering our employees   to Advance Possibilities in   their local communities by   donating their time and   resources to help those   most in need.
","('Access_And_Affordability', 0.9326283931732178)","('Product_Quality_And_Safety', 0.006616548635065556)","('Human_Rights_And_Community_Relations', 0.005246161948889494)","(['Health Outcome Contribution'], 0.9326283931732178)","('NON-ESG', 0.006616548635065556)","('NON-ESG', 0.005246161948889494)"
Line 441,"We focus our community engagement efforts on three key areas:  Health We aim to decrease health  disparities for the underserved  by providing access to quality  care, supporting prevention  and awareness programs and  helping to prepare children for a  healthy journey into adulthood.Education By supporting education and  STEM (Science, Technology,   Engineering and Math)   programming for K-12 students  around the globe, we are  helping to develop the diverse  future talent that will enable   us to create health solutions   for generations to come.Community Through engagement and  recognition programs,  we are  empowering our employees   to Advance Possibilities in   their local communities by   donating their time and   resources to help those   most in need.
","('Human_Rights_And_Community_Relations', 0.5511646270751953)","('Access_And_Affordability', 0.2898394465446472)","('Employee_Health_And_Safety', 0.01961706392467022)","(['Community Relations'], 0.5511646270751953)","('NON-ESG', 0.2898394465446472)","('NON-ESG', 0.01961706392467022)"
Line 442,"OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.PROMOTING HEALTH EQUITY Fostering Healthy Communities Our work in healthcare comes with a profound  responsibility to those around us.
","('Access_And_Affordability', 0.43934983015060425)","('Human_Rights_And_Community_Relations', 0.2626536190509796)","('Employee_Health_And_Safety', 0.08828224986791611)","('NON-ESG', 0.43934983015060425)","('NON-ESG', 0.2626536190509796)","('NON-ESG', 0.08828224986791611)"
Line 443,"As the industry  landscape evolves, we know that preventing illness is  just as important as treating it.
","('Employee_Health_And_Safety', 0.9448420405387878)","('Critical_Incident_Risk_Management', 0.014123665168881416)","('Product_Quality_And_Safety', 0.003447664203122258)","(['Operational Eco-Efficiency'], 0.9448420405387878)","('NON-ESG', 0.014123665168881416)","('NON-ESG', 0.003447664203122258)"
Line 444,"Our health awareness  programs provide education and resources to help  people around the world live better and healthier  lives.
","('Access_And_Affordability', 0.6137986183166504)","('Employee_Health_And_Safety', 0.14152655005455017)","('Human_Rights_And_Community_Relations', 0.06605010479688644)","(['Health Outcome Contribution'], 0.6137986183166504)","('NON-ESG', 0.14152655005455017)","('NON-ESG', 0.06605010479688644)"
Line 445,"Additionally, we work with global organizations  to bring new resources to regions where people lack  access, information and basic care.
","('Access_And_Affordability', 0.8843421339988708)","('Human_Rights_And_Community_Relations', 0.017247477546334267)","('Critical_Incident_Risk_Management', 0.012867022305727005)","(['Health Outcome Contribution'], 0.8843421339988708)","('NON-ESG', 0.017247477546334267)","('NON-ESG', 0.012867022305727005)"
Line 446,"We are also focused on reducing risk and decreasing  health disparities in chronic disease for underserved  populations.
","('Access_And_Affordability', 0.9445034265518188)","('Critical_Incident_Risk_Management', 0.005119352601468563)","('Product_Quality_And_Safety', 0.004952081944793463)","(['Health Outcome Contribution'], 0.9445034265518188)","('NON-ESG', 0.005119352601468563)","('NON-ESG', 0.004952081944793463)"
Line 447,"We strive to help as many patients  as possible improve their health by sharing our  products, expertise, time and resources.
","('Employee_Health_And_Safety', 0.5532398819923401)","('Access_And_Affordability', 0.11026690155267715)","('Product_Design_And_Lifecycle_Management', 0.05300639569759369)","(['Operational Eco-Efficiency'], 0.5532398819923401)","('NON-ESG', 0.11026690155267715)","('NON-ESG', 0.05300639569759369)"
Line 448,"Our global  collaborations with Project Hope, Partners in Health  and Children’s HeartLink have helped to increase  the investment in, and number of, global healthcare  workers focused on chronic disease.
","('Employee_Health_And_Safety', 0.8874569535255432)","('Access_And_Affordability', 0.02205182984471321)","('Product_Quality_And_Safety', 0.010356866754591465)","(['Operational Eco-Efficiency'], 0.8874569535255432)","('NON-ESG', 0.02205182984471321)","('NON-ESG', 0.010356866754591465)"
Line 449,"Since 2016, the  combined impact of these partnerships has included  training for 2,255 healthcare workers and chronic   disease screening, education or care for 20,147   people in India, South Africa, Malaysia and Mexico.
","('Employee_Health_And_Safety', 0.636730432510376)","('Access_And_Affordability', 0.16430076956748962)","('Product_Quality_And_Safety', 0.027285093441605568)","(['Operational Eco-Efficiency'], 0.636730432510376)","('NON-ESG', 0.16430076956748962)","('NON-ESG', 0.027285093441605568)"
Line 450,"Project HOPE in South Africa Boston Scientific collaborated with Project HOPE,  a U.S.-based global health and humanitarian relief  organization, to implement new health screening  protocols in South Africa, a priority set by South  Africa’s Ministry of Health.
","('Employee_Health_And_Safety', 0.45739561319351196)","('Critical_Incident_Risk_Management', 0.3036671578884125)","('Access_And_Affordability', 0.05443429574370384)","('NON-ESG', 0.45739561319351196)","('NON-ESG', 0.3036671578884125)","('NON-ESG', 0.05443429574370384)"
Line 451,"The project focused on  creating standards for screening and on increasing   the skills of local community health workers to  reduce occurrence of noncommunicable diseases.
","('Employee_Health_And_Safety', 0.9221790432929993)","('Access_And_Affordability', 0.017167354002594948)","('Human_Rights_And_Community_Relations', 0.0090078916400671)","(['Operational Eco-Efficiency'], 0.9221790432929993)","('NON-ESG', 0.017167354002594948)","('NON-ESG', 0.0090078916400671)"
Line 452,"Project HOPE teams have completed training of  more than 350 community health workers on   effective health screening of diabetes and   hypertension, as well as nearly 50 nurses.
","('Employee_Health_And_Safety', 0.6512838006019592)","('Access_And_Affordability', 0.14445331692695618)","('Employee_Engagement_Inclusion_And_Diversity', 0.0358336940407753)","(['Operational Eco-Efficiency'], 0.6512838006019592)","('NON-ESG', 0.14445331692695618)","('NON-ESG', 0.0358336940407753)"
Line 453,"As a  result of Boston Scientific funding and employee   volunteers, Project HOPE expects to reach  60,000 people who will receive screening and  health services from newly trained community  health workers in South Africa.
","('Employee_Health_And_Safety', 0.7063199281692505)","('Access_And_Affordability', 0.11310002952814102)","('Human_Rights_And_Community_Relations', 0.05885426327586174)","(['Operational Eco-Efficiency'], 0.7063199281692505)","('NON-ESG', 0.11310002952814102)","('NON-ESG', 0.05885426327586174)"
Line 454,"Health Camp in India Boston Scientific teams in India and Marlborough,   Massachusetts, joined forces with HCS Wellness,   a firm in India that helps workplaces build   wellness programs, to provide a healthcare   camp for children at an underprivileged school   in Gurgaon, India.
","('Access_And_Affordability', 0.8422064781188965)","('Employee_Health_And_Safety', 0.03246753662824631)","('Product_Quality_And_Safety', 0.021202290430665016)","(['Health Outcome Contribution'], 0.8422064781188965)","('NON-ESG', 0.03246753662824631)","('NON-ESG', 0.021202290430665016)"
Line 455,"More than 200 children were  given health tutorials and medical, dental and   eye screenings to determine their need for   eyeglasses, vaccines and additional dental   procedures.
","('Employee_Health_And_Safety', 0.4171885550022125)","('Access_And_Affordability', 0.2547013759613037)","('Employee_Engagement_Inclusion_And_Diversity', 0.06282739341259003)","('NON-ESG', 0.4171885550022125)","('NON-ESG', 0.2547013759613037)","('NON-ESG', 0.06282739341259003)"
Line 456,"The teams also handed out school   supplies, dental care items and fleece blankets.
","('Access_And_Affordability', 0.3291022479534149)","('Employee_Health_And_Safety', 0.2772381603717804)","('Critical_Incident_Risk_Management', 0.11265145242214203)","('NON-ESG', 0.3291022479534149)","('NON-ESG', 0.2772381603717804)","('NON-ESG', 0.11265145242214203)"
Line 457,"25,000+    People reached in 2018 by  Close the Gap health equity  activities and initiatives100+   U.S. Congress members  educated on the impact of  critical limb ischemia and  lower extremity amputations  among African Americans17   States with high cardio- vascular disease mortality  and/or significant health  disparity* benefited from  education and awareness  activities  433,000+    Impressions from the Close  the Gap Twitter account in  201873%    Positive response to all  tweets and campaigns OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Close the Gap Health Equity Initiative  Boston Scientific is leading efforts to promote health  equity through our Close the Gap initiative , which  aims to eliminate care disparities and improve  patients’ access to health services regardless of age,  gender, race, ethnicity or primary language.
","('Employee_Health_And_Safety', 0.854287326335907)","('Access_And_Affordability', 0.02885570004582405)","('Employee_Engagement_Inclusion_And_Diversity', 0.023268112912774086)","(['Operational Eco-Efficiency'], 0.854287326335907)","('NON-ESG', 0.02885570004582405)","('NON-ESG', 0.023268112912774086)"
Line 458,"25,000+    People reached in 2018 by  Close the Gap health equity  activities and initiatives100+   U.S. Congress members  educated on the impact of  critical limb ischemia and  lower extremity amputations  among African Americans17   States with high cardio- vascular disease mortality  and/or significant health  disparity* benefited from  education and awareness  activities  433,000+    Impressions from the Close  the Gap Twitter account in  201873%    Positive response to all  tweets and campaigns OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Close the Gap Health Equity Initiative  Boston Scientific is leading efforts to promote health  equity through our Close the Gap initiative , which  aims to eliminate care disparities and improve  patients’ access to health services regardless of age,  gender, race, ethnicity or primary language.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9616280198097229)","('Access_And_Affordability', 0.005204399581998587)","('Human_Rights_And_Community_Relations', 0.00334731861948967)","(['Human Capital Development'], 0.9616280198097229)","('NON-ESG', 0.005204399581998587)","('NON-ESG', 0.00334731861948967)"
Line 459,"The  company collaborates with diverse stakeholders  to advocate for broader minority representation in  clinical trials, to support patient advocacy efforts,  and to reach underserved patient populations with  culturally relevant education and resources delivered  through events, programs and social media dialogue.
","('Access_And_Affordability', 0.7400839924812317)","('Employee_Engagement_Inclusion_And_Diversity', 0.10840331017971039)","('Human_Rights_And_Community_Relations', 0.026572443544864655)","(['Health Outcome Contribution'], 0.7400839924812317)","('NON-ESG', 0.10840331017971039)","('NON-ESG', 0.026572443544864655)"
Line 460,"In 2018, nearly 60 Close the Gap events took place in  communities across the United States.
","('Access_And_Affordability', 0.1589682698249817)","('Human_Rights_And_Community_Relations', 0.13332611322402954)","('Critical_Incident_Risk_Management', 0.11156503111124039)","('NON-ESG', 0.1589682698249817)","('NON-ESG', 0.13332611322402954)","('NON-ESG', 0.11156503111124039)"
Line 461,"*Measured by the Agency for Healthcare Research and Quality.Close the Gap By the NumbersTaking Action to Close the Gap Collaborating at Pride The Close the Gap team collaborates closely  with the PACE (People Accepting and   Celebrating Equality) ERG to create relevant  LGBTQ+ educational materials focused on  health disparities in the community.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9178379774093628)","('Human_Rights_And_Community_Relations', 0.017196262255311012)","('Access_And_Affordability', 0.010746962390840054)","(['Human Capital Development'], 0.9178379774093628)","('NON-ESG', 0.017196262255311012)","('NON-ESG', 0.010746962390840054)"
Line 462,"At the June 2018 Twin Cities Pride Festival  in Minneapolis, Minnesota, volunteer   physicians from the Minneapolis Heart   Institute Foundation answered questions   from participants about heart disease   while volunteer nurses performed more  than 100 blood pressure screenings and  provided education on existing health   disparities in the LGBTQ+ community.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8793933391571045)","('Employee_Health_And_Safety', 0.023588508367538452)","('Access_And_Affordability', 0.022413890808820724)","(['Human Capital Development'], 0.8793933391571045)","('NON-ESG', 0.023588508367538452)","('NON-ESG', 0.022413890808820724)"
Line 463,"This outreach will serve as a model for us   at future Pride events in the U.S.  OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.INSPIRING THE NEXT    GENERATION OF LEADERS   To inspire a global and diverse generation of future  science, technology, engineering and math (STEM)  innovators, Boston Scientific provides challenging  and fun opportunities to expose children to STEM  experiences and future careers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8523306846618652)","('Business_Model_Resilience', 0.021521734073758125)","('Product_Design_And_Lifecycle_Management', 0.015467257238924503)","(['Human Capital Development'], 0.8523306846618652)","('NON-ESG', 0.021521734073758125)","('NON-ESG', 0.015467257238924503)"
Line 464,"Our volunteers bring STEM experiences to students  in the communities where we operate, collaborating  with educators to understand their students' needs  and shape a customized approach.
","('Access_And_Affordability', 0.3852783739566803)","('Employee_Engagement_Inclusion_And_Diversity', 0.23253247141838074)","('Human_Rights_And_Community_Relations', 0.09326827526092529)","('NON-ESG', 0.3852783739566803)","('NON-ESG', 0.23253247141838074)","('NON-ESG', 0.09326827526092529)"
Line 465,"From mentoring  and sharing career experiences to hands-on   experiments and tours of Boston Scientific facilities,  we work to introduce students from underrepresented  populations to the possibilities STEM learning can  provide and maintain dedicated STEM teams at 13  Boston Scientific sites.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7027344703674316)","('Access_And_Affordability', 0.08494392782449722)","('Customer_Welfare', 0.02705380879342556)","(['Human Capital Development'], 0.7027344703674316)","('NON-ESG', 0.08494392782449722)","('NON-ESG', 0.02705380879342556)"
Line 466,"In 2018, our teams achieved:   10,500+ STEM volunteer hours   1,300+ STEM volunteers   200+ STEM events Our STEM programming is intended to help grow   a future pipeline of diverse talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9393966197967529)","('Employee_Health_And_Safety', 0.006331874523311853)","('Customer_Welfare', 0.005836827214807272)","(['Human Capital Development'], 0.9393966197967529)","('NON-ESG', 0.006331874523311853)","('NON-ESG', 0.005836827214807272)"
Line 467,"An important   part of our STEM outreach efforts has been finding  creative and interactive ways for Boston Scientific  employees to share their passion for their work with  young learners.
","('Access_And_Affordability', 0.41225898265838623)","('Employee_Engagement_Inclusion_And_Diversity', 0.2557773292064667)","('Human_Rights_And_Community_Relations', 0.04455290362238884)","('NON-ESG', 0.41225898265838623)","('NON-ESG', 0.2557773292064667)","('NON-ESG', 0.04455290362238884)"
Line 468,"We’ve created career cards, videos  and other tools to introduce students to employees  in a variety of STEM roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9264386296272278)","('Employee_Health_And_Safety', 0.006903257220983505)","('Product_Design_And_Lifecycle_Management', 0.006273728329688311)","(['Human Capital Development'], 0.9264386296272278)","('NON-ESG', 0.006903257220983505)","('NON-ESG', 0.006273728329688311)"
Line 469,"Left: Each year, the Boston Scientific Arden Hills,   Minnesota, STEM team hosts an annual Girl Scout   Patch Day with the Society of Women Engineers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.49948352575302124)","('Human_Rights_And_Community_Relations', 0.13384561240673065)","('Employee_Health_And_Safety', 0.08797537535429001)","('NON-ESG', 0.49948352575302124)","('NON-ESG', 0.13384561240673065)","('NON-ESG', 0.08797537535429001)"
Line 470,"Junior Girl Scouts participate in activities to learn   about engineering, science and package design.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5591191053390503)","('Access_And_Affordability', 0.07417512685060501)","('Employee_Health_And_Safety', 0.05947161838412285)","(['Human Capital Development'], 0.5591191053390503)","('NON-ESG', 0.07417512685060501)","('NON-ESG', 0.05947161838412285)"
Line 471,"Left: In 2018, Boston Scientific introduced students   to a new friend, Procedure Pal.
","('Access_And_Affordability', 0.2541447579860687)","('Employee_Engagement_Inclusion_And_Diversity', 0.19725683331489563)","('Employee_Health_And_Safety', 0.06890961527824402)","('NON-ESG', 0.2541447579860687)","('NON-ESG', 0.19725683331489563)","('NON-ESG', 0.06890961527824402)"
Line 472,"Designed to help  demonstrate how some Boston Scientific devices are  used, Procedure Pal is an interactive table-top model  that helps kids see real examples of where devices   are placed within the body and how each works.
","('Product_Design_And_Lifecycle_Management', 0.8684030771255493)","('Customer_Welfare', 0.016532812267541885)","('Energy_Management', 0.013967905193567276)","(['Product Stewardship'], 0.8684030771255493)","('NON-ESG', 0.016532812267541885)","('NON-ESG', 0.013967905193567276)"
Line 473,"Our  volunteers can explain medical procedures such as   deep brain stimulation for the treatment of Parkinson’s  disease symptoms and the implantation of cardiac   pacemakers to help the heart beat more regularly.
","('Employee_Health_And_Safety', 0.2611345052719116)","('Access_And_Affordability', 0.16716600954532623)","('Customer_Welfare', 0.07628727704286575)","('NON-ESG', 0.2611345052719116)","('NON-ESG', 0.16716600954532623)","('NON-ESG', 0.07628727704286575)"
Line 474,"Created by Boston Scientific volunteers from   Minnesota and Massachusetts, Procedure Pal models  have been featured in demonstrations globally,   including here in our Galway, Ireland facility.Right: Through the “Little Doctors” program   in China, Boston Scientific employees share practical   and fun lessons on first aid, CPR and trauma dressing  with local students.
","('Employee_Health_And_Safety', 0.8896233439445496)","('Critical_Incident_Risk_Management', 0.05846673995256424)","('Access_And_Affordability', 0.006004902999848127)","(['Operational Eco-Efficiency'], 0.8896233439445496)","('NON-ESG', 0.05846673995256424)","('NON-ESG', 0.006004902999848127)"
Line 475,"STEM Spotlight: Nurturing Talent for the Future S.T.E.M. OUR PEOPLE BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.states.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7917803525924683)","('Business_Model_Resilience', 0.02713806740939617)","('Access_And_Affordability', 0.02111176587641239)","(['Human Capital Development'], 0.7917803525924683)","('NON-ESG', 0.02713806740939617)","('NON-ESG', 0.02111176587641239)"
Line 476,"We also managed an Employee Disaster   Relief Fund to support individuals and families   impacted by large natural weather events and   disasters.
","('Critical_Incident_Risk_Management', 0.971944272518158)","('Employee_Health_And_Safety', 0.0031957265455275774)","('Physical_Impacts_Of_Climate_Change', 0.003130708821117878)","(['Risk & Crisis Management'], 0.971944272518158)","('NON-ESG', 0.0031957265455275774)","('NON-ESG', 0.003130708821117878)"
Line 477,"Many people who were impacted by   Hurricane Maria in September 2017 continued   to benefit from this fund in 2018, with Boston   Scientific employees and the company donating   $810,000 in 2018, adding to the more than   $4 million given in 2017.
","('Physical_Impacts_Of_Climate_Change', 0.9106245636940002)","('Critical_Incident_Risk_Management', 0.019817819818854332)","('Air_Quality', 0.007389598060399294)","(['Climate Change'], 0.9106245636940002)","('NON-ESG', 0.019817819818854332)","('NON-ESG', 0.007389598060399294)"
Line 478,"Possibility Grants  In 2018, Boston Scientific offered Massachusetts   and Minnesota employees the opportunity to   nominate local non-profits for Possibility Grants   intended to help solve a significant problem in   a local community.
","('Human_Rights_And_Community_Relations', 0.6618888974189758)","('Management_Of_Legal_And_Regulatory_Framework', 0.10448148101568222)","('Access_And_Affordability', 0.09365967661142349)","(['Community Relations'], 0.6618888974189758)","('NON-ESG', 0.10448148101568222)","('NON-ESG', 0.09365967661142349)"
Line 479,"Ten award winners received   a total of nearly $14,000 to support projects and   programs including a new indoor arena for a   therapeutic horseback riding program for young  adults with special needs, a middle school garden  and compost program, and new computers for a  teen crisis center.
","('Access_And_Affordability', 0.8638548851013184)","('Employee_Engagement_Inclusion_And_Diversity', 0.021777784451842308)","('Employee_Health_And_Safety', 0.01770729199051857)","(['Health Outcome Contribution'], 0.8638548851013184)","('NON-ESG', 0.021777784451842308)","('NON-ESG', 0.01770729199051857)"
Line 480,"GIVING BACK TO OUR COMMUNITIES In 2018, our global network of Boston Scientific   employee volunteers raised awareness through   more than 600 community engagement events   in 33 countries.
","('Human_Rights_And_Community_Relations', 0.8673258423805237)","('Access_And_Affordability', 0.024383150041103363)","('Employee_Health_And_Safety', 0.011611659079790115)","(['Community Relations'], 0.8673258423805237)","('NON-ESG', 0.024383150041103363)","('NON-ESG', 0.011611659079790115)"
Line 481,"We have an awards program to recognize   outstanding employee volunteers and received   more than 250 nominations highlighting the   work of employees who are making a difference  through culturally and locally relevant community  service.
","('Human_Rights_And_Community_Relations', 0.7452928423881531)","('Employee_Engagement_Inclusion_And_Diversity', 0.10970894992351532)","('Employee_Health_And_Safety', 0.02702323906123638)","(['Community Relations'], 0.7452928423881531)","('NON-ESG', 0.10970894992351532)","('NON-ESG', 0.02702323906123638)"
Line 482,"We also help communities in need through the   Boston Scientific Employee Matching Gifts Program  and the Employee Disaster Relief Fund.
","('Critical_Incident_Risk_Management', 0.9662674069404602)","('Employee_Health_And_Safety', 0.006315253209322691)","('Air_Quality', 0.0031536465976387262)","(['Risk & Crisis Management'], 0.9662674069404602)","('NON-ESG', 0.006315253209322691)","('NON-ESG', 0.0031536465976387262)"
Line 483,"Through   our Employee Matching Gifts Program, employees  can contribute to a cause they care about with   Boston Scientific matching their gift.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5580844879150391)","('Business_Ethics', 0.06354045122861862)","('Labor_Practices', 0.05140314996242523)","(['Corporate Governance'], 0.5580844879150391)","('NON-ESG', 0.06354045122861862)","('NON-ESG', 0.05140314996242523)"
Line 484,"In 2018, we   provided $8.9 million in charitable contributions   to support communities around the world,   targeted mostly to health and education efforts.
","('Access_And_Affordability', 0.6762740612030029)","('Human_Rights_And_Community_Relations', 0.08670602738857269)","('Management_Of_Legal_And_Regulatory_Framework', 0.0834653228521347)","(['Health Outcome Contribution'], 0.6762740612030029)","('NON-ESG', 0.08670602738857269)","('NON-ESG', 0.0834653228521347)"
Line 485,"In addition, we provided over $72 million in   funding for research and education efforts   across a wide category of health and disease  Living Our Caring Value: 43,000+  hours   volunteering in our   communities 8,500+  employee   volunteers around the world  600+  employee   volunteering events   worldwide Boston Scientific volunteers in Maple Grove,   Minnesota, participated in an event called Free   Bikes for Kids to benefit local children.
","('Access_And_Affordability', 0.3959149420261383)","('Employee_Health_And_Safety', 0.25732627511024475)","('Human_Rights_And_Community_Relations', 0.09778667986392975)","('NON-ESG', 0.3959149420261383)","('NON-ESG', 0.25732627511024475)","('NON-ESG', 0.09778667986392975)"
Line 486,"BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.OUR PRACTICES OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.As we work together to   advance science for life,   the quality and safety of   our products and services   is our top priority.
","('Product_Quality_And_Safety', 0.8231141567230225)","('Product_Design_And_Lifecycle_Management', 0.06086968630552292)","('Selling_Practices_And_Product_Labeling', 0.025811271741986275)","(['Product Quality & Recall Management'], 0.8231141567230225)","('NON-ESG', 0.06086968630552292)","('NON-ESG', 0.025811271741986275)"
Line 487,"We are  committed to applying safe,  ethical and sustainable   business practices in all that  we do to make a meaningful  difference in the lives of   patients and their families.
","('Human_Rights_And_Community_Relations', 0.400409996509552)","('Business_Ethics', 0.1482510268688202)","('Employee_Health_And_Safety', 0.0687410905957222)","('NON-ESG', 0.400409996509552)","('NON-ESG', 0.1482510268688202)","('NON-ESG', 0.0687410905957222)"
Line 488,"WORKING RESPONSIBLY We work responsibly to research, develop, man- ufacture and deliver our innovative products with  our commitment to strong corporate governance,  impeccable ethics and compliance with industry  regulations.
","('Business_Ethics', 0.9625660181045532)","('Management_Of_Legal_And_Regulatory_Framework', 0.0061976611614227295)","('Competitive_Behavior', 0.004252622835338116)","(['Business Ethics'], 0.9625660181045532)","('NON-ESG', 0.0061976611614227295)","('NON-ESG', 0.004252622835338116)"
Line 489,"GOVERNANCE Boston Scientific is committed to doing business   with integrity and honesty.
","('Business_Ethics', 0.9643922448158264)","('Data_Security', 0.002978793578222394)","('Customer_Privacy', 0.0027342664543539286)","(['Business Ethics'], 0.9643922448158264)","('NON-ESG', 0.002978793578222394)","('NON-ESG', 0.0027342664543539286)"
Line 490,"An ethical workplace and  governing structure begins with our Board of  OUR PRACTICES Directors and executive leadership, who oversee   the implementation of guidelines to ensure we   act ethically in our business practices, comply   with local tax and business laws and regulations,   and remain transparent in our reporting.
","('Business_Ethics', 0.8577467799186707)","('Management_Of_Legal_And_Regulatory_Framework', 0.04091794043779373)","('Director_Removal', 0.017929241061210632)","(['Business Ethics'], 0.8577467799186707)","('NON-ESG', 0.04091794043779373)","('NON-ESG', 0.017929241061210632)"
Line 491,"All of   our employees are responsible for applying these  guidelines to interactions with customers, suppliers  and investors, and in the communities in which   we operate.
","('Supply_Chain_Management', 0.7279086709022522)","('Labor_Practices', 0.04226326942443848)","('Human_Rights_And_Community_Relations', 0.03286157548427582)","(['Supply Chain Management'], 0.7279086709022522)","('NON-ESG', 0.04226326942443848)","('NON-ESG', 0.03286157548427582)"
Line 492,"Our Board maintains charters for governing its   committees.
","('Director_Removal', 0.571912407875061)","('Management_Of_Legal_And_Regulatory_Framework', 0.1464930772781372)","('Business_Ethics', 0.035758454352617264)","(['Anti-Crime Policy & Measures'], 0.571912407875061)","('NON-ESG', 0.1464930772781372)","('NON-ESG', 0.035758454352617264)"
Line 493,"The current committees of the Board  are the Audit Committee, Executive Compensation  and Human Resources Committee, Finance   Committee, and Nominating and Governance   Committee.
","('Management_Of_Legal_And_Regulatory_Framework', 0.41222748160362244)","('Director_Removal', 0.2095385193824768)","('Business_Ethics', 0.06134247034788132)","('NON-ESG', 0.41222748160362244)","('NON-ESG', 0.2095385193824768)","('NON-ESG', 0.06134247034788132)"
Line 494,"A nominating and governance   committee reviews our Board composition and   committee membership annually to ensure it   reflects the needs of our diverse stakeholders.
","('Director_Removal', 0.5435900092124939)","('Employee_Engagement_Inclusion_And_Diversity', 0.09995359182357788)","('Management_Of_Legal_And_Regulatory_Framework', 0.07442285865545273)","(['Anti-Crime Policy & Measures'], 0.5435900092124939)","('NON-ESG', 0.09995359182357788)","('NON-ESG', 0.07442285865545273)"
Line 495,"Risk management is essential to our governance.
","('Systemic_Risk_Management', 0.8398672342300415)","('Business_Model_Resilience', 0.04433182626962662)","('Physical_Impacts_Of_Climate_Change', 0.014800818637013435)","(['Risk & Crisis Management'], 0.8398672342300415)","('NON-ESG', 0.04433182626962662)","('NON-ESG', 0.014800818637013435)"
Line 496,"Our Board oversees an Enterprise Risk Management  program, which identifies strategic, operational,  financial, legal and compliance risks so we can   anticipate and adapt to potential challenges.
","('Systemic_Risk_Management', 0.8767685890197754)","('Business_Model_Resilience', 0.030736494809389114)","('Management_Of_Legal_And_Regulatory_Framework', 0.016056187450885773)","(['Risk & Crisis Management'], 0.8767685890197754)","('NON-ESG', 0.030736494809389114)","('NON-ESG', 0.016056187450885773)"
Line 497,"We  continually evaluate our corporate governance  guidelines, committee charters and Code of Conduct,  taking into consideration relevant laws, regulations  and listing requirements, as well as best practices  suggested by recognized governance authorities.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9634482264518738)","('Director_Removal', 0.004986255429685116)","('Business_Ethics', 0.004524776712059975)","(['Corporate Governance'], 0.9634482264518738)","('NON-ESG', 0.004986255429685116)","('NON-ESG', 0.004524776712059975)"
Line 498,"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.COMPLIANCE, ETHICS AND INTEGRITY Our company values underpin our commitment to  ethical and honest business practices in everything  we do.
","('Business_Ethics', 0.9709435105323792)","('Product_Quality_And_Safety', 0.0023093477357178926)","('Competitive_Behavior', 0.002176816575229168)","(['Business Ethics'], 0.9709435105323792)","('NON-ESG', 0.0023093477357178926)","('NON-ESG', 0.002176816575229168)"
Line 499,"Our employees are expected to:    Act honestly and ethically in all company matters    Protect the privacy of patients, customers and  employees    Treat each other with respect and fairness    Hold each other accountable to ensure quality in  all that we do The Global Compliance team, led by our chief   compliance officer, supports the company’s world- wide culture of compliance and ethics through   partnerships and collaboration with commercial  team members and other key stakeholders.
","('Business_Ethics', 0.9681206941604614)","('Product_Quality_And_Safety', 0.0028717024251818657)","('Competitive_Behavior', 0.0027669882401823997)","(['Business Ethics'], 0.9681206941604614)","('NON-ESG', 0.0028717024251818657)","('NON-ESG', 0.0027669882401823997)"
Line 500,"The   chief compliance officer reports quarterly to the   audit committee of the Board of Directors.
","('Director_Removal', 0.6407159566879272)","('Management_Of_Legal_And_Regulatory_Framework', 0.13039501011371613)","('Business_Ethics', 0.03273221477866173)","(['Anti-Crime Policy & Measures'], 0.6407159566879272)","('NON-ESG', 0.13039501011371613)","('NON-ESG', 0.03273221477866173)"
Line 501,"Code of Conduct for Employees and Channel Partners Boston Scientific strives to comply with applicable  laws in every relationship, every day.
","('Management_Of_Legal_And_Regulatory_Framework', 0.553104043006897)","('Business_Ethics', 0.11971300095319748)","('Labor_Practices', 0.11580339819192886)","(['Corporate Governance'], 0.553104043006897)","('NON-ESG', 0.11971300095319748)","('NON-ESG', 0.11580339819192886)"
Line 502,"Our Code of  Conduct is the foundation for our existing policies  and must be read and fully understood by every  employee.
","('Management_Of_Legal_And_Regulatory_Framework', 0.755049467086792)","('Business_Ethics', 0.08992452174425125)","('Director_Removal', 0.0315345898270607)","(['Corporate Governance'], 0.755049467086792)","('NON-ESG', 0.08992452174425125)","('NON-ESG', 0.0315345898270607)"
Line 503,"Additionally, we have multiple training  curriculums which are required for all employees.
","('Employee_Engagement_Inclusion_And_Diversity', 0.39760923385620117)","('Employee_Health_And_Safety', 0.10925047099590302)","('Access_And_Affordability', 0.10245529562234879)","('NON-ESG', 0.39760923385620117)","('NON-ESG', 0.10925047099590302)","('NON-ESG', 0.10245529562234879)"
Line 504,"Our Code of Conduct training curriculum provides  ongoing education to employees on our policies,   corruption and compliance-related risks, and resources   for asking questions and reporting concerns.
","('Business_Ethics', 0.967093288898468)","('Management_Of_Legal_And_Regulatory_Framework', 0.006515104789286852)","('Product_Quality_And_Safety', 0.002369383117184043)","(['Business Ethics'], 0.967093288898468)","('NON-ESG', 0.006515104789286852)","('NON-ESG', 0.002369383117184043)"
Line 505,"It also  features real-life, scenario-based content.Our U.S. Customer Interactions training provides  guidance on the laws, policies, principles and   processes for interacting with healthcare   professionals licensed to practice in the U.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6304851770401001)","('Access_And_Affordability', 0.049956489354372025)","('Competitive_Behavior', 0.03761487081646919)","(['Corporate Governance'], 0.6304851770401001)","('NON-ESG', 0.049956489354372025)","('NON-ESG', 0.03761487081646919)"
Line 506,"S.
","('Product_Design_And_Lifecycle_Management', 0.09914591163396835)","('Waste_And_Hazardous_Materials_Management', 0.09464520215988159)","('Management_Of_Legal_And_Regulatory_Framework', 0.07568437606096268)","('NON-ESG', 0.09914591163396835)","('NON-ESG', 0.09464520215988159)","('NON-ESG', 0.07568437606096268)"
Line 507,"Our anti-corruption training course reviews the   compliance requirements for interacting with   healthcare professionals, public officials and   other third parties, such as our channel partners  (e.g., distributors, dealers and agents) outside   of the U.S. Our Channel Partner Code of Conduct sets forth  expectations for our channel partners (i.e.,   distributors, dealers and agents) doing business   on our behalf.
","('Business_Ethics', 0.9688997268676758)","('Management_Of_Legal_And_Regulatory_Framework', 0.004481736104935408)","('Competitive_Behavior', 0.0025591698940843344)","(['Business Ethics'], 0.9688997268676758)","('NON-ESG', 0.004481736104935408)","('NON-ESG', 0.0025591698940843344)"
Line 508,"All channel partners annually certify  adherence to the Boston Scientific and Channel   Partner Codes of Conduct as part of on-boarding   or renewal procedures as well as complete   mandatory training.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6118115186691284)","('Business_Ethics', 0.09976864606142044)","('Product_Quality_And_Safety', 0.07258927822113037)","(['Corporate Governance'], 0.6118115186691284)","('NON-ESG', 0.09976864606142044)","('NON-ESG', 0.07258927822113037)"
Line 509,"Boston Scientific requires   channel partners to abide by anti-bribery and   anti-corruption laws, such as the U.S. Foreign   Corrupt Practices Act, the U.K. Bribery Act and   other national laws.
","('Business_Ethics', 0.9745473265647888)","('Management_Of_Legal_And_Regulatory_Framework', 0.0031623125541955233)","('Competitive_Behavior', 0.002265096176415682)","(['Business Ethics'], 0.9745473265647888)","('NON-ESG', 0.0031623125541955233)","('NON-ESG', 0.002265096176415682)"
Line 510,"We monitor and support   our channel partners through our Third Party   Program, which includes on-site auditing and   other procedures that validate channel partners’  compliance with our requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8189235329627991)","('Business_Ethics', 0.09200800955295563)","('Competitive_Behavior', 0.013129731640219688)","(['Corporate Governance'], 0.8189235329627991)","('NON-ESG', 0.09200800955295563)","('NON-ESG', 0.013129731640219688)"
Line 511,"Compliance Program We have a comprehensive compliance program to  prevent, detect and respond, if needed, to conduct  that does not align to our Code of Conduct.
","('Business_Ethics', 0.6334306001663208)","('Management_Of_Legal_And_Regulatory_Framework', 0.20215733349323273)","('Systemic_Risk_Management', 0.018127016723155975)","(['Business Ethics'], 0.6334306001663208)","('NON-ESG', 0.20215733349323273)","('NON-ESG', 0.018127016723155975)"
Line 512,"Our  program also includes periodic assessments of our  compliance program’s effectiveness and an annual risk assessment, using internal and external inputs,   to determine strategic focus areas across all elements   of our compliance program.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5785257816314697)","('Business_Ethics', 0.24468988180160522)","('Systemic_Risk_Management', 0.0351029671728611)","(['Corporate Governance'], 0.5785257816314697)","('NON-ESG', 0.24468988180160522)","('NON-ESG', 0.0351029671728611)"
Line 513,"Boston Scientific Advice Line We encourage employees to ask questions and   report concerns, including anything that conflicts  with our Code of Conduct, through our advice line,  which is operated by a third party and available 24  hours a day in multiple languages.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5459838509559631)","('Business_Ethics', 0.23968984186649323)","('Product_Quality_And_Safety', 0.031234508380293846)","(['Corporate Governance'], 0.5459838509559631)","('NON-ESG', 0.23968984186649323)","('NON-ESG', 0.031234508380293846)"
Line 514,"Our Non-Retaliation Policy prohibits any form of   retaliation, direct or indirect, against an individual  who raises a concern in good faith.
","('Business_Ethics', 0.8961048722267151)","('Management_Of_Legal_And_Regulatory_Framework', 0.017020950093865395)","('Competitive_Behavior', 0.014235186390578747)","(['Business Ethics'], 0.8961048722267151)","('NON-ESG', 0.017020950093865395)","('NON-ESG', 0.014235186390578747)"
Line 515,"This policy   extends to anyone who assists with, or cooperates   in, an investigation or report of misconduct.EMPLOYEE EXPECTATIONS: Act honestly and ethically.
","('Business_Ethics', 0.9508269429206848)","('Employee_Health_And_Safety', 0.006544701289385557)","('Management_Of_Legal_And_Regulatory_Framework', 0.003924173768609762)","(['Business Ethics'], 0.9508269429206848)","('NON-ESG', 0.006544701289385557)","('NON-ESG', 0.003924173768609762)"
Line 516,"Protect privacy of patients,  customers and employees.
","('Customer_Privacy', 0.8461242914199829)","('Data_Security', 0.07261000573635101)","('Waste_And_Hazardous_Materials_Management', 0.0066719357855618)","(['Privacy Protection'], 0.8461242914199829)","('NON-ESG', 0.07261000573635101)","('NON-ESG', 0.0066719357855618)"
Line 517,"Be respectful and fair.
","('Business_Ethics', 0.6118792295455933)","('Labor_Practices', 0.08610351383686066)","('Human_Rights_And_Community_Relations', 0.05655723065137863)","(['Business Ethics'], 0.6118792295455933)","('NON-ESG', 0.08610351383686066)","('NON-ESG', 0.05655723065137863)"
Line 518,"Hold each other   accountable, to ensure  quality in all we do.
","('Business_Ethics', 0.3843021094799042)","('Management_Of_Legal_And_Regulatory_Framework', 0.23953236639499664)","('Systemic_Risk_Management', 0.06124972924590111)","('NON-ESG', 0.3843021094799042)","('NON-ESG', 0.23953236639499664)","('NON-ESG', 0.06124972924590111)"
Line 519,"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.DEVELOPING INNOVATIVE PRODUCTS It takes an unwavering focus to deliver life-changing  treatments.
","('Product_Design_And_Lifecycle_Management', 0.9534938335418701)","('Customer_Welfare', 0.006700053811073303)","('Product_Quality_And_Safety', 0.0062939743511378765)","(['Product Stewardship'], 0.9534938335418701)","('NON-ESG', 0.006700053811073303)","('NON-ESG', 0.0062939743511378765)"
Line 520,"We foster an environment of creativity to  transform new ideas into breakthrough services and  solutions that create value for patients, customers  and employees.
","('Product_Design_And_Lifecycle_Management', 0.3563268482685089)","('Access_And_Affordability', 0.11513160169124603)","('Customer_Welfare', 0.10337108373641968)","('NON-ESG', 0.3563268482685089)","('NON-ESG', 0.11513160169124603)","('NON-ESG', 0.10337108373641968)"
Line 521,"Our teams collaborate internally   and externally to solve the challenges that matter  most, always with a focus on patients.
","('Access_And_Affordability', 0.28074902296066284)","('Human_Rights_And_Community_Relations', 0.27605974674224854)","('Business_Model_Resilience', 0.04591166228055954)","('NON-ESG', 0.28074902296066284)","('NON-ESG', 0.27605974674224854)","('NON-ESG', 0.04591166228055954)"
Line 522,"Our Global Approach to Innovation  Boston Scientific new product development teams  follow the Product Life Cycle Process (PLCP), a global  process that integrates business, technical and   quality system tasks to drive innovative product   ideas from strategy through commercialization to  product end-of-life.
","('Product_Design_And_Lifecycle_Management', 0.9641856551170349)","('Product_Quality_And_Safety', 0.004036301746964455)","('Customer_Welfare', 0.0035178049001842737)","(['Product Stewardship'], 0.9641856551170349)","('NON-ESG', 0.004036301746964455)","('NON-ESG', 0.0035178049001842737)"
Line 523,"This methodology helps us   share experience and knowledge across the   company and ensures a consistent, quality-focused  approach to new products and services.
","('Product_Design_And_Lifecycle_Management', 0.9503172636032104)","('Product_Quality_And_Safety', 0.007929853163659573)","('Customer_Welfare', 0.005248510744422674)","(['Product Stewardship'], 0.9503172636032104)","('NON-ESG', 0.007929853163659573)","('NON-ESG', 0.005248510744422674)"
Line 524,"To better meet the needs of patients and customers  in global markets, we have research and development  sites in the United States, European Union, Costa   Rica, India and China.
","('Customer_Welfare', 0.32944080233573914)","('Access_And_Affordability', 0.14854209125041962)","('Product_Design_And_Lifecycle_Management', 0.07296773046255112)","('NON-ESG', 0.32944080233573914)","('NON-ESG', 0.14854209125041962)","('NON-ESG', 0.07296773046255112)"
Line 525,"These sites help us closely   align our R&D teams designing products with   our manufacturing teams building products.
","('Product_Design_And_Lifecycle_Management', 0.9656611084938049)","('Product_Quality_And_Safety', 0.003421313362196088)","('Customer_Welfare', 0.0030297127086669207)","(['Product Stewardship'], 0.9656611084938049)","('NON-ESG', 0.003421313362196088)","('NON-ESG', 0.0030297127086669207)"
Line 526,"In   addition, our R&D Centers of Excellence help us   share expertise and capabilities across our global  product development network.
","('Product_Design_And_Lifecycle_Management', 0.89262455701828)","('Supply_Chain_Management', 0.015925291925668716)","('Business_Model_Resilience', 0.014630415476858616)","(['Product Stewardship'], 0.89262455701828)","('NON-ESG', 0.015925291925668716)","('NON-ESG', 0.014630415476858616)"
Line 527,"Pre-Clinical Sciences  Boston Scientific conducts pre-clinical research   to investigate and demonstrate the safety and   efficacy of our medical device products prior to   human clinical trials and use.
","('Product_Quality_And_Safety', 0.5296853184700012)","('Selling_Practices_And_Product_Labeling', 0.11788992583751678)","('Customer_Welfare', 0.09614840894937515)","(['Product Quality & Recall Management'], 0.5296853184700012)","('NON-ESG', 0.11788992583751678)","('NON-ESG', 0.09614840894937515)"
Line 528,"To ensure excellence   in our pre-clinical research and science, our policies  set standards to be certain that we are consistently  pursuing product efficacy, fulfilling regulatory   requirements and engaging in essential training.
","('Product_Quality_And_Safety', 0.33847013115882874)","('Selling_Practices_And_Product_Labeling', 0.11174260079860687)","('Customer_Welfare', 0.10891049355268478)","('NON-ESG', 0.33847013115882874)","('NON-ESG', 0.11174260079860687)","('NON-ESG', 0.10891049355268478)"
Line 529,"At times, to ensure we meet our obligations of   safety in new products and therapies, animal   testing is utilized and serves as an important   component of our research and development   efforts.
","('Product_Quality_And_Safety', 0.8769649267196655)","('Selling_Practices_And_Product_Labeling', 0.02661501243710518)","('Customer_Welfare', 0.012158231809735298)","(['Product Quality & Recall Management'], 0.8769649267196655)","('NON-ESG', 0.02661501243710518)","('NON-ESG', 0.012158231809735298)"
Line 530,"The FDA may require evidence from   pre-clinical testing prior to commencing human  clinical trials.
","('Competitive_Behavior', 0.2557988166809082)","('Management_Of_Legal_And_Regulatory_Framework', 0.17361904680728912)","('Product_Quality_And_Safety', 0.09241596609354019)","('NON-ESG', 0.2557988166809082)","('NON-ESG', 0.17361904680728912)","('NON-ESG', 0.09241596609354019)"
Line 531,"We are committed to the humane care and   treatment of laboratory animals, and use   alternative testing whenever such methods   are feasible, scientifically valid and appropriate.
","('Ecological_Impacts', 0.171044260263443)","('Waste_And_Hazardous_Materials_Management', 0.1271595060825348)","('Selling_Practices_And_Product_Labeling', 0.10749861598014832)","('NON-ESG', 0.171044260263443)","('NON-ESG', 0.1271595060825348)","('NON-ESG', 0.10749861598014832)"
Line 532,"Our pre-clinical research personnel are highly   trained with multiple certifications and our   facilities meet or exceed applicable laws and  regulatory authority requirements, guidelines and  standards.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9304623007774353)","('Product_Quality_And_Safety', 0.011236047372221947)","('Business_Ethics', 0.010384704917669296)","(['Corporate Governance'], 0.9304623007774353)","('NON-ESG', 0.011236047372221947)","('NON-ESG', 0.010384704917669296)"
Line 533,"Finally, we are routinely audited by our  own internal experts and relevant government   agencies including FDA, USDA and AAALAC.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8756033778190613)","('Business_Ethics', 0.04487178847193718)","('Competitive_Behavior', 0.0072301821783185005)","(['Corporate Governance'], 0.8756033778190613)","('NON-ESG', 0.04487178847193718)","('NON-ESG', 0.0072301821783185005)"
Line 534,"Clinical Trials Advancing our product pipeline to include new  and expanded indications requires a commitment  to leading transformative and innovative science.
","('Customer_Welfare', 0.36995983123779297)","('Product_Design_And_Lifecycle_Management', 0.14348730444908142)","('Selling_Practices_And_Product_Labeling', 0.07053164392709732)","('NON-ESG', 0.36995983123779297)","('NON-ESG', 0.14348730444908142)","('NON-ESG', 0.07053164392709732)"
Line 535,"Clinical trials are critical to our assurance that the  products we offer are of the highest quality and   safety.
","('Product_Quality_And_Safety', 0.8937253355979919)","('Product_Design_And_Lifecycle_Management', 0.012967786751687527)","('Selling_Practices_And_Product_Labeling', 0.01166868768632412)","(['Product Quality & Recall Management'], 0.8937253355979919)","('NON-ESG', 0.012967786751687527)","('NON-ESG', 0.01166868768632412)"
Line 536,"We conduct trials in accordance with   international and national regulatory requirements  with dedication to our quality systems, which   are designed for legal and regulatory compliance,   as well as for enhancing delivery of global trial   operations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9508242607116699)","('Business_Ethics', 0.008932196535170078)","('Competitive_Behavior', 0.0066383229568600655)","(['Corporate Governance'], 0.9508242607116699)","('NON-ESG', 0.008932196535170078)","('NON-ESG', 0.0066383229568600655)"
Line 537,"In 2018, we invested in operational   enhancements that will prepare our trials for   compliance with the General Data Protection   Regulation, E.U. Medical Device Regulation and   Risk-Based Monitoring as well as additional   enhancements to drive ISO (International   Standards Organization) and operational   excellence.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9687340259552002)","('Business_Ethics', 0.0026599718257784843)","('Product_Quality_And_Safety', 0.0025349310599267483)","(['Corporate Governance'], 0.9687340259552002)","('NON-ESG', 0.0026599718257784843)","('NON-ESG', 0.0025349310599267483)"
Line 538,"CLINICAL STUDIES AT A GLANCE: There were 150  active clinical studies in 2018,   including more than 55,000 patients globally.Recognize Development Excellence is an annual   Boston Scientific program that recognizes and   rewards cross-functional teams who develop   meaningful innovations for patients, customers   and company.Now in its fourth year, the Boston Scientific   Connected Patient Challenge is an open   competition to promote the development of   meaningful innovation to address complex   healthcare challenges.
","('Competitive_Behavior', 0.4468323588371277)","('Customer_Welfare', 0.08022558689117432)","('Business_Model_Resilience', 0.0624423548579216)","('NON-ESG', 0.4468323588371277)","('NON-ESG', 0.08022558689117432)","('NON-ESG', 0.0624423548579216)"
Line 539,"CLINICAL STUDIES AT A GLANCE: There were 150  active clinical studies in 2018,   including more than 55,000 patients globally.Recognize Development Excellence is an annual   Boston Scientific program that recognizes and   rewards cross-functional teams who develop   meaningful innovations for patients, customers   and company.Now in its fourth year, the Boston Scientific   Connected Patient Challenge is an open   competition to promote the development of   meaningful innovation to address complex   healthcare challenges.
","('Business_Ethics', 0.1598837673664093)","('Competitive_Behavior', 0.1578827202320099)","('Product_Design_And_Lifecycle_Management', 0.0800221711397171)","('NON-ESG', 0.1598837673664093)","('NON-ESG', 0.1578827202320099)","('NON-ESG', 0.0800221711397171)"
Line 540,"The 2018 competition,  co-sponsored by Google Cloud, focused on the   role of the Internet of Things in influencing   patient outcomes.
","('Competitive_Behavior', 0.885746955871582)","('Management_Of_Legal_And_Regulatory_Framework', 0.02724721096456051)","('Business_Ethics', 0.007528040092438459)","(['Business Ethics'], 0.885746955871582)","('NON-ESG', 0.02724721096456051)","('NON-ESG', 0.007528040092438459)"
Line 541,"The winner, XcellCure, a startup   biotechnology company, developed the AmiAware  cardiac microarray concept to detect early warning  signs of a heart attack in patients with chest pain.
","('Employee_Health_And_Safety', 0.39925533533096313)","('Critical_Incident_Risk_Management', 0.26167118549346924)","('Systemic_Risk_Management', 0.02868574485182762)","('NON-ESG', 0.39925533533096313)","('NON-ESG', 0.26167118549346924)","('NON-ESG', 0.02868574485182762)"
Line 542,"The award enabled the company to further   develop the platform and clinical strategy.
","('Access_And_Affordability', 0.2436496764421463)","('Customer_Welfare', 0.10467728227376938)","('Selling_Practices_And_Product_Labeling', 0.07039695233106613)","('NON-ESG', 0.2436496764421463)","('NON-ESG', 0.10467728227376938)","('NON-ESG', 0.07039695233106613)"
Line 543,"Boston Scientific leaders demonstrate their   commitment to innovation though the ImagineIF  Innovation Fund.
","('Business_Model_Resilience', 0.2571415305137634)","('Competitive_Behavior', 0.1370188593864441)","('Product_Design_And_Lifecycle_Management', 0.08079926669597626)","('NON-ESG', 0.2571415305137634)","('NON-ESG', 0.1370188593864441)","('NON-ESG', 0.08079926669597626)"
Line 544,"Employees are encouraged to   participate in a venture-style contest that solicits   breakthrough ideas across the organization.
","('Competitive_Behavior', 0.57423335313797)","('Business_Ethics', 0.05581779405474663)","('Employee_Engagement_Inclusion_And_Diversity', 0.05157171189785004)","(['Business Ethics'], 0.57423335313797)","('NON-ESG', 0.05581779405474663)","('NON-ESG', 0.05157171189785004)"
Line 545,"This   program helps to continuously reinforce our   meaningful innovation core value.
","('Product_Design_And_Lifecycle_Management', 0.35084423422813416)","('Business_Model_Resilience', 0.1734444499015808)","('Competitive_Behavior', 0.14477722346782684)","('NON-ESG', 0.35084423422813416)","('NON-ESG', 0.1734444499015808)","('NON-ESG', 0.14477722346782684)"
Line 546,"Since the 2014  launch, we’ve funded more than 50 projects.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6939098238945007)","('GHG_Emissions', 0.06714578717947006)","('Access_And_Affordability', 0.037935469299554825)","(['Corporate Governance'], 0.6939098238945007)","('NON-ESG', 0.06714578717947006)","('NON-ESG', 0.037935469299554825)"
Line 547,"Focus on Innovation Celebrating Our Teams Recognizing Development Excellence Improving Patient Care with Digital Health OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.46RECOGNITION FOR INNOVATION EXCELLENCE IN    Forbes Most Innovative Companies: Boston Scientific named to Forbes' list of The World's Most   Innovative Companies    Clarivate: Boston Scientific recognized for the third consecutive year as a Derwent Top 100 Global   Innovator by Clarivate Analytics   Prix Galien: The Boston Scientific WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device received   the Prix Galien USA 2018 Award for Best Medical Technology, one of the global health innovation   industry’s most prized honors  Every employee makes an impact on the quality of patient  care and has an opportunity to innovate so that we can keep  improving.
","('Business_Model_Resilience', 0.40815940499305725)","('Product_Design_And_Lifecycle_Management', 0.1073569506406784)","('Supply_Chain_Management', 0.05585095286369324)","('NON-ESG', 0.40815940499305725)","('NON-ESG', 0.1073569506406784)","('NON-ESG', 0.05585095286369324)"
Line 548,"Focus on Innovation Celebrating Our Teams Recognizing Development Excellence Improving Patient Care with Digital Health OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.46RECOGNITION FOR INNOVATION EXCELLENCE IN    Forbes Most Innovative Companies: Boston Scientific named to Forbes' list of The World's Most   Innovative Companies    Clarivate: Boston Scientific recognized for the third consecutive year as a Derwent Top 100 Global   Innovator by Clarivate Analytics   Prix Galien: The Boston Scientific WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device received   the Prix Galien USA 2018 Award for Best Medical Technology, one of the global health innovation   industry’s most prized honors  Every employee makes an impact on the quality of patient  care and has an opportunity to innovate so that we can keep  improving.
","('Product_Design_And_Lifecycle_Management', 0.2532421946525574)","('Access_And_Affordability', 0.10501006245613098)","('Customer_Welfare', 0.09947504103183746)","('NON-ESG', 0.2532421946525574)","('NON-ESG', 0.10501006245613098)","('NON-ESG', 0.09947504103183746)"
Line 549,"We will never be satisfied with the status quo.
","('Competitive_Behavior', 0.39941728115081787)","('Business_Ethics', 0.08195984363555908)","('Business_Model_Resilience', 0.056327223777770996)","('NON-ESG', 0.39941728115081787)","('NON-ESG', 0.08195984363555908)","('NON-ESG', 0.056327223777770996)"
Line 550,"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Collaborating on Solutions to Improve Patient Care  The Boston Scientific ADVANTICS™ Innovative  Healthcare Solutions portfolio helps customers  solve complex challenges.
","('Access_And_Affordability', 0.17147864401340485)","('Customer_Welfare', 0.14211523532867432)","('Product_Design_And_Lifecycle_Management', 0.10943958908319473)","('NON-ESG', 0.17147864401340485)","('NON-ESG', 0.14211523532867432)","('NON-ESG', 0.10943958908319473)"
Line 551,"Using clinical and   operational expertise, our team works together   with cardiovascular staff to improve the patient   experience, grow their Structural Heart programs  and optimize cardiovascular lab performance.
","('Access_And_Affordability', 0.2703137695789337)","('Customer_Welfare', 0.1489735096693039)","('Employee_Engagement_Inclusion_And_Diversity', 0.10450085997581482)","('NON-ESG', 0.2703137695789337)","('NON-ESG', 0.1489735096693039)","('NON-ESG', 0.10450085997581482)"
Line 552,"Recent collaborations include:   A 300+ bed hospital that offers advanced   services in cardiovascular medicine where   we identified improvement opportunities   within the Structural Heart program, including  increasing patient access to care and efficiency  of care.
","('Access_And_Affordability', 0.8355951905250549)","('Customer_Welfare', 0.01782030053436756)","('Critical_Incident_Risk_Management', 0.01765417493879795)","(['Health Outcome Contribution'], 0.8355951905250549)","('NON-ESG', 0.01782030053436756)","('NON-ESG', 0.01765417493879795)"
Line 553,"As a result, the hospital has been able  to treat more patients who benefited from a  streamlined referral process and operational  improvements.
","('Access_And_Affordability', 0.6478415727615356)","('Customer_Welfare', 0.038447849452495575)","('Critical_Incident_Risk_Management', 0.03223725035786629)","(['Health Outcome Contribution'], 0.6478415727615356)","('NON-ESG', 0.038447849452495575)","('NON-ESG', 0.03223725035786629)"
Line 554,"A 500+ bed hospital where we facilitated   same-day discharges for patients who under - went percutaneous coronary intervention   (PCI).
","('Employee_Health_And_Safety', 0.4307308793067932)","('Access_And_Affordability', 0.2526468336582184)","('Product_Quality_And_Safety', 0.05216866359114647)","('NON-ESG', 0.4307308793067932)","('NON-ESG', 0.2526468336582184)","('NON-ESG', 0.05216866359114647)"
Line 555,"Within 12 months, more than 30 percent   of patients who would have previously   required an overnight stay were discharged   the same day and able to recover in the   comfort of their own homes.
","('Access_And_Affordability', 0.4132605493068695)","('Employee_Health_And_Safety', 0.22814396023750305)","('Employee_Engagement_Inclusion_And_Diversity', 0.05108233168721199)","('NON-ESG', 0.4132605493068695)","('NON-ESG', 0.22814396023750305)","('NON-ESG', 0.05108233168721199)"
Line 556,"This resulted in  decreased costs and increased inpatient bed  capacity.QUALITY AND SAFETY Quality is integrated into every aspect of our   work to ensure we design, test, manufacture and   distribute high-quality, safe and effective devices.
","('Product_Quality_And_Safety', 0.6443220376968384)","('Employee_Health_And_Safety', 0.2169402837753296)","('Product_Design_And_Lifecycle_Management', 0.017470858991146088)","(['Product Quality & Recall Management'], 0.6443220376968384)","('NON-ESG', 0.2169402837753296)","('NON-ESG', 0.017470858991146088)"
Line 557,"Our commitment to quality begins with our Quality  Policy, a one-line statement that is highly visible in  our facilities: “I improve the quality of patient care  and all things Boston Scientific.” This commitment   is supported by Quality Systems Basics training for   all Boston Scientific employees.
","('Access_And_Affordability', 0.27984216809272766)","('Product_Quality_And_Safety', 0.22464461624622345)","('Employee_Engagement_Inclusion_And_Diversity', 0.06039150059223175)","('NON-ESG', 0.27984216809272766)","('NON-ESG', 0.22464461624622345)","('NON-ESG', 0.06039150059223175)"
Line 558,"The following key elements are included in our   approach to quality:   A Quality Master Plan that helps us strategically  plan and prioritize quality improvement projects  that emphasize prevention and will lead to higher  quality products, with better patient outcomes   and fewer customer complaints    A strategy we call Best4, with the goal of   delivering industry-leading performance in   (1) compliance,   (2) outcomes,   (3) efficiency and   (4) agility    A Global Quality System that integrates customer  feedback and regulatory requirements into our  processesFocus on Quality: Connecting our teams to   customers and patients Annual employee events are held at Boston   Scientific sites to celebrate the impact our work   has on improving the quality of patient care.
","('Product_Design_And_Lifecycle_Management', 0.6011755466461182)","('Product_Quality_And_Safety', 0.2248598039150238)","('Customer_Welfare', 0.022597696632146835)","(['Product Stewardship'], 0.6011755466461182)","('NON-ESG', 0.2248598039150238)","('NON-ESG', 0.022597696632146835)"
Line 559,"The following key elements are included in our   approach to quality:   A Quality Master Plan that helps us strategically  plan and prioritize quality improvement projects  that emphasize prevention and will lead to higher  quality products, with better patient outcomes   and fewer customer complaints    A strategy we call Best4, with the goal of   delivering industry-leading performance in   (1) compliance,   (2) outcomes,   (3) efficiency and   (4) agility    A Global Quality System that integrates customer  feedback and regulatory requirements into our  processesFocus on Quality: Connecting our teams to   customers and patients Annual employee events are held at Boston   Scientific sites to celebrate the impact our work   has on improving the quality of patient care.
","('Access_And_Affordability', 0.6330632567405701)","('Product_Quality_And_Safety', 0.04893583059310913)","('Customer_Welfare', 0.04254557192325592)","(['Health Outcome Contribution'], 0.6330632567405701)","('NON-ESG', 0.04893583059310913)","('NON-ESG', 0.04254557192325592)"
Line 560,"The theme of these events is “Everyone Makes   an Impact,” reinforcing the importance of   every employee’s role.
","('Employee_Engagement_Inclusion_And_Diversity', 0.45896539092063904)","('Human_Rights_And_Community_Relations', 0.151821106672287)","('Employee_Health_And_Safety', 0.09050130844116211)","('NON-ESG', 0.45896539092063904)","('NON-ESG', 0.151821106672287)","('NON-ESG', 0.09050130844116211)"
Line 561,"Patients and physicians  attend as guest speakers to share personal   experiences, and employees participate in   activities to reaffirm their commitment to the   Boston Scientific Quality Policy.
","('Access_And_Affordability', 0.22261351346969604)","('Employee_Health_And_Safety', 0.17466957867145538)","('Employee_Engagement_Inclusion_And_Diversity', 0.12013198435306549)","('NON-ESG', 0.22261351346969604)","('NON-ESG', 0.17466957867145538)","('NON-ESG', 0.12013198435306549)"
Line 562,"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.Our Quality Mission, ""We exceed expectations with  customer-centric quality solutions that transform  patient lives,"" is at the forefront of our product   development process and complements our   Quality Policy.
","('Product_Design_And_Lifecycle_Management', 0.9161626696586609)","('Product_Quality_And_Safety', 0.02310647815465927)","('Customer_Welfare', 0.008828498423099518)","(['Product Stewardship'], 0.9161626696586609)","('NON-ESG', 0.02310647815465927)","('NON-ESG', 0.008828498423099518)"
Line 563,"Our Global Design Controls process,   integrated with Risk Management and Usability   Engineering helps us leverage complex technologies  to create safe and effective solutions.
","('Systemic_Risk_Management', 0.907774031162262)","('Competitive_Behavior', 0.015224521979689598)","('Business_Model_Resilience', 0.012762668542563915)","(['Risk & Crisis Management'], 0.907774031162262)","('NON-ESG', 0.015224521979689598)","('NON-ESG', 0.012762668542563915)"
Line 564,"We use an   iterative process that centers on the needs of the  final user at every stage of design and development.
","('Product_Design_And_Lifecycle_Management', 0.741216242313385)","('Business_Model_Resilience', 0.050819020718336105)","('Supply_Chain_Management', 0.021395089104771614)","(['Product Stewardship'], 0.741216242313385)","('NON-ESG', 0.050819020718336105)","('NON-ESG', 0.021395089104771614)"
Line 565,"Our employees are encouraged to spend time   outside our offices to observe procedures and   talk to patients as well as healthcare providers.
","('Access_And_Affordability', 0.41896918416023254)","('Employee_Health_And_Safety', 0.21307061612606049)","('Critical_Incident_Risk_Management', 0.051700469106435776)","('NON-ESG', 0.41896918416023254)","('NON-ESG', 0.21307061612606049)","('NON-ESG', 0.051700469106435776)"
Line 566,"A key aspect of product quality includes the   materials used in our manufacturing processes.
","('Product_Design_And_Lifecycle_Management', 0.9603766798973083)","('Product_Quality_And_Safety', 0.006074895150959492)","('Selling_Practices_And_Product_Labeling', 0.0038024606183171272)","(['Product Stewardship'], 0.9603766798973083)","('NON-ESG', 0.006074895150959492)","('NON-ESG', 0.0038024606183171272)"
Line 567,"Boston Scientific has globally harmonized processes   and systems to provide an efficient, flexible and   comprehensive approach to compliance with   medical, environmental and other material   regulations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9625535607337952)","('Human_Rights_And_Community_Relations', 0.0033322253730148077)","('Air_Quality', 0.0027092220261693)","(['Corporate Governance'], 0.9625535607337952)","('NON-ESG', 0.0033322253730148077)","('NON-ESG', 0.0027092220261693)"
Line 568,"This includes component material   and device material assessment.
","('Waste_And_Hazardous_Materials_Management', 0.7309762239456177)","('Product_Design_And_Lifecycle_Management', 0.046672869473695755)","('Supply_Chain_Management', 0.04651394858956337)","(['Operational Eco-Efficiency'], 0.7309762239456177)","('NON-ESG', 0.046672869473695755)","('NON-ESG', 0.04651394858956337)"
Line 569,"We carefully   select the materials used in our products as well   as our suppliers so that we can provide safe   and effective solutions.
","('Product_Design_And_Lifecycle_Management', 0.9536016583442688)","('Product_Quality_And_Safety', 0.007239344529807568)","('Selling_Practices_And_Product_Labeling', 0.005599573254585266)","(['Product Stewardship'], 0.9536016583442688)","('NON-ESG', 0.007239344529807568)","('NON-ESG', 0.005599573254585266)"
Line 570,"Our teams continually   monitor and comply with global regulations   to ensure our products continue to meet all   applicable requirements.Continually Improving with Quality Initiatives Each year we undertake several targeted quality and  compliance initiatives to ensure ongoing compliance  with changing global industry regulations, while also  focusing on continuously improving our products.
","('Management_Of_Legal_And_Regulatory_Framework', 0.417506605386734)","('Product_Quality_And_Safety', 0.31389161944389343)","('Business_Ethics', 0.05773094296455383)","('NON-ESG', 0.417506605386734)","('NON-ESG', 0.31389161944389343)","('NON-ESG', 0.05773094296455383)"
Line 571,"Highlights of our 2018 accomplishments include:   Implemented a global design controls process    that fully integrates usability engineering and risk  management for effective new product develop- ment as well as customer-centric product designs.
","('Product_Design_And_Lifecycle_Management', 0.959860622882843)","('Product_Quality_And_Safety', 0.005624778568744659)","('Customer_Welfare', 0.004530900623649359)","(['Product Stewardship'], 0.959860622882843)","('NON-ESG', 0.005624778568744659)","('NON-ESG', 0.004530900623649359)"
Line 572,"Enabled innovation and expansion into new   technologies with the launch of our new Global  Process for Digital Health Development and   Validation.
","('Access_And_Affordability', 0.43922048807144165)","('Product_Quality_And_Safety', 0.08305186033248901)","('Employee_Engagement_Inclusion_And_Diversity', 0.05395020544528961)","('NON-ESG', 0.43922048807144165)","('NON-ESG', 0.08305186033248901)","('NON-ESG', 0.05395020544528961)"
Line 573,"Adapted to the evolving regulatory environment  with programs to implement General Data   Protection Regulation (GDPR) and continued to  prepare for the European Union Medical Device  Regulation (MDR).
","('Management_Of_Legal_And_Regulatory_Framework', 0.972109854221344)","('Energy_Management', 0.0022855685092508793)","('Ecological_Impacts', 0.0018752198666334152)","(['Corporate Governance'], 0.972109854221344)","('NON-ESG', 0.0022855685092508793)","('NON-ESG', 0.0018752198666334152)"
Line 574,"Executed enterprise training   for both initiatives and implemented new policies  and procedure updates to ensure compliance.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9441418647766113)","('Human_Rights_And_Community_Relations', 0.007916847243905067)","('Access_And_Affordability', 0.00425766920670867)","(['Corporate Governance'], 0.9441418647766113)","('NON-ESG', 0.007916847243905067)","('NON-ESG', 0.00425766920670867)"
Line 575,"Invested in advancements in Post Market Quality  assurance , including implementation of a global  complaint management system that will enable  continued evolution in post market surveillance.
","('Competitive_Behavior', 0.33033186197280884)","('Business_Ethics', 0.23194928467273712)","('Systemic_Risk_Management', 0.14640985429286957)","('NON-ESG', 0.33033186197280884)","('NON-ESG', 0.23194928467273712)","('NON-ESG', 0.14640985429286957)"
Line 576,"Launched Workstation Built-in Quality prevention  program to enable quality at the source where   the product is being built.
","('Product_Quality_And_Safety', 0.4490215480327606)","('Product_Design_And_Lifecycle_Management', 0.39747342467308044)","('Supply_Chain_Management', 0.015039101243019104)","('NON-ESG', 0.4490215480327606)","('NON-ESG', 0.39747342467308044)","('NON-ESG', 0.015039101243019104)"
Line 577,"Implemented new lab management system for   our Pathology franchise that provides end-to-end  specimen processing and traceability with slide  printing, barcode scanning technology and   enhanced quality control processes.
","('Business_Ethics', 0.16849620640277863)","('Product_Quality_And_Safety', 0.15746831893920898)","('Waste_And_Hazardous_Materials_Management', 0.14926761388778687)","('NON-ESG', 0.16849620640277863)","('NON-ESG', 0.15746831893920898)","('NON-ESG', 0.14926761388778687)"
Line 578,"SUSTAINABLE SUPPLY CHAIN   With approximately 15,000 life-changing products,  our manufacturing and supply chain teams play   a critical role in ensuring that we plan, source,   manufacture and distribute a reliable supply of  high-quality products to meet our customers’   evolving needs.
","('Product_Design_And_Lifecycle_Management', 0.9272235631942749)","('Supply_Chain_Management', 0.019411375746130943)","('Product_Quality_And_Safety', 0.004914010874927044)","(['Product Stewardship'], 0.9272235631942749)","('NON-ESG', 0.019411375746130943)","('NON-ESG', 0.004914010874927044)"
Line 579,"To guide our work, we use a   strategic quality process to prioritize, execute   and monitor manufacturing and supply chain   efforts.
","('Supply_Chain_Management', 0.9541595578193665)","('Product_Design_And_Lifecycle_Management', 0.0035256007686257362)","('Employee_Health_And_Safety', 0.0034098068717867136)","(['Supply Chain Management'], 0.9541595578193665)","('NON-ESG', 0.0035256007686257362)","('NON-ESG', 0.0034098068717867136)"
Line 580,"The process enables our global teams   to work toward a common set of objectives.
","('Business_Model_Resilience', 0.30107787251472473)","('Human_Rights_And_Community_Relations', 0.2185772806406021)","('Employee_Engagement_Inclusion_And_Diversity', 0.06209298595786095)","('NON-ESG', 0.30107787251472473)","('NON-ESG', 0.2185772806406021)","('NON-ESG', 0.06209298595786095)"
Line 581,"Maintaining the highest-quality component   supply requires a rigorous supply chain and   supplier risk-management approach.
","('Supply_Chain_Management', 0.9462003111839294)","('Physical_Impacts_Of_Climate_Change', 0.004445570055395365)","('Product_Design_And_Lifecycle_Management', 0.004124847706407309)","(['Supply Chain Management'], 0.9462003111839294)","('NON-ESG', 0.004445570055395365)","('NON-ESG', 0.004124847706407309)"
Line 582,"Our sourcing  team monitors supplier risk level to ensure that   we partner with long-term suppliers that share   our customer focus.
","('Supply_Chain_Management', 0.9491140842437744)","('Product_Design_And_Lifecycle_Management', 0.005416023079305887)","('Business_Model_Resilience', 0.004193392116576433)","(['Supply Chain Management'], 0.9491140842437744)","('NON-ESG', 0.005416023079305887)","('NON-ESG', 0.004193392116576433)"
Line 583,"Our supply chain team   facilitates planning for Boston Scientific products  across divisions and regions.
","('Supply_Chain_Management', 0.6600282192230225)","('Product_Design_And_Lifecycle_Management', 0.19173641502857208)","('Waste_And_Hazardous_Materials_Management', 0.0163878221064806)","(['Supply Chain Management'], 0.6600282192230225)","('NON-ESG', 0.19173641502857208)","('NON-ESG', 0.0163878221064806)"
Line 584,"Both teams enable   our network of manufacturing plants and global   distribution centers to provide the right product   at the right place and the right time.
","('Product_Design_And_Lifecycle_Management', 0.9607835412025452)","('Product_Quality_And_Safety', 0.0044339364394545555)","('Customer_Welfare', 0.0038884112145751715)","(['Product Stewardship'], 0.9607835412025452)","('NON-ESG', 0.0044339364394545555)","('NON-ESG', 0.0038884112145751715)"
Line 585,"Partnering to Set Industry Standards for Quality   and Compliance We collaborate with trade associations and   regulatory bodies around the world to set new  standards in quality and to anticipate and address  changing regulatory guidelines.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8590191602706909)","('Product_Quality_And_Safety', 0.03281756862998009)","('Business_Ethics', 0.02813578210771084)","(['Corporate Governance'], 0.8590191602706909)","('NON-ESG', 0.03281756862998009)","('NON-ESG', 0.02813578210771084)"
Line 586,"We are committed   to having patient-focused, high-performing   quality systems and helping influence industry   and regulatory approaches to quality.In the U.S., we participate in the Case for Quality   Voluntary Improvement Program, a multi-year   initiative led by the U.S. Food and Drug   Administration (FDA) in conjunction with the   Medical Device Innovation Consortium (MDIC)   to improve product quality using best practices,   standards, tools and metrics.
","('Product_Quality_And_Safety', 0.6552842855453491)","('Product_Design_And_Lifecycle_Management', 0.13793861865997314)","('Business_Ethics', 0.02178192138671875)","(['Product Quality & Recall Management'], 0.6552842855453491)","('NON-ESG', 0.13793861865997314)","('NON-ESG', 0.02178192138671875)"
Line 587,"In 2017, we were one   of the first companies invited to participate in the  agency’s Voluntary Medical Device Manufacturing  and Product Quality Program.
","('Product_Design_And_Lifecycle_Management', 0.8942367434501648)","('Product_Quality_And_Safety', 0.04523583501577377)","('Customer_Welfare', 0.007422750350087881)","(['Product Stewardship'], 0.8942367434501648)","('NON-ESG', 0.04523583501577377)","('NON-ESG', 0.007422750350087881)"
Line 588,"This pilot program  uses an independent assessment to evaluate   the capability of medical device organizations to   produce high quality devices and improve patient  safety.
","('Product_Quality_And_Safety', 0.6845754981040955)","('Employee_Health_And_Safety', 0.1685047149658203)","('Product_Design_And_Lifecycle_Management', 0.03255489468574524)","(['Product Quality & Recall Management'], 0.6845754981040955)","('NON-ESG', 0.1685047149658203)","('NON-ESG', 0.03255489468574524)"
Line 589,"To date, we’ve had four successful year-one  and one successful year-two appraisals:   Year One Appraisals:  Arden Hills, Minnesota;   Clonmel, Ireland; Maple Grove, Minnesota;   Galway, Ireland  Year Two Appraisal:  Arden Hills, Minnesota We also participate in the FDA 510K improvement  and Software for Digital Health programs.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21465955674648285)","('Product_Quality_And_Safety', 0.143940269947052)","('Customer_Welfare', 0.11210755258798599)","('NON-ESG', 0.21465955674648285)","('NON-ESG', 0.143940269947052)","('NON-ESG', 0.11210755258798599)"
Line 590,"In May 2017, new European Union MDR was   published with the goal of strengthening the   regulatory platform across the EU to further   enhance patient safety.
","('Product_Quality_And_Safety', 0.8845192193984985)","('Access_And_Affordability', 0.011928255669772625)","('Management_Of_Legal_And_Regulatory_Framework', 0.009748087264597416)","(['Product Quality & Recall Management'], 0.8845192193984985)","('NON-ESG', 0.011928255669772625)","('NON-ESG', 0.009748087264597416)"
Line 591,"By May 2020, companies  must demonstrate compliance with the MDR for   all products that require CE mark, including existing  commercialized products that must apply for CE  mark renewal.
","('Product_Quality_And_Safety', 0.5097454190254211)","('Product_Design_And_Lifecycle_Management', 0.12416186183691025)","('Selling_Practices_And_Product_Labeling', 0.06575625389814377)","(['Product Quality & Recall Management'], 0.5097454190254211)","('NON-ESG', 0.12416186183691025)","('NON-ESG', 0.06575625389814377)"
Line 592,"Boston Scientific global quality and  regulatory teams have continued to collaborate   with industry trade group MedTech Europe and   OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.“ Usability is a critical design  component for a safe and  effective device.”  — Roz Burke,   Senior Vice President,   Global Quality and   Regulatory Affairs “ Usability engineering   helps us understand what   customers do, why they do   it and what they’re trying   to accomplish.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7682056427001953)","('Business_Ethics', 0.062260791659355164)","('Competitive_Behavior', 0.039981111884117126)","(['Corporate Governance'], 0.7682056427001953)","('NON-ESG', 0.062260791659355164)","('NON-ESG', 0.039981111884117126)"
Line 593,"With this  knowledge, we can create  innovative solutions that   drive healthcare forward.” — David Feygin,   Chief Digital Health Officer   OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.other working groups to ensure we are prepared   for the implementation of MDR requirements.
","('Business_Model_Resilience', 0.29158514738082886)","('Customer_Welfare', 0.10286874324083328)","('Access_And_Affordability', 0.09902263432741165)","('NON-ESG', 0.29158514738082886)","('NON-ESG', 0.10286874324083328)","('NON-ESG', 0.09902263432741165)"
Line 594,"Effective May 25, 2018, the GDPR, a new European  Union (EU) law, governs how companies use person- al data (customer, employee and patient data).
","('Customer_Privacy', 0.9537827372550964)","('Data_Security', 0.009007371962070465)","('Waste_And_Hazardous_Materials_Management', 0.002853184239938855)","(['Privacy Protection'], 0.9537827372550964)","('NON-ESG', 0.009007371962070465)","('NON-ESG', 0.002853184239938855)"
Line 595,"The  GDPR broadly impacts our company since EU per - sonal data is collected, processed and stored globally.
","('Customer_Privacy', 0.7724800705909729)","('Data_Security', 0.05838602036237717)","('Labor_Practices', 0.014890450052917004)","(['Privacy Protection'], 0.7724800705909729)","('NON-ESG', 0.05838602036237717)","('NON-ESG', 0.014890450052917004)"
Line 596,"Our global privacy team collaborated with MedTech  Europe as part of the data protection working group  as well as the trade association AdvaMed in its new  Data Stewardship and Privacy Working Group as part  of our effort to comply with the new regulation.
","('Data_Security', 0.9361315369606018)","('Customer_Privacy', 0.01648573763668537)","('Systemic_Risk_Management', 0.003969088196754456)","(['Information Security/Cybersecurity & System Availability'], 0.9361315369606018)","('NON-ESG', 0.01648573763668537)","('NON-ESG', 0.003969088196754456)"
Line 597,"Measuring and Monitoring Effectiveness of   Quality and Compliance Boston Scientific conducts internal audits to   verify that our Global Quality System conforms   to internal and external requirements and is   effectively implemented and maintained.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5228258371353149)","('Business_Ethics', 0.29996180534362793)","('Product_Quality_And_Safety', 0.03951986879110336)","(['Corporate Governance'], 0.5228258371353149)","('NON-ESG', 0.29996180534362793)","('NON-ESG', 0.03951986879110336)"
Line 598,"We   plan and execute internal audits and conduct   follow-up actions including re-audit of prior   observations and the verification of actions   taken.
","('Business_Ethics', 0.7677063345909119)","('Management_Of_Legal_And_Regulatory_Framework', 0.07380995154380798)","('Systemic_Risk_Management', 0.026381835341453552)","(['Business Ethics'], 0.7677063345909119)","('NON-ESG', 0.07380995154380798)","('NON-ESG', 0.026381835341453552)"
Line 599,"External regulatory agencies also review our   performance to ensure quality and compliance,   with the following results in 2018:  External Regulatory Inspections*  Percent External Regulatory Inspections    Resulting in No Findings*  67% Average Findings per External    Regulatory Inspection*  0.Average Findings per FDA Inspection 0.*Includes Notified Body, Competent Authority, FDAProduct Performance Boston Scientific reviews customer feedback as   well as experience with our devices.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8799629807472229)","('Business_Ethics', 0.04914534091949463)","('Product_Quality_And_Safety', 0.012227426283061504)","(['Corporate Governance'], 0.8799629807472229)","('NON-ESG', 0.04914534091949463)","('NON-ESG', 0.012227426283061504)"
Line 600,"This information  provides valuable inputs for our Quality System as  well as future product iterations and innovations.
","('Product_Design_And_Lifecycle_Management', 0.9632649421691895)","('Product_Quality_And_Safety', 0.0048804203979671)","('Selling_Practices_And_Product_Labeling', 0.0031712574418634176)","(['Product Stewardship'], 0.9632649421691895)","('NON-ESG', 0.0048804203979671)","('NON-ESG', 0.0031712574418634176)"
Line 601,"Our Corrective and Preventive Action (CAPA) process  establishes a system to collect and analyze data   to find root causes for potential compliance and  quality problems.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6441269516944885)","('Business_Ethics', 0.11821715533733368)","('Human_Rights_And_Community_Relations', 0.030704669654369354)","(['Corporate Governance'], 0.6441269516944885)","('NON-ESG', 0.11821715533733368)","('NON-ESG', 0.030704669654369354)"
Line 602,"Our teams are then able to   address any potential issues and prevent future   issues or recurrences.
","('Systemic_Risk_Management', 0.45114266872406006)","('Management_Of_Legal_And_Regulatory_Framework', 0.1169661283493042)","('Physical_Impacts_Of_Climate_Change', 0.06730205565690994)","('NON-ESG', 0.45114266872406006)","('NON-ESG', 0.1169661283493042)","('NON-ESG', 0.06730205565690994)"
Line 603,"We initiate field actions   (product advisories, product advisory updates,   product retrievals), including follow-up and closure,  to ensure regulatory or field safety issues are   quickly and effectively addressed.
","('Product_Quality_And_Safety', 0.9213102459907532)","('Selling_Practices_And_Product_Labeling', 0.010778287425637245)","('Employee_Health_And_Safety', 0.010655774734914303)","(['Product Quality & Recall Management'], 0.9213102459907532)","('NON-ESG', 0.010778287425637245)","('NON-ESG', 0.010655774734914303)"
Line 604,"In 2018, Boston Scientific had zero Class I recalls   and zero Open FDA Warning Letters.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31264227628707886)","('Product_Quality_And_Safety', 0.27488580346107483)","('Business_Ethics', 0.07310917973518372)","('NON-ESG', 0.31264227628707886)","('NON-ESG', 0.27488580346107483)","('NON-ESG', 0.07310917973518372)"
Line 605,"OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.PACKAGING AND LABELING Packaging of our medical devices ensures protection  during sterilization, distribution, storage and use.
","('Product_Design_And_Lifecycle_Management', 0.6674362421035767)","('Selling_Practices_And_Product_Labeling', 0.12978409230709076)","('Product_Quality_And_Safety', 0.03735736384987831)","(['Product Stewardship'], 0.6674362421035767)","('NON-ESG', 0.12978409230709076)","('NON-ESG', 0.03735736384987831)"
Line 606,"We collaborate with our customers to understand  their needs and requirements with usability   assessments.
","('Product_Design_And_Lifecycle_Management', 0.4728538990020752)","('Business_Model_Resilience', 0.11788226664066315)","('Supply_Chain_Management', 0.08658561110496521)","('NON-ESG', 0.4728538990020752)","('NON-ESG', 0.11788226664066315)","('NON-ESG', 0.08658561110496521)"
Line 607,"Additionally, we have a global   Sustainability Packaging and Labeling Steering   Committee that works with our CSR Council to   develop our strategy and prioritize global goals   and projects.
","('Product_Design_And_Lifecycle_Management', 0.548043429851532)","('Selling_Practices_And_Product_Labeling', 0.18052266538143158)","('Customer_Welfare', 0.0749160423874855)","(['Product Stewardship'], 0.548043429851532)","('NON-ESG', 0.18052266538143158)","('NON-ESG', 0.0749160423874855)"
Line 608,"We continuously evaluate our   packaging and supply chain practices to optimize   design, reduce waste and limit emissions.
","('Supply_Chain_Management', 0.6570322513580322)","('Product_Design_And_Lifecycle_Management', 0.13187730312347412)","('Waste_And_Hazardous_Materials_Management', 0.061498720198869705)","(['Supply Chain Management'], 0.6570322513580322)","('NON-ESG', 0.13187730312347412)","('NON-ESG', 0.061498720198869705)"
Line 609,"In 2018,  with key improvements, our global packaging   teams:  Eliminated 120 tons of packaging from landfills    Avoided 2,500 pallet shipments   Repurposed 1,000 products during development Boston Scientific also ensures that we have the   controls in place to initiate, review and finalize   product labeling to meet global labeling regulations.
","('Selling_Practices_And_Product_Labeling', 0.7479454278945923)","('Product_Design_And_Lifecycle_Management', 0.09115016460418701)","('Product_Quality_And_Safety', 0.040300626307725906)","(['Marketing Practices'], 0.7479454278945923)","('NON-ESG', 0.09115016460418701)","('NON-ESG', 0.040300626307725906)"
Line 610,"Our labeling ensures proper identification and   prevents mix-ups by remaining legible and   attached to the product throughout its lifecycle.
","('Selling_Practices_And_Product_Labeling', 0.6014218330383301)","('Product_Design_And_Lifecycle_Management', 0.22054147720336914)","('Customer_Welfare', 0.04595354571938515)","(['Marketing Practices'], 0.6014218330383301)","('NON-ESG', 0.22054147720336914)","('NON-ESG', 0.04595354571938515)"
Line 611,"This additional focus on our packaging and   labeling design enables us to meet the needs   of our customers while reducing our overall   environmental footprint.
","('Product_Design_And_Lifecycle_Management', 0.9299231767654419)","('Selling_Practices_And_Product_Labeling', 0.016588503494858742)","('Customer_Welfare', 0.00940747931599617)","(['Product Stewardship'], 0.9299231767654419)","('NON-ESG', 0.016588503494858742)","('NON-ESG', 0.00940747931599617)"
Line 612,"Reducing corrugated material  Final packaging and labeling processes of our   Microspheres product lines were relocated   from our Cork, Ireland manufacturing facility   to our Kerkrade European Distribution Center,  allowing sterile pack units to be packed and  shipped without shelf cartons.
","('Product_Design_And_Lifecycle_Management', 0.7653189301490784)","('Waste_And_Hazardous_Materials_Management', 0.07185874879360199)","('Selling_Practices_And_Product_Labeling', 0.03466655686497688)","(['Product Stewardship'], 0.7653189301490784)","('NON-ESG', 0.07185874879360199)","('NON-ESG', 0.03466655686497688)"
Line 613,"This resulted in   a 73 percent reduction of annual corrugated  material consumption.
","('Energy_Management', 0.9197290539741516)","('Product_Design_And_Lifecycle_Management', 0.02599993161857128)","('Water_And_Wastewater_Management', 0.005742594134062529)","(['Operational Eco-Efficiency'], 0.9197290539741516)","('NON-ESG', 0.02599993161857128)","('NON-ESG', 0.005742594134062529)"
Line 614,"Eliminating pallet shipments Our teams updated our Electrophysiology   catheter thermoformed tray design to enable   local sourcing of components in Heredia, Costa  Rica.
","('Product_Design_And_Lifecycle_Management', 0.6640742421150208)","('Customer_Welfare', 0.09392040967941284)","('Energy_Management', 0.054991770535707474)","(['Product Stewardship'], 0.6640742421150208)","('NON-ESG', 0.09392040967941284)","('NON-ESG', 0.054991770535707474)"
Line 615,"This eliminated the shipment of over   47 pallets annually.
","('Waste_And_Hazardous_Materials_Management', 0.21651463210582733)","('Employee_Health_And_Safety', 0.13541054725646973)","('Access_And_Affordability', 0.11215796321630478)","('NON-ESG', 0.21651463210582733)","('NON-ESG', 0.13541054725646973)","('NON-ESG', 0.11215796321630478)"
Line 616,"2018 WorldStar Packaging Award Winner The development of a new package design for   Ureteral Stents met customers’ expectations,  eliminated the need for 120,000 pounds   of plastic per year, optimized storage, use   and post-surgical waste in healthcare facilities   and maintained product functionality.
","('Waste_And_Hazardous_Materials_Management', 0.942021906375885)","('Product_Design_And_Lifecycle_Management', 0.017561089247465134)","('Water_And_Wastewater_Management', 0.003979633562266827)","(['Operational Eco-Efficiency'], 0.942021906375885)","('NON-ESG', 0.017561089247465134)","('NON-ESG', 0.003979633562266827)"
Line 617,"The   WorldStar Packaging Awards Competition   is one of the major events of the World   Packaging Organization and is the pre-  eminent international award in packaging.Packaging Reduction OUR PRACTICES BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.SUPPORTING SMALL BUSINESS    AND SUPPLIER DIVERSITY Boston Scientific builds diversity and inclusion into  every aspect of our business, including our supply  chain.
","('Supply_Chain_Management', 0.7535196542739868)","('Product_Design_And_Lifecycle_Management', 0.05593084543943405)","('Employee_Engagement_Inclusion_And_Diversity', 0.025912653654813766)","(['Supply Chain Management'], 0.7535196542739868)","('NON-ESG', 0.05593084543943405)","('NON-ESG', 0.025912653654813766)"
Line 618,"As part of our procurement process, we strive  to partner with certified companies that share our  dedication to improving the quality of patient care.
","('Access_And_Affordability', 0.5144200325012207)","('Customer_Welfare', 0.06180235370993614)","('Energy_Management', 0.05626325681805611)","(['Health Outcome Contribution'], 0.5144200325012207)","('NON-ESG', 0.06180235370993614)","('NON-ESG', 0.05626325681805611)"
Line 619,"In 2018, we worked with more than 700 diverse   supplier businesses, including:   Minority-owned   Small   Small disadvantaged   Veteran-owned   Service disabled veteran-owned   HUBZone   Disability-owned   LGBT-owned In 2018, $322 million of our spend was attributed to  our work with diverse suppliers, a 6 percent increase  from 2017.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9186052680015564)","('Labor_Practices', 0.0126749686896801)","('Employee_Health_And_Safety', 0.00784521084278822)","(['Human Capital Development'], 0.9186052680015564)","('NON-ESG', 0.0126749686896801)","('NON-ESG', 0.00784521084278822)"
Line 620,"In addition, we conducted more than   120 capability assessments with diverse suppliers  and participated in trade shows that promoted  diverse suppliers.
","('Supply_Chain_Management', 0.9061582684516907)","('Product_Design_And_Lifecycle_Management', 0.011761856265366077)","('Customer_Welfare', 0.008995944634079933)","(['Supply Chain Management'], 0.9061582684516907)","('NON-ESG', 0.011761856265366077)","('NON-ESG', 0.008995944634079933)"
Line 621,"Additionally, we strengthened our commitment to  supplier diversity in 2018 by establishing a full-time  management role to focus on this aspect of our  operations.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9697598814964294)","('Employee_Health_And_Safety', 0.0020812335424125195)","('Business_Model_Resilience', 0.002019049134105444)","(['Human Capital Development'], 0.9697598814964294)","('NON-ESG', 0.0020812335424125195)","('NON-ESG', 0.002019049134105444)"
Line 622,"Our Manager of Supplier Diversity is  charged with setting our approach, policies, goals  and targets to align with our values and business  objectives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9472184181213379)","('Customer_Welfare', 0.004313673358410597)","('Employee_Health_And_Safety', 0.003952683415263891)","(['Human Capital Development'], 0.9472184181213379)","('NON-ESG', 0.004313673358410597)","('NON-ESG', 0.003952683415263891)"
Line 623,"In 2019, we expect to increase spending  with diverse suppliers by 5 percent and to conduct  an additional 100 capability assessments.Working with Responsible Suppliers We have robust standards for the more than 10,000  global suppliers with which we work to deliver our  innovative medical solutions to physicians and  patients.
","('Supply_Chain_Management', 0.8615154027938843)","('Product_Design_And_Lifecycle_Management', 0.043520838022232056)","('Customer_Welfare', 0.012304225005209446)","(['Supply Chain Management'], 0.8615154027938843)","('NON-ESG', 0.043520838022232056)","('NON-ESG', 0.012304225005209446)"
Line 624,"We actively look for suppliers that deliver  industry-leading quality, reliability and value as we  work to meet our customers’ needs.
","('Supply_Chain_Management', 0.8707395195960999)","('Product_Design_And_Lifecycle_Management', 0.04660041257739067)","('Business_Model_Resilience', 0.009274991229176521)","(['Supply Chain Management'], 0.8707395195960999)","('NON-ESG', 0.04660041257739067)","('NON-ESG', 0.009274991229176521)"
Line 625,"Quality is the most important aspect of our supplier  relationships, and all direct materials suppliers are  required to comply with Boston Scientific quality  standards.
","('Supply_Chain_Management', 0.6834793090820312)","('Product_Quality_And_Safety', 0.07176461070775986)","('Product_Design_And_Lifecycle_Management', 0.049272824078798294)","(['Supply Chain Management'], 0.6834793090820312)","('NON-ESG', 0.07176461070775986)","('NON-ESG', 0.049272824078798294)"
Line 626,"We seek partnerships with suppliers   that share our commitment to strong ethics and  full compliance with all applicable laws.
","('Business_Ethics', 0.9413146376609802)","('Management_Of_Legal_And_Regulatory_Framework', 0.01733885332942009)","('Product_Quality_And_Safety', 0.004996274132281542)","(['Business Ethics'], 0.9413146376609802)","('NON-ESG', 0.01733885332942009)","('NON-ESG', 0.004996274132281542)"
Line 627,"In 2018,  we further standardized our supplier performance  assessment tools and expanded our robust criteria  to include key corporate social responsibility topics  among key strategic business requirements.
","('Supply_Chain_Management', 0.8991028666496277)","('Human_Rights_And_Community_Relations', 0.011037558317184448)","('Product_Design_And_Lifecycle_Management', 0.010282482020556927)","(['Supply Chain Management'], 0.8991028666496277)","('NON-ESG', 0.011037558317184448)","('NON-ESG', 0.010282482020556927)"
Line 628,"While  this evaluation process takes time, it allows us to  foster relationships with responsible suppliers that  support our business continuity and risk mitigation  strategy.
","('Supply_Chain_Management', 0.919613242149353)","('Business_Model_Resilience', 0.010237593203783035)","('Product_Design_And_Lifecycle_Management', 0.009990577585995197)","(['Supply Chain Management'], 0.919613242149353)","('NON-ESG', 0.010237593203783035)","('NON-ESG', 0.009990577585995197)"
Line 629,"Boston Scientific representatives attending a 2018  Massachusetts LGBT Chamber of Commerce event.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8735737204551697)","('Human_Rights_And_Community_Relations', 0.014522652141749859)","('Director_Removal', 0.01041509211063385)","(['Human Capital Development'], 0.8735737204551697)","('NON-ESG', 0.014522652141749859)","('NON-ESG', 0.01041509211063385)"
Line 630,""" Embracing differences in   perspectives and cultures   of our suppliers furthers   our goals in innovation   and positively impacts the  economies in which we   live and work.”   — Ed Mackey, Executive Vice President,   Global OperationsIn 2018, we spent $322   million with 700+ diverse  suppliers, a 6% increase  from 2017.
","('Supply_Chain_Management', 0.8252147436141968)","('Product_Design_And_Lifecycle_Management', 0.03500230610370636)","('Employee_Engagement_Inclusion_And_Diversity', 0.020159482955932617)","(['Supply Chain Management'], 0.8252147436141968)","('NON-ESG', 0.03500230610370636)","('NON-ESG', 0.020159482955932617)"
Line 631,"NON-GAAP RECONCILIATIONS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.This Performance Report contains forward-looking statements within the meaning of the federal securities laws.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9694806933403015)","('Business_Ethics', 0.0034128238912671804)","('Director_Removal', 0.00217924895696342)","(['Corporate Governance'], 0.9694806933403015)","('NON-ESG', 0.0034128238912671804)","('NON-ESG', 0.00217924895696342)"
Line 632,"See the discussion under “Safe Harbor for   Forward-Looking Statements” in the Annual Report on Form 10-K for the year ended December 31, 2018, for matters to be considered in this regard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.46589717268943787)","('Systemic_Risk_Management', 0.13678018748760223)","('Business_Model_Resilience', 0.06473131477832794)","('NON-ESG', 0.46589717268943787)","('NON-ESG', 0.13678018748760223)","('NON-ESG', 0.06473131477832794)"
Line 633,"In addition,   please see our Annual Report on Form 10-K for a description of our Non-GAAP adjustments and the reasons for excluding each item.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9386876225471497)","('GHG_Emissions', 0.0055693392641842365)","('Human_Rights_And_Community_Relations', 0.005568617023527622)","(['Corporate Governance'], 0.9386876225471497)","('NON-ESG', 0.0055693392641842365)","('NON-ESG', 0.005568617023527622)"
Line 634,"YEAR ENDED DECEMBER 31,              5-Year   PERCENTAGE CHANGE IN NET SALES  2018 2017 2016 2015 2014 Average Percentage change in net sales, as reported 8.6 % 7.9 % 12 % 1 % 3 % 7 % Less: Impact of foreign currency fluctuations 0.6 % 0.1 % — % (7)% (3)% (1)% Percentage change in net sales, operational 8.0 % 7.8 % 12 % 8 % 6 % 8 % Less: Impact of certain acquisitions 0.8 % 1.2 % 2 % 3 % 2 % 1 % Percentage change in net sales, organic 7.2 % 6.6 % 10 % 5 % 4 % 7 %  YEAR ENDED DECEMBER 31, OPERATING MARGIN 2 0 1 8  2017 2016 2015 Operating margin, reported 15.3 % 14.2 % 5.3 % (3.8)% (4.1)%  Less: Non-GAAP adjustments (10.2)% (10.8)% (18.8)% (26.1)% (24.3)% Operating margin, adjusted 25.5 % 25.0 % 24.1 % 22.3 % 20.2 % Basis Point Improvement from 2017 50  Basis Point Improvement from 2014 Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.
","('Systemic_Risk_Management', 0.4409887194633484)","('Competitive_Behavior', 0.09993758052587509)","('Business_Model_Resilience', 0.0932941734790802)","('NON-ESG', 0.4409887194633484)","('NON-ESG', 0.09993758052587509)","('NON-ESG', 0.0932941734790802)"
Line 635,"YEAR ENDED DECEMBER 31,              5-Year   PERCENTAGE CHANGE IN NET SALES  2018 2017 2016 2015 2014 Average Percentage change in net sales, as reported 8.6 % 7.9 % 12 % 1 % 3 % 7 % Less: Impact of foreign currency fluctuations 0.6 % 0.1 % — % (7)% (3)% (1)% Percentage change in net sales, operational 8.0 % 7.8 % 12 % 8 % 6 % 8 % Less: Impact of certain acquisitions 0.8 % 1.2 % 2 % 3 % 2 % 1 % Percentage change in net sales, organic 7.2 % 6.6 % 10 % 5 % 4 % 7 %  YEAR ENDED DECEMBER 31, OPERATING MARGIN 2 0 1 8  2017 2016 2015 Operating margin, reported 15.3 % 14.2 % 5.3 % (3.8)% (4.1)%  Less: Non-GAAP adjustments (10.2)% (10.8)% (18.8)% (26.1)% (24.3)% Operating margin, adjusted 25.5 % 25.0 % 24.1 % 22.3 % 20.2 % Basis Point Improvement from 2017 50  Basis Point Improvement from 2014 Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.
","('Systemic_Risk_Management', 0.507448673248291)","('Business_Model_Resilience', 0.12651270627975464)","('Management_Of_Legal_And_Regulatory_Framework', 0.04438285902142525)","(['Risk & Crisis Management'], 0.507448673248291)","('NON-ESG', 0.12651270627975464)","('NON-ESG', 0.04438285902142525)"
Line 636,"Amounts may not add due to rounding.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3407299816608429)","('Competitive_Behavior', 0.21437682211399078)","('Business_Ethics', 0.055159490555524826)","('NON-ESG', 0.3407299816608429)","('NON-ESG', 0.21437682211399078)","('NON-ESG', 0.055159490555524826)"
Line 637,"NON-GAAP RECONCILIATIONS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8539456725120544)","('Systemic_Risk_Management', 0.03596652299165726)","('Business_Ethics', 0.017902027815580368)","(['Corporate Governance'], 0.8539456725120544)","('NON-ESG', 0.03596652299165726)","('NON-ESG', 0.017902027815580368)"
Line 638,"YEAR ENDED DECEMBER 31, 2018        Less: Impact of  Less: Impact   PERCENTAGE CHANGE IN NET SALES   Reported Foreign Currency Operational of Certain Organic  BY BUSINESS AND SEGMENT  Basis Fluctuations  Basis Acquisitions Basis Endoscopy  8.8 % 0.5 % 8.3 % — % 8.3 % Urology and Pelvic Health  10.8 % 0.2 % 10.6 % 2.5 % 8.1 % MedSurg†  9.7 % 0.4 % 9.3 % 1.1 % 8.2 % Cardiac Rhythm Management  2.9 % 0.8 % 2.1 % — % 2.1 % Electrophysiology  12.1 % 1.2 % 10.9 % — % 10.9 % Neuromodulation  22.7 % 0.2 % 22.5 % — % 22.5 % Rhythm and Neuro†  8.3 % 0.7 % 7.6 % — % 7.6 % Interventional Cardiology  7.1 % 0.5 % 6.6 % 2.1 % 4.5 % Peripheral Interventions  9.8 % 0.6 % 9.2 % — % 9.2 % Cardiovascular  7.9 % 0.5 % 7.4 % 1.4 % 6.0 %  YEAR ENDED DECEMBER 31, 2018         Less: Impact of         Reported  Foreign Currency Operational  PERCENTAGE CHANGE IN NET SALES BY REGION    Basis Fluctuations  Basis U.S.    7.3% — % 7.3% EMEA† (Europe, Middle East and Africa)    12.2% 3.2 % 9.0% APAC† (Asia-Pacific)    8.8% 1.3 % 7.5% LACA (Latin America and Canada)    6.8% (9.0)% 15.8% Emerging Markets    18.0% (3.4)% 21.4% Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.
","('Customer_Welfare', 0.11952842026948929)","('Access_And_Affordability', 0.11137718707323074)","('Employee_Engagement_Inclusion_And_Diversity', 0.10528939962387085)","('NON-ESG', 0.11952842026948929)","('NON-ESG', 0.11137718707323074)","('NON-ESG', 0.10528939962387085)"
Line 639,"YEAR ENDED DECEMBER 31, 2018        Less: Impact of  Less: Impact   PERCENTAGE CHANGE IN NET SALES   Reported Foreign Currency Operational of Certain Organic  BY BUSINESS AND SEGMENT  Basis Fluctuations  Basis Acquisitions Basis Endoscopy  8.8 % 0.5 % 8.3 % — % 8.3 % Urology and Pelvic Health  10.8 % 0.2 % 10.6 % 2.5 % 8.1 % MedSurg†  9.7 % 0.4 % 9.3 % 1.1 % 8.2 % Cardiac Rhythm Management  2.9 % 0.8 % 2.1 % — % 2.1 % Electrophysiology  12.1 % 1.2 % 10.9 % — % 10.9 % Neuromodulation  22.7 % 0.2 % 22.5 % — % 22.5 % Rhythm and Neuro†  8.3 % 0.7 % 7.6 % — % 7.6 % Interventional Cardiology  7.1 % 0.5 % 6.6 % 2.1 % 4.5 % Peripheral Interventions  9.8 % 0.6 % 9.2 % — % 9.2 % Cardiovascular  7.9 % 0.5 % 7.4 % 1.4 % 6.0 %  YEAR ENDED DECEMBER 31, 2018         Less: Impact of         Reported  Foreign Currency Operational  PERCENTAGE CHANGE IN NET SALES BY REGION    Basis Fluctuations  Basis U.S.    7.3% — % 7.3% EMEA† (Europe, Middle East and Africa)    12.2% 3.2 % 9.0% APAC† (Asia-Pacific)    8.8% 1.3 % 7.5% LACA (Latin America and Canada)    6.8% (9.0)% 15.8% Emerging Markets    18.0% (3.4)% 21.4% Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.
","('Systemic_Risk_Management', 0.64814293384552)","('Business_Model_Resilience', 0.0729532241821289)","('Management_Of_Legal_And_Regulatory_Framework', 0.06486290693283081)","(['Risk & Crisis Management'], 0.64814293384552)","('NON-ESG', 0.0729532241821289)","('NON-ESG', 0.06486290693283081)"
Line 640,"YEAR ENDED DECEMBER 31, 2018        Less: Impact of  Less: Impact   PERCENTAGE CHANGE IN NET SALES   Reported Foreign Currency Operational of Certain Organic  BY BUSINESS AND SEGMENT  Basis Fluctuations  Basis Acquisitions Basis Endoscopy  8.8 % 0.5 % 8.3 % — % 8.3 % Urology and Pelvic Health  10.8 % 0.2 % 10.6 % 2.5 % 8.1 % MedSurg†  9.7 % 0.4 % 9.3 % 1.1 % 8.2 % Cardiac Rhythm Management  2.9 % 0.8 % 2.1 % — % 2.1 % Electrophysiology  12.1 % 1.2 % 10.9 % — % 10.9 % Neuromodulation  22.7 % 0.2 % 22.5 % — % 22.5 % Rhythm and Neuro†  8.3 % 0.7 % 7.6 % — % 7.6 % Interventional Cardiology  7.1 % 0.5 % 6.6 % 2.1 % 4.5 % Peripheral Interventions  9.8 % 0.6 % 9.2 % — % 9.2 % Cardiovascular  7.9 % 0.5 % 7.4 % 1.4 % 6.0 %  YEAR ENDED DECEMBER 31, 2018         Less: Impact of         Reported  Foreign Currency Operational  PERCENTAGE CHANGE IN NET SALES BY REGION    Basis Fluctuations  Basis U.S.    7.3% — % 7.3% EMEA† (Europe, Middle East and Africa)    12.2% 3.2 % 9.0% APAC† (Asia-Pacific)    8.8% 1.3 % 7.5% LACA (Latin America and Canada)    6.8% (9.0)% 15.8% Emerging Markets    18.0% (3.4)% 21.4% Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.
","('Systemic_Risk_Management', 0.2820894718170166)","('Business_Model_Resilience', 0.1562984585762024)","('Competitive_Behavior', 0.14746488630771637)","('NON-ESG', 0.2820894718170166)","('NON-ESG', 0.1562984585762024)","('NON-ESG', 0.14746488630771637)"
Line 641,"Amounts may not add due to rounding.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3407299816608429)","('Competitive_Behavior', 0.21437682211399078)","('Business_Ethics', 0.055159490555524826)","('NON-ESG', 0.3407299816608429)","('NON-ESG', 0.21437682211399078)","('NON-ESG', 0.055159490555524826)"
Line 642,"NON-GAAP RECONCILIATIONS BOSTON SCIENTIFIC 2018 PERFORMANCE REPORT p.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8539456725120544)","('Systemic_Risk_Management', 0.03596652299165726)","('Business_Ethics', 0.017902027815580368)","(['Corporate Governance'], 0.8539456725120544)","('NON-ESG', 0.03596652299165726)","('NON-ESG', 0.017902027815580368)"
Line 643,"YEAR ENDED DECEMBER 31, EARNINGS PER SHARE 2018 2017 2016 2015 2014 GAAP earnings (loss) per share (EPS) $ 1.19 $0.08 $0.25 $(0.18) $(0.09) $(0.09) Non-GAAP adjustments 0.28 1.18 0.86 1.11a 0.93b 0.82c Adjusted EPS $ 1.47 $ 1.26 $  1.11 $ 0.93 $ 0.84 $  0.Less: Impact of 2018 net tax benefitd 0.07 —   Adjusted EPS, excluding 2018 net tax benefit $1.40 $ 1.Adjusted EPS growth from prior year 17% 13% 20% 11% 15%  Adjusted EPS growth from prior year, excluding net tax benefit 11%  5-Year Average Adjusted EPS growth, excluding net tax benefit 14%   a Assumes dilution of 21.5 million shares for the year ended December 31, 2015.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8895657658576965)","('Systemic_Risk_Management', 0.01732412911951542)","('Business_Ethics', 0.0132582513615489)","(['Corporate Governance'], 0.8895657658576965)","('NON-ESG', 0.01732412911951542)","('NON-ESG', 0.0132582513615489)"
Line 644,"YEAR ENDED DECEMBER 31, EARNINGS PER SHARE 2018 2017 2016 2015 2014 GAAP earnings (loss) per share (EPS) $ 1.19 $0.08 $0.25 $(0.18) $(0.09) $(0.09) Non-GAAP adjustments 0.28 1.18 0.86 1.11a 0.93b 0.82c Adjusted EPS $ 1.47 $ 1.26 $  1.11 $ 0.93 $ 0.84 $  0.Less: Impact of 2018 net tax benefitd 0.07 —   Adjusted EPS, excluding 2018 net tax benefit $1.40 $ 1.Adjusted EPS growth from prior year 17% 13% 20% 11% 15%  Adjusted EPS growth from prior year, excluding net tax benefit 11%  5-Year Average Adjusted EPS growth, excluding net tax benefit 14%   a Assumes dilution of 21.5 million shares for the year ended December 31, 2015.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9213961362838745)","('Business_Ethics', 0.013037106022238731)","('Director_Removal', 0.011324279010295868)","(['Corporate Governance'], 0.9213961362838745)","('NON-ESG', 0.013037106022238731)","('NON-ESG', 0.011324279010295868)"
Line 645,"b Assumes dilution of 23.7 million shares for the year ended December 31, 2014.
","('Systemic_Risk_Management', 0.37765565514564514)","('Business_Ethics', 0.10919584333896637)","('Competitive_Behavior', 0.10405869781970978)","('NON-ESG', 0.37765565514564514)","('NON-ESG', 0.10919584333896637)","('NON-ESG', 0.10405869781970978)"
Line 646,"c Assumes dilution of 19.5 million shares for the year ended December 31, 2013.
","('Systemic_Risk_Management', 0.29669609665870667)","('Management_Of_Legal_And_Regulatory_Framework', 0.1169954389333725)","('Business_Ethics', 0.10546247661113739)","('NON-ESG', 0.29669609665870667)","('NON-ESG', 0.1169954389333725)","('NON-ESG', 0.10546247661113739)"
Line 647,"d  Full year 2018 net tax benefit of $0.07 includes a second quarter $0.06 benefit from settling the IRS Stipulation of Settled Issues for the 2001 through 2010 tax years, offset by a fourth quarter $0.05 charge for our previously announced tax reinvestment strategy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9683254361152649)","('Energy_Management', 0.0031914657447487116)","('Access_And_Affordability', 0.0024173862766474485)","(['Corporate Governance'], 0.9683254361152649)","('NON-ESG', 0.0031914657447487116)","('NON-ESG', 0.0024173862766474485)"
Line 648,"In addition, the net benefit includes a $0.06 benefit   in the fourth quarter for the settlement with the IRS of our 2011 through 2013 tax years.
","('Management_Of_Legal_And_Regulatory_Framework', 0.953965425491333)","('Access_And_Affordability', 0.005643816664814949)","('Labor_Practices', 0.0039484561420977116)","(['Corporate Governance'], 0.953965425491333)","('NON-ESG', 0.005643816664814949)","('NON-ESG', 0.0039484561420977116)"
Line 649,"YEAR ENDED DECEMBER 31, ADJUSTED FREE CASH FLOW (IN MILLIONS)   2018  Operating cash flow, reported   $    310 $1,Less: Purchases of property, plant and equipment  316 Add: Proceed on disposals of property, plant and equipment  14 — Free cash flow, reported   8 1,Plus: Restructuring and restructuring-related payments  89 Plus: Acquisition-related payments  205 Plus: Certain discrete tax payments  977 (239) Plus: Litigation-related settlements  791 Adjusted free cash flow  $2,070 $1,Adjusted free cash flow growth from prior year  20% Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.
","('Business_Ethics', 0.5423313975334167)","('Systemic_Risk_Management', 0.1619122475385666)","('Management_Of_Legal_And_Regulatory_Framework', 0.12074915319681168)","(['Business Ethics'], 0.5423313975334167)","('NON-ESG', 0.1619122475385666)","('NON-ESG', 0.12074915319681168)"
Line 650,"YEAR ENDED DECEMBER 31, ADJUSTED FREE CASH FLOW (IN MILLIONS)   2018  Operating cash flow, reported   $    310 $1,Less: Purchases of property, plant and equipment  316 Add: Proceed on disposals of property, plant and equipment  14 — Free cash flow, reported   8 1,Plus: Restructuring and restructuring-related payments  89 Plus: Acquisition-related payments  205 Plus: Certain discrete tax payments  977 (239) Plus: Litigation-related settlements  791 Adjusted free cash flow  $2,070 $1,Adjusted free cash flow growth from prior year  20% Percentages are calculated using unrounded numbers and may not recalculate precisely due to rounding.
","('Management_Of_Legal_And_Regulatory_Framework', 0.28647756576538086)","('Competitive_Behavior', 0.086421437561512)","('Customer_Privacy', 0.07619230449199677)","('NON-ESG', 0.28647756576538086)","('NON-ESG', 0.086421437561512)","('NON-ESG', 0.07619230449199677)"
Line 651,"Amounts may not add due to rounding.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3407299816608429)","('Competitive_Behavior', 0.21437682211399078)","('Business_Ethics', 0.055159490555524826)","('NON-ESG', 0.3407299816608429)","('NON-ESG', 0.21437682211399078)","('NON-ESG', 0.055159490555524826)"
Line 652,"Boston Scientific Corporation 300 Boston Scientific Way Marlborough, MA 01752-bostonscientific.com© 2019 Boston Scientific Corporation or its affiliates.
","('Competitive_Behavior', 0.15373201668262482)","('Management_Of_Legal_And_Regulatory_Framework', 0.13883787393569946)","('Customer_Welfare', 0.08600714802742004)","('NON-ESG', 0.15373201668262482)","('NON-ESG', 0.13883787393569946)","('NON-ESG', 0.08600714802742004)"
Line 653,"All rights reserved.
","('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 654,PR2018,"('Physical_Impacts_Of_Climate_Change', 0.264691561460495)","('Management_Of_Legal_And_Regulatory_Framework', 0.20197129249572754)","('Business_Model_Resilience', 0.09292672574520111)","('NON-ESG', 0.264691561460495)","('NON-ESG', 0.20197129249572754)","('NON-ESG', 0.09292672574520111)"
